Infections, Meningococcal
Conditions
Brief summary
The main purposes for conducting the study are firstly to assess immunological non-inferiority of the MenABCWY vaccine, administered according to 0, 2 month schedule to healthy adolescents 10 to 18 years of age, to those of the licensed rMenB+OMV vaccine (Bexsero™) in terms of hSBA GMTs at one month after the second vaccination, secondly to give the flexibility for the national vaccination program by showing the safety and immunogenicity of MenABCWY administrated according to four different vaccination schedules and additionally to evaluate a potential benefit of the 3-dose vaccination series.
Interventions
BIOLOGICALBexsero
Two doses administered intramuscularly into the deltoid area at Months 0 and 2 in rMenB\_0\_2 Group.
OTHERSaline Placebo
One dose administered intramusculary in the deltoid muscle at Month 1 in ABCWY\_ 0\_2 Group and rMenB\_0\_2 Group, Month 2 in ABCWY\_0\_6 Group and ABCWY\_0\_11 Group and Month 6 in ABCWY\_0\_1 Group.
BIOLOGICALHavrix
Two doses administered in the deltoid muscle at Month 2 and 12 in ABCWY\_0\_1 Group, Month 1 and 12 in Group ABCWY\_0\_6 Group and ABCWY\_0\_2\_6 Group , Month 0 and 6 in ABCWY\_0\_11 Group and Month 6 and 12 in ABCWY\_ 0\_2 Group and rMenB\_0\_2 Group.
BIOLOGICALMenABCWY
Two to three doses administered in the deltoid muscle at Month 0 and 1 in ABCWY\_0\_1 Group, Month 0 and 6 in ABCWY\_0\_6 Group, Month 1 and 12 in ABCWY\_0\_11 Group, Month 0, 2 and 6 in ABCWY\_0\_2\_6 Group, Month 0 and 2 in ABCWY\_ 0\_2 Group and rMenB\_0\_2 Group.
Sponsors
GlaxoSmithKline
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
10 Years to 18 Years
Healthy volunteers
Yes
Inclusion criteria
1. Adolecents from 10-18 yearsof age, generally in good health, and available for all study visits, and who/whose legally acceptable representative has given written informed consent at the time of enrollment. 2. Individuals of who the investigator believes can and will comply with the requirements of the protocol (e.g. use of an eDiary, return for follow-up visits, available for phone contacts). 3. Female subjects of childbearing potential must have a negative urine preganancy test.
Exclusion criteria
1. Serious, acute, or chronic illness. Previous or suspected disease caused by N. meningitidis. Previous immunization with any menincococcal or Hepatitis A vaccines. 2. Exposure to individuals with clicically proven meningococcal disease or clinical bacterial meningitis without further microbiologic characteriszation.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Human Serum Bactericidal Assay (hSBA) Geometric Mean Titers (GMTs) Against N. Meningitidis Serogroup B Test Strains When Administered According to 0_2 Month Schedule. | At baseline (Month 0) and 1 month after the last meningococcal vaccination (Month 3) | The non-inferiority of the Meningococcal (groups A, C, W and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant (MenABCWY) vaccine to Meningococcal (group B) multicomponent recombinant adsorbed (Bexsero) vaccine, administered according to 0, 2 month schedule, as measured by hSBA GMTs against N.meningitidis serogroup B test strains at 1 month after the last meningococcal vaccination, is reported. The test strains assessed were Meningitis B NZ98/254 Ab, Meningitis B M14459 Ab, Meningitis B M07-0241084 Ab and Meningitis B 96217 Ab. This outcome measure was evaluated in the rMenB\_0\_2 and ABCWY\_ 0\_2 Groups. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentages of Subjects With hSBA Titers ≥LLQ Against N. Meningitidis Serogroups A, C, W and y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_2 Month Schedule. | At baseline (Month 0) and 1 month after the last meningococcal vaccination (Month 3 for ABCWY_ 0_2 Group and Month 7 for ABCWY_0_2_6 Group) | The immunogenicity of MenABCWY vaccine, administered according to 0, 2, 6 month schedule, was compared with those, administered according to 0, 2 month schedule, as measured by the percentages of subjects with hSBA titers ≥ LLQ against N. meningitidis serogroup B test strains at 1 month after the last meningococcal vaccination. |
| hSBA GMTs Against Each of N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_1 Month, 0_2 Month, 0_6 Month and 0, 11 Month Schedule. | At 1 Month after the last vaccination (Month 2 for ABCWY_0_1 Group, Month 3 for ABCWY_0_2 Group, Month 7 for ABCWY_0_6 Group and Month 13 for ABCWY_0_11 Group) | The immunogenicity of MenABCWY vaccine, administered according to 0, 2 months schedule, was compared with those, administered according to 0, 1 month, 0, 6 month and 0, 11 month schedules as measured by hSBA GMTs against N. meningitidis serogroups A, C, W and Y and serogroup B test strains at 1 month after the second meningococcal vaccination. |
| Percentages of Subjects With hSBA Titers ≥ Lower Limit of Quantitation (LLQ) Against N. Meningitidis Serogroup B Test Strains When Administered According to 0_2 Month Schedule. | At baseline (Month 0) and 1 month after the last meningococcal vaccination (Month 3) | A sufficient immune response following Bexsero vaccine, administered according to 0, 2 month schedule, as measured by the percentage of subjects with hSBA titers ≥ Lower Limit of Quantitation (LLQ) against N. meningitidis serogroup B test strains at 1 month after the last meningococcal vaccination, was to be demonstrated. Criterion: the immune response was to be considered sufficient if the lower limit of the two-sided 95% CI for the percentage of subjects with hSBA titers ≥ LLQ was greater than 75% for each of the four serogroup B test strains. The test strains assessed were Meningitis B NZ98/254 Ab, Meningitis B M14459 Ab, Meningitis B M07-0241084 Ab and Meningitis B 96217 Ab. |
| hSBA GMTs Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_6 Month Schedule. | At 1 month after last vaccination (Month 7) | The immunogenicity of MenABCWY vaccine, administered according to 0, 2, 6 months schedule was compared with those administered according to 0, 6 months schedule, as measured by hSBA GMTs against N. meningitidis serogroups A, C, W and Y and serogroup B test strains at 1 month after the last meningococcal vaccination. |
| Percentages of Subjects With hSBA Titers ≥ Lower Limit of Quantitation (LLQ) Against Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_6 Month Schedule. | At baseline (Month 0) and 1 month after the last meningococcal vaccination (Month 7) | The immunogenicity of MenABCWY vaccine, administered according to 0, 2, 6 month schedule, was compared with those, administered according to 0, 6 month schedule, as measured by the percentages of subjects with hSBA titers ≥ LLQ against serogroups A, C, W and Y and serogroup B test strains at 1 month after the last meningococcal vaccination. |
| Percentages of Subjects With hSBA Titers ≥ LLQ Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_1 Month, 0_2 Month, 0_6 Month and 0_11 Month Schedule. | At 1 month after second vaccination (Month 2 for ABCWY_0_1 Group, Month 3 for ABCWY_0_2 Group , Month 7 for ABCWY_0_6 Group and Month 13 for ABCWY_0_11 Group) | The immunogenicity of MenABCWY vaccine, administered according to 0, 2 month schedule, was compared with those, administered according to 0, 1 month, 0, 6 month and 0, 11 month schedules, as measured by the percentages of subjects with hSBA titers ≥ LLQ against N. meningitidis serogroups A, C, W and Y and serogroup B test strains at 1 month after the second meningococcal vaccination. |
| hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | At Month 0, Month 2, Month 3, Month 7 and Month 13 | The kinetic of immune response (at Months 0, 2, 3, 7 and 13) following different vaccination schedules as measured by the adjusted hSBA GMTs against serogroups A,C, W and Y and serogroup B test strains was assessed. |
| Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | At Month 0, Month 2, Month 3, Month 7 and Month 13. | The kinetic of immune response (at Months 0, 2, 3, 7 and 13) following different vaccination schedules as measured by the percentages of subjects with hSBA titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 against NZ98/254 B strain was assessed. |
| Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | At Month 0, Month 2, Month 3, Month 7 and Month 13. | The kinetic of immune response (at Months 0, 2, 3, 7 and 13) following different vaccination schedules as measured by the percentages of subjects with hSBA titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 against M14459 B strain was assessed. |
| Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | At Month 0, Month 2, Month 3, Month 7 and Month 13. | The kinetic of immune response (at Months 0, 2, 3, 7 and 13) following different vaccination schedules as measured by the percentages of subjects with hSBA titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 against M07-0241084 B strain was assessed. |
| Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | At Month 0, Month 2, Month 3, Month 7 and Month 13. | The kinetic of immune response (at Months 0, 2, 3, 7 and 13) following different vaccination schedules as measured by the percentages of subjects with hSBA titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 against 96217 B strain was assessed. |
| hSBA GMTs Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_2 Month Schedule. | At baseline (Month 0) and 1 month after the last meningococcal vaccination (Month 3 for ABCWY_ 0_2 Group and Month 7 for ABCWY_0_2_6 Group) | The immunogenicity of MenABCWY vaccine, administered according to 0, 2, 6 months schedule was compared with those administered according to 0, 2 months schedule, as measured by hSBA GMTs against N. meningitidis serogroup B test strains and serogroups A,C, W and Y at 1 month after the last meningococcal vaccination. The B test strains assessed were Meningitis B NZ98/254 Ab, Meningitis B M14459 Ab, Meningitis B M07-0241084 Ab and Meningitis B 96217 Ab. This outcome measure was evaluated in the ABCWY\_ 0\_2 and ABCWY\_0\_2\_6 Groups. 1 month post last meningococcal vaccination corresponds to Month 3 for ABCWY\_0\_2 Group and Month 7 for ABCWY\_0\_2\_6 Group. |
| Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | At Month 0, Month 2, Month 3, Month 7 and Month 13. | The kinetic of immune response (at Months 0, 2, 3, 7 and 13) following different vaccination schedules as measured by the percentages of subjects with hSBA titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 against C human serogroup was assessed. |
| Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | At Month 0, Month 2, Month 3, Month 7 and Month 13. | The kinetic of immune response (at Months 0, 2, 3, 7 and 13) following different vaccination schedules as measured by the percentages of subjects with hSBA titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 against W human serogroup was assessed. |
| Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | At Month 0, Month 2, Month 3, Month 7 and Month 13. | The kinetic of immune response (at Months 0, 2, 3, 7 and 13) following different vaccination schedules as measured by the percentages of subjects with hSBA titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 against Y human serogroup was assessed. |
| Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | At Month 2, Month 3, Month 7 and Month 13 | The kinetic of immune response (at Months 2, 3, 7 and 13) following different vaccination schedules as measured by the percentages of subjects with two-, three- and four-fold titer rise against serogroups A, C, W and Y and serogroup B test strains was assessed. The two/three/four fold titer rise is defined as: a) for subjects with prevaccination hSBA titers ≤ LLQ, a postvaccination hSBA ≥ 2/3/4 LLQ; b) for subjects with a prevaccination hSBA titers ≥ LLQ, an increase of at least 2/3/4 times of the prevaccination hSBA titer. |
| The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | From Month 0 to Month 13 | The area under the curve for percentage of subjects with hSBA titers ≥ LLQ for all serogroups (A, C, W and Y) and for all serogroup B test strains (M14459, 96217, NZ98/254 and M07-0241084) was summarized overall (from Month 0 to Month 13) and by period (from Month 0 to Month 2, Month 2 to Month 3, Month 3 to Month 7 and Month 7 to Month 13) by vaccine groups. It was computed as the sum of the trapezoidal areas and the time unit used was the month. AUC 0\_13 = (r0+r2)(2-0)/2 + (r2+r3)(3-2)/2 + (r3+r7)(7-3)/2 + (r7+r13)(13-7)/2 with ri = percentages of subjects with both hSBA titers \>= LLQ against N. meningitis for all serogroups A, C, W and Y and for all serogroup B test strains at Month 1. |
| Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Within 30 minutes after vaccination | Number of participants reporting any solicited local or systemic AEs and other indicators of reactogenicity within 30 minutes after each vaccination. Assessed solicited symptoms were Pain, erythema and induration. Assessed solicited systemic symptoms were Fatigue, headache, myalgia, arthralgia, loss of appetite, nausea, chills, and fever (body temperature ≥38.0°C). |
| Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Within 30 minutes after vaccination | An unsolicited adverse event is an adverse event that was not solicited and that was spontaneously communicated by a participant and/or parent/legal guardian who has signed the informed consent. Number of participants reporting any unsolicited AE within 30 minutes after each vaccination. |
| Number of Participants Reporting Unsolicited AEs From Day 1 to Day 30 After Any Vaccination. | Day 1 through Day 30 after any vaccination | The number of participants reporting unsolicited AEs and possibly or probably related unsolicited AEs were assessed. |
| Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | At Day 1 (6 hours) to Day 7 after vaccination | Number of participants reporting any solicited local or systemic AEs and other indicators of reactogenicity from Day 1 (6 hours) to Day 7 after any meningococcal vaccination is reported. |
| Number of Participants Reporting Any Serious AE (SAE), Medically Attended AEs (MAAEs), AEs Leading to Premature Withdrawal | During the entire study period (Month 0 to Month 13) | The number of participants reporting any SAE, possibly or probably related SAE(s), medically-attended AEs, AEs leading to premature withdrawal, AEs leading to death, AEs leading to hospitalization and AEs leading to dose reduction, interruption and delay in study vaccination during the entire study period is reported. |
| Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | At Month 0, Month 2, Month 3, Month 7 and Month 13. | The kinetic of immune response (at Months 0, 2, 3, 7 and 13) following different vaccination schedules as measured by the percentages of subjects with hSBA titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 against A human serogroup was assessed. |
Countries
Finland, Poland, United States
Participant flow
Recruitment details
Subjects were recruited from 32 centers from Finland, Poland and United States.
Pre-assignment details
All subjects were included in the trial.
Participants by arm
| Arm | Count |
|---|---|
| rMenB_0_2 Group Subjects received two injections of Bexsero vaccine at Visit Month 0 and Visit Month 2, Havrix vaccine at Visit Month 6 and Visit Month 12 and saline placebo at Visit Month 1. | 228 |
| ABCWY_ 0_2 Group Subjects received MenABCWY vaccine at Visit Month 0 and Visit Month 2, Havrix vaccine at Visit Month 6 and Visit Month 12 and saline placebo at Visit Month 1. | 232 |
| ABCWY_0_1 Group Subjects received MenABCWY vaccine at Visit Month 0 and Visit Month 1, Havrix vaccine at Visit Month 2 and Visit Month 12 and saline placebo at Visit Month 6. | 157 |
| ABCWY_0_6 Group Subjects received MenABCWY vaccine at Visit Month 0 and Visit Month 6, Havrix vaccine at Visit Month 1 and Visit Month 12 and saline placebo at Visit Month 2. | 134 |
| ABCWY_0_11 Group Subjects received MenABCWY vaccine at Visit Month 1 and Visit Month 12, Havrix vaccine at Visit Month 0 and Visit Month 6 and saline placebo at Visit Month 2. | 152 |
| ABCWY_0_2_6 Group Subjects received MenABCWY vaccine at Visit Month 0, Visit Month 2 and Visit Month 6 and Havrix vaccine at Visit Month 1 and Visit Month 12. | 160 |
| Total | 1,063 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 |
|---|---|---|---|---|---|---|---|
| Overall Study | Adverse Event | 1 | 2 | 2 | 2 | 0 | 1 |
| Overall Study | Lost to Follow-up | 6 | 7 | 4 | 1 | 8 | 4 |
| Overall Study | Other | 2 | 1 | 2 | 1 | 0 | 1 |
| Overall Study | Protocol Violation | 2 | 1 | 0 | 1 | 2 | 3 |
| Overall Study | Withdrawal by Subject | 8 | 10 | 8 | 6 | 5 | 4 |
Baseline characteristics
| Characteristic | rMenB_0_2 Group | ABCWY_ 0_2 Group | ABCWY_0_1 Group | ABCWY_0_6 Group | ABCWY_0_11 Group | ABCWY_0_2_6 Group | Total |
|---|---|---|---|---|---|---|---|
| Age, Continuous | 14.5 Years STANDARD_DEVIATION 3.09 | 14.2 Years STANDARD_DEVIATION 3.17 | 14.4 Years STANDARD_DEVIATION 3.01 | 14.4 Years STANDARD_DEVIATION 3.06 | 14.5 Years STANDARD_DEVIATION 3.1 | 14.3 Years STANDARD_DEVIATION 3.16 | 14.4 Years STANDARD_DEVIATION 3.1 |
| Sex: Female, Male Female | 130 Participants | 119 Participants | 101 Participants | 76 Participants | 89 Participants | 96 Participants | 611 Participants |
| Sex: Female, Male Male | 98 Participants | 113 Participants | 56 Participants | 58 Participants | 63 Participants | 64 Participants | 452 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk |
|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 228 | 0 / 231 | 0 / 155 | 0 / 134 | 0 / 151 | 0 / 159 |
| other Total, other adverse events | 226 / 228 | 229 / 231 | 153 / 155 | 131 / 134 | 151 / 151 | 158 / 159 |
| serious Total, serious adverse events | 9 / 228 | 3 / 231 | 8 / 155 | 7 / 134 | 2 / 151 | 6 / 159 |
Outcome results
Primary
Human Serum Bactericidal Assay (hSBA) Geometric Mean Titers (GMTs) Against N. Meningitidis Serogroup B Test Strains When Administered According to 0_2 Month Schedule.
The non-inferiority of the Meningococcal (groups A, C, W and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant (MenABCWY) vaccine to Meningococcal (group B) multicomponent recombinant adsorbed (Bexsero) vaccine, administered according to 0, 2 month schedule, as measured by hSBA GMTs against N.meningitidis serogroup B test strains at 1 month after the last meningococcal vaccination, is reported. The test strains assessed were Meningitis B NZ98/254 Ab, Meningitis B M14459 Ab, Meningitis B M07-0241084 Ab and Meningitis B 96217 Ab. This outcome measure was evaluated in the rMenB\_0\_2 and ABCWY\_ 0\_2 Groups.
Time frame: At baseline (Month 0) and 1 month after the last meningococcal vaccination (Month 3)
Population: Analysis was done on Per Protocol Set (PPS)-Month 3, which included all screened subjects who received a study vaccination, provided evaluable serum samples at pre- \& post-vaccination, with results available for at least 1 serogroup B test strain \& who was not excluded due to protocol deviations/other reasons defined before unblinding/analysis
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| ABCWY_ 0_2 Group | Human Serum Bactericidal Assay (hSBA) Geometric Mean Titers (GMTs) Against N. Meningitidis Serogroup B Test Strains When Administered According to 0_2 Month Schedule. | M14459 strain (Month 0) | 1.28 Titers |
| ABCWY_ 0_2 Group | Human Serum Bactericidal Assay (hSBA) Geometric Mean Titers (GMTs) Against N. Meningitidis Serogroup B Test Strains When Administered According to 0_2 Month Schedule. | M14459 strain (Month 3) | 11.64 Titers |
| ABCWY_ 0_2 Group | Human Serum Bactericidal Assay (hSBA) Geometric Mean Titers (GMTs) Against N. Meningitidis Serogroup B Test Strains When Administered According to 0_2 Month Schedule. | M07-0241084 strain (Month 0) | 2.12 Titers |
| ABCWY_ 0_2 Group | Human Serum Bactericidal Assay (hSBA) Geometric Mean Titers (GMTs) Against N. Meningitidis Serogroup B Test Strains When Administered According to 0_2 Month Schedule. | M07-0241084 strain (Month 3) | 8.19 Titers |
| ABCWY_ 0_2 Group | Human Serum Bactericidal Assay (hSBA) Geometric Mean Titers (GMTs) Against N. Meningitidis Serogroup B Test Strains When Administered According to 0_2 Month Schedule. | 96217 strain (Month 0) | 2.93 Titers |
| ABCWY_ 0_2 Group | Human Serum Bactericidal Assay (hSBA) Geometric Mean Titers (GMTs) Against N. Meningitidis Serogroup B Test Strains When Administered According to 0_2 Month Schedule. | 96217 strain (Month 3) | 150.82 Titers |
| ABCWY_ 0_2 Group | Human Serum Bactericidal Assay (hSBA) Geometric Mean Titers (GMTs) Against N. Meningitidis Serogroup B Test Strains When Administered According to 0_2 Month Schedule. | NZ98/254 strain (Month 0) | 1.27 Titers |
| ABCWY_ 0_2 Group | Human Serum Bactericidal Assay (hSBA) Geometric Mean Titers (GMTs) Against N. Meningitidis Serogroup B Test Strains When Administered According to 0_2 Month Schedule. | NZ98/254 strain (Month 3) | 11.95 Titers |
| rMenB_0_2 Group | Human Serum Bactericidal Assay (hSBA) Geometric Mean Titers (GMTs) Against N. Meningitidis Serogroup B Test Strains When Administered According to 0_2 Month Schedule. | NZ98/254 strain (Month 3) | 24.31 Titers |
| rMenB_0_2 Group | Human Serum Bactericidal Assay (hSBA) Geometric Mean Titers (GMTs) Against N. Meningitidis Serogroup B Test Strains When Administered According to 0_2 Month Schedule. | M14459 strain (Month 0) | 1.31 Titers |
| rMenB_0_2 Group | Human Serum Bactericidal Assay (hSBA) Geometric Mean Titers (GMTs) Against N. Meningitidis Serogroup B Test Strains When Administered According to 0_2 Month Schedule. | 96217 strain (Month 0) | 2.36 Titers |
| rMenB_0_2 Group | Human Serum Bactericidal Assay (hSBA) Geometric Mean Titers (GMTs) Against N. Meningitidis Serogroup B Test Strains When Administered According to 0_2 Month Schedule. | M14459 strain (Month 3) | 15.78 Titers |
| rMenB_0_2 Group | Human Serum Bactericidal Assay (hSBA) Geometric Mean Titers (GMTs) Against N. Meningitidis Serogroup B Test Strains When Administered According to 0_2 Month Schedule. | NZ98/254 strain (Month 0) | 1.15 Titers |
| rMenB_0_2 Group | Human Serum Bactericidal Assay (hSBA) Geometric Mean Titers (GMTs) Against N. Meningitidis Serogroup B Test Strains When Administered According to 0_2 Month Schedule. | M07-0241084 strain (Month 0) | 2.16 Titers |
| rMenB_0_2 Group | Human Serum Bactericidal Assay (hSBA) Geometric Mean Titers (GMTs) Against N. Meningitidis Serogroup B Test Strains When Administered According to 0_2 Month Schedule. | 96217 strain (Month 3) | 229.29 Titers |
| rMenB_0_2 Group | Human Serum Bactericidal Assay (hSBA) Geometric Mean Titers (GMTs) Against N. Meningitidis Serogroup B Test Strains When Administered According to 0_2 Month Schedule. | M07-0241084 strain (Month 3) | 11.56 Titers |
Comparison: Non-inferiority response against N. meningitidis serogroup B test strain M14459 of the MenABCWY vaccine to that of the Bexsero vaccine, administered according to 0, 2 month schedule.95% CI: [0.53, 1.02]ANCOVA
Comparison: Non-inferiority response against N. meningitidis serogroup B test strain M07-0241084 of the MenABCWY vaccine to that of the Bexsero vaccine, administered according to 0, 2 month schedule.95% CI: [0.54, 0.94]ANCOVA
Comparison: Non-inferiority response against N. meningitidis serogroup B test strain 96217 of the MenABCWY vaccine to that of the Bexsero vaccine, administered according to 0, 2 month schedule.95% CI: [0.51, 0.85]ANCOVA
Comparison: Non-inferiority response against N. meningitidis serogroup B test strain NZ98/254 of the MenABCWY vaccine to that of the Bexsero vaccine, administered according to 0, 2 month schedule.95% CI: [0.37, 0.66]ANCOVA
Secondary
hSBA GMTs Against Each of N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_1 Month, 0_2 Month, 0_6 Month and 0, 11 Month Schedule.
The immunogenicity of MenABCWY vaccine, administered according to 0, 2 months schedule, was compared with those, administered according to 0, 1 month, 0, 6 month and 0, 11 month schedules as measured by hSBA GMTs against N. meningitidis serogroups A, C, W and Y and serogroup B test strains at 1 month after the second meningococcal vaccination.
Time frame: At 1 Month after the last vaccination (Month 2 for ABCWY_0_1 Group, Month 3 for ABCWY_0_2 Group, Month 7 for ABCWY_0_6 Group and Month 13 for ABCWY_0_11 Group)
Population: Analysis was done on the FAS- 1 month after last meningococcal vaccination, which included all screened subjects who provided informed consent, received a study vaccination \& provided evaluable serum samples at 1 month after last vaccination whose results were available for atleast 1 serogroup or B strain
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| ABCWY_ 0_2 Group | hSBA GMTs Against Each of N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_1 Month, 0_2 Month, 0_6 Month and 0, 11 Month Schedule. | M14459 strain | 12.72 Titers |
| ABCWY_ 0_2 Group | hSBA GMTs Against Each of N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_1 Month, 0_2 Month, 0_6 Month and 0, 11 Month Schedule. | M07-0241084 strain | 9.15 Titers |
| ABCWY_ 0_2 Group | hSBA GMTs Against Each of N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_1 Month, 0_2 Month, 0_6 Month and 0, 11 Month Schedule. | C human serogroup | 162.57 Titers |
| ABCWY_ 0_2 Group | hSBA GMTs Against Each of N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_1 Month, 0_2 Month, 0_6 Month and 0, 11 Month Schedule. | Y human serogroup | 71.66 Titers |
| ABCWY_ 0_2 Group | hSBA GMTs Against Each of N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_1 Month, 0_2 Month, 0_6 Month and 0, 11 Month Schedule. | A human serogroup | 69.61 Titers |
| ABCWY_ 0_2 Group | hSBA GMTs Against Each of N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_1 Month, 0_2 Month, 0_6 Month and 0, 11 Month Schedule. | 96217 strain | 165.47 Titers |
| ABCWY_ 0_2 Group | hSBA GMTs Against Each of N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_1 Month, 0_2 Month, 0_6 Month and 0, 11 Month Schedule. | W human serogroup | 215.72 Titers |
| ABCWY_ 0_2 Group | hSBA GMTs Against Each of N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_1 Month, 0_2 Month, 0_6 Month and 0, 11 Month Schedule. | NZ98/254 strain | 12.32 Titers |
| rMenB_0_2 Group | hSBA GMTs Against Each of N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_1 Month, 0_2 Month, 0_6 Month and 0, 11 Month Schedule. | W human serogroup | 197.69 Titers |
| rMenB_0_2 Group | hSBA GMTs Against Each of N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_1 Month, 0_2 Month, 0_6 Month and 0, 11 Month Schedule. | A human serogroup | 79.87 Titers |
| rMenB_0_2 Group | hSBA GMTs Against Each of N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_1 Month, 0_2 Month, 0_6 Month and 0, 11 Month Schedule. | C human serogroup | 145.73 Titers |
| rMenB_0_2 Group | hSBA GMTs Against Each of N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_1 Month, 0_2 Month, 0_6 Month and 0, 11 Month Schedule. | M14459 strain | 9.19 Titers |
| rMenB_0_2 Group | hSBA GMTs Against Each of N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_1 Month, 0_2 Month, 0_6 Month and 0, 11 Month Schedule. | NZ98/254 strain | 6.33 Titers |
| rMenB_0_2 Group | hSBA GMTs Against Each of N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_1 Month, 0_2 Month, 0_6 Month and 0, 11 Month Schedule. | M07-0241084 strain | 6.59 Titers |
| rMenB_0_2 Group | hSBA GMTs Against Each of N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_1 Month, 0_2 Month, 0_6 Month and 0, 11 Month Schedule. | Y human serogroup | 57.45 Titers |
| rMenB_0_2 Group | hSBA GMTs Against Each of N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_1 Month, 0_2 Month, 0_6 Month and 0, 11 Month Schedule. | 96217 strain | 117.28 Titers |
| ABCWY_0_6 Group | hSBA GMTs Against Each of N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_1 Month, 0_2 Month, 0_6 Month and 0, 11 Month Schedule. | C human serogroup | 225.00 Titers |
| ABCWY_0_6 Group | hSBA GMTs Against Each of N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_1 Month, 0_2 Month, 0_6 Month and 0, 11 Month Schedule. | M14459 strain | 26.48 Titers |
| ABCWY_0_6 Group | hSBA GMTs Against Each of N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_1 Month, 0_2 Month, 0_6 Month and 0, 11 Month Schedule. | Y human serogroup | 120.76 Titers |
| ABCWY_0_6 Group | hSBA GMTs Against Each of N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_1 Month, 0_2 Month, 0_6 Month and 0, 11 Month Schedule. | W human serogroup | 376.03 Titers |
| ABCWY_0_6 Group | hSBA GMTs Against Each of N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_1 Month, 0_2 Month, 0_6 Month and 0, 11 Month Schedule. | M07-0241084 strain | 15.04 Titers |
| ABCWY_0_6 Group | hSBA GMTs Against Each of N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_1 Month, 0_2 Month, 0_6 Month and 0, 11 Month Schedule. | NZ98/254 strain | 13.64 Titers |
| ABCWY_0_6 Group | hSBA GMTs Against Each of N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_1 Month, 0_2 Month, 0_6 Month and 0, 11 Month Schedule. | 96217 strain | 237.89 Titers |
| ABCWY_0_6 Group | hSBA GMTs Against Each of N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_1 Month, 0_2 Month, 0_6 Month and 0, 11 Month Schedule. | A human serogroup | 140.76 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Each of N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_1 Month, 0_2 Month, 0_6 Month and 0, 11 Month Schedule. | Y human serogroup | 209.53 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Each of N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_1 Month, 0_2 Month, 0_6 Month and 0, 11 Month Schedule. | NZ98/254 strain | 15.87 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Each of N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_1 Month, 0_2 Month, 0_6 Month and 0, 11 Month Schedule. | M14459 strain | 29.57 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Each of N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_1 Month, 0_2 Month, 0_6 Month and 0, 11 Month Schedule. | M07-0241084 strain | 16.22 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Each of N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_1 Month, 0_2 Month, 0_6 Month and 0, 11 Month Schedule. | 96217 strain | 244.97 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Each of N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_1 Month, 0_2 Month, 0_6 Month and 0, 11 Month Schedule. | A human serogroup | 162.76 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Each of N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_1 Month, 0_2 Month, 0_6 Month and 0, 11 Month Schedule. | C human serogroup | 292.61 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Each of N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_1 Month, 0_2 Month, 0_6 Month and 0, 11 Month Schedule. | W human serogroup | 531.79 Titers |
Secondary
hSBA GMTs Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_2 Month Schedule.
The immunogenicity of MenABCWY vaccine, administered according to 0, 2, 6 months schedule was compared with those administered according to 0, 2 months schedule, as measured by hSBA GMTs against N. meningitidis serogroup B test strains and serogroups A,C, W and Y at 1 month after the last meningococcal vaccination. The B test strains assessed were Meningitis B NZ98/254 Ab, Meningitis B M14459 Ab, Meningitis B M07-0241084 Ab and Meningitis B 96217 Ab. This outcome measure was evaluated in the ABCWY\_ 0\_2 and ABCWY\_0\_2\_6 Groups. 1 month post last meningococcal vaccination corresponds to Month 3 for ABCWY\_0\_2 Group and Month 7 for ABCWY\_0\_2\_6 Group.
Time frame: At baseline (Month 0) and 1 month after the last meningococcal vaccination (Month 3 for ABCWY_ 0_2 Group and Month 7 for ABCWY_0_2_6 Group)
Population: Analysis was done on the FAS-1 month after the last meningococcal vaccination.All subjects in All Enrolled Set who received a study meningococcal vaccination \& provided evaluable serum samples at pre- \& at one month after the last meningococcal vaccination whose result is available for at least one A,C,W,or Y serogroup or serogroup B test strain.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| ABCWY_ 0_2 Group | hSBA GMTs Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_2 Month Schedule. | M14459 strain (Month 0) | 1.21 Titers |
| ABCWY_ 0_2 Group | hSBA GMTs Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_2 Month Schedule. | M14459 strain (Month 3/Month 7) | 12.17 Titers |
| ABCWY_ 0_2 Group | hSBA GMTs Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_2 Month Schedule. | M07-0241084 strain (Month 0) | 2.36 Titers |
| ABCWY_ 0_2 Group | hSBA GMTs Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_2 Month Schedule. | M07-0241084 strain (Month 3/Month 7) | 8.91 Titers |
| ABCWY_ 0_2 Group | hSBA GMTs Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_2 Month Schedule. | 96217 strain (Month 0) | 2.31 Titers |
| ABCWY_ 0_2 Group | hSBA GMTs Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_2 Month Schedule. | 96217 strain (Month 3/Month7) | 174.27 Titers |
| ABCWY_ 0_2 Group | hSBA GMTs Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_2 Month Schedule. | NZ98/254 strain (Month 0) | 1.24 Titers |
| ABCWY_ 0_2 Group | hSBA GMTs Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_2 Month Schedule. | NZ98/254 strain (Month 3/Month7) | 12.57 Titers |
| ABCWY_ 0_2 Group | hSBA GMTs Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_2 Month Schedule. | A human serogroup (Month 0) | 1.19 Titers |
| ABCWY_ 0_2 Group | hSBA GMTs Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_2 Month Schedule. | A human serogroup (Month 3/Month7) | 66.73 Titers |
| ABCWY_ 0_2 Group | hSBA GMTs Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_2 Month Schedule. | C human serogroup (Month 0) | 3.59 Titers |
| ABCWY_ 0_2 Group | hSBA GMTs Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_2 Month Schedule. | C human serogroup (Month 3/Month7) | 158.8 Titers |
| ABCWY_ 0_2 Group | hSBA GMTs Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_2 Month Schedule. | W human serogroup (Month 0) | 5.20 Titers |
| ABCWY_ 0_2 Group | hSBA GMTs Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_2 Month Schedule. | W human serogroup (Month 3/Month7) | 206.62 Titers |
| ABCWY_ 0_2 Group | hSBA GMTs Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_2 Month Schedule. | Y human serogroup (Month 0) | 1.33 Titers |
| ABCWY_ 0_2 Group | hSBA GMTs Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_2 Month Schedule. | Y human serogroup (Month 3/Month7) | 79.84 Titers |
| rMenB_0_2 Group | hSBA GMTs Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_2 Month Schedule. | Y human serogroup (Month 3/Month7) | 163.69 Titers |
| rMenB_0_2 Group | hSBA GMTs Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_2 Month Schedule. | M14459 strain (Month 0) | 1.12 Titers |
| rMenB_0_2 Group | hSBA GMTs Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_2 Month Schedule. | A human serogroup (Month 0) | 1.10 Titers |
| rMenB_0_2 Group | hSBA GMTs Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_2 Month Schedule. | M14459 strain (Month 3/Month 7) | 27.09 Titers |
| rMenB_0_2 Group | hSBA GMTs Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_2 Month Schedule. | W human serogroup (Month 0) | 4.64 Titers |
| rMenB_0_2 Group | hSBA GMTs Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_2 Month Schedule. | M07-0241084 strain (Month 0) | 2.05 Titers |
| rMenB_0_2 Group | hSBA GMTs Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_2 Month Schedule. | A human serogroup (Month 3/Month7) | 125.45 Titers |
| rMenB_0_2 Group | hSBA GMTs Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_2 Month Schedule. | M07-0241084 strain (Month 3/Month 7) | 18.03 Titers |
| rMenB_0_2 Group | hSBA GMTs Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_2 Month Schedule. | Y human serogroup (Month 0) | 1.26 Titers |
| rMenB_0_2 Group | hSBA GMTs Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_2 Month Schedule. | 96217 strain (Month 0) | 2.28 Titers |
| rMenB_0_2 Group | hSBA GMTs Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_2 Month Schedule. | C human serogroup (Month 0) | 3.19 Titers |
| rMenB_0_2 Group | hSBA GMTs Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_2 Month Schedule. | 96217 strain (Month 3/Month7) | 298.76 Titers |
| rMenB_0_2 Group | hSBA GMTs Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_2 Month Schedule. | W human serogroup (Month 3/Month7) | 295.9 Titers |
| rMenB_0_2 Group | hSBA GMTs Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_2 Month Schedule. | NZ98/254 strain (Month 0) | 1.07 Titers |
| rMenB_0_2 Group | hSBA GMTs Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_2 Month Schedule. | C human serogroup (Month 3/Month7) | 376.44 Titers |
| rMenB_0_2 Group | hSBA GMTs Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_2 Month Schedule. | NZ98/254 strain (Month 3/Month7) | 17.55 Titers |
Secondary
hSBA GMTs Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_6 Month Schedule.
The immunogenicity of MenABCWY vaccine, administered according to 0, 2, 6 months schedule was compared with those administered according to 0, 6 months schedule, as measured by hSBA GMTs against N. meningitidis serogroups A, C, W and Y and serogroup B test strains at 1 month after the last meningococcal vaccination.
Time frame: At 1 month after last vaccination (Month 7)
Population: Analysis was done on the FAS- 1 month after last meningococcal vaccination, which included all screened subjects who provided informed consent, received a study vaccination \& provided evaluable serum samples at 1 month after last vaccination whose results were available for atleast 1 serogroup or B strains
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| ABCWY_ 0_2 Group | hSBA GMTs Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_6 Month Schedule. | NZ98/254 strain | 13.62 Titers |
| ABCWY_ 0_2 Group | hSBA GMTs Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_6 Month Schedule. | M14459 strain | 27.82 Titers |
| ABCWY_ 0_2 Group | hSBA GMTs Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_6 Month Schedule. | M07-0241084 strain | 17.43 Titers |
| ABCWY_ 0_2 Group | hSBA GMTs Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_6 Month Schedule. | 96217 strain | 240.13 Titers |
| ABCWY_ 0_2 Group | hSBA GMTs Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_6 Month Schedule. | Serogroup A | 140.14 Titers |
| ABCWY_ 0_2 Group | hSBA GMTs Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_6 Month Schedule. | Serogroup C | 246.48 Titers |
| ABCWY_ 0_2 Group | hSBA GMTs Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_6 Month Schedule. | Serogroup W | 341.90 Titers |
| ABCWY_ 0_2 Group | hSBA GMTs Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_6 Month Schedule. | Serogroup Y | 123.96 Titers |
| rMenB_0_2 Group | hSBA GMTs Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_6 Month Schedule. | Serogroup Y | 151.36 Titers |
| rMenB_0_2 Group | hSBA GMTs Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_6 Month Schedule. | NZ98/254 strain | 17.13 Titers |
| rMenB_0_2 Group | hSBA GMTs Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_6 Month Schedule. | Serogroup A | 128.75 Titers |
| rMenB_0_2 Group | hSBA GMTs Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_6 Month Schedule. | M14459 strain | 29.27 Titers |
| rMenB_0_2 Group | hSBA GMTs Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_6 Month Schedule. | Serogroup W | 282.74 Titers |
| rMenB_0_2 Group | hSBA GMTs Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_6 Month Schedule. | M07-0241084 strain | 20.92 Titers |
| rMenB_0_2 Group | hSBA GMTs Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_6 Month Schedule. | Serogroup C | 413.60 Titers |
| rMenB_0_2 Group | hSBA GMTs Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_6 Month Schedule. | 96217 strain | 291.63 Titers |
Secondary
hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules.
The kinetic of immune response (at Months 0, 2, 3, 7 and 13) following different vaccination schedules as measured by the adjusted hSBA GMTs against serogroups A,C, W and Y and serogroup B test strains was assessed.
Time frame: At Month 0, Month 2, Month 3, Month 7 and Month 13
Population: Analysis was done on the FAS Month 13 which included all screened subjects who received a study vaccination \& provided evaluable serum samples at month 0 and atleast from month 2 to 13 and provided results for atleast one serogroup or serogroup B test strain.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| ABCWY_ 0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | M07-0241084 strain (Month 0) | 2.26 Titers |
| ABCWY_ 0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | NZ98/254 strain (Month 2) | 2.67 Titers |
| ABCWY_ 0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | NZ98/254 strain (Month 3) | 27.17 Titers |
| ABCWY_ 0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | NZ98/254 strain (Month 7) | 3.00 Titers |
| ABCWY_ 0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | NZ98/254 strain (Month 13) | 2.33 Titers |
| ABCWY_ 0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | M14459 strain(Month 0) | 1.37 Titers |
| ABCWY_ 0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | M14459 strain (Month 2) | 2.83 Titers |
| ABCWY_ 0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | M14459 strain (Month 3) | 18.29 Titers |
| ABCWY_ 0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | M14459 strain (Month 7) | 3.52 Titers |
| ABCWY_ 0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | M14459 strain (Month 13) | 2.46 Titers |
| ABCWY_ 0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | NZ98/254 strain (Month 0) | 1.22 Titers |
| ABCWY_ 0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | M07-0241084 strain (Month 2) | 5.09 Titers |
| ABCWY_ 0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | M07-0241084 strain(Month 3) | 13.91 Titers |
| ABCWY_ 0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | M07-0241084 strain (Month 7) | 5.42 Titers |
| ABCWY_ 0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | M07-0241084 strain(Month 13) | 4.45 Titers |
| ABCWY_ 0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | 96217 strain (Month 0) | 2.32 Titers |
| ABCWY_ 0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | 96217 strain(Month 2) | 16.48 Titers |
| ABCWY_ 0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | 96217 strain(Month 3) | 263.56 Titers |
| ABCWY_ 0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | 96217 strain (Month 7) | 61.46 Titers |
| ABCWY_ 0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | 96217 strain (Month 13) | 33.07 Titers |
| ABCWY_ 0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup A (Month 0) | 1.37 Titers |
| ABCWY_ 0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup A (Month 2) | 4.05 Titers |
| ABCWY_ 0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup A (Month 3) | 106.70 Titers |
| ABCWY_ 0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup A (Month 7) | 14.15 Titers |
| ABCWY_ 0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup A (Month 13) | 5.80 Titers |
| ABCWY_ 0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup C (Month 0) | 3.46 Titers |
| ABCWY_ 0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup C (Month 2) | 9.47 Titers |
| ABCWY_ 0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup C (Month 3) | 41.25 Titers |
| ABCWY_ 0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup C (Month 7) | 11.03 Titers |
| ABCWY_ 0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup C (Month 13) | 8.45 Titers |
| ABCWY_ 0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup W (Month 0) | 6.43 Titers |
| ABCWY_ 0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup W (Month 2) | 17.43 Titers |
| ABCWY_ 0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup W (Month 3) | 138.43 Titers |
| ABCWY_ 0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup W (Month 7) | 22.53 Titers |
| ABCWY_ 0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup W (Month 13) | 12.63 Titers |
| ABCWY_ 0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup Y (Month 0) | 1.72 Titers |
| ABCWY_ 0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup Y (Month 2) | 2.36 Titers |
| ABCWY_ 0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup Y (Month 3) | 3.12 Titers |
| ABCWY_ 0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup Y (Month 7) | 2.44 Titers |
| ABCWY_ 0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup Y (Month 13) | 2.28 Titers |
| rMenB_0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup C (Month 3) | 184.05 Titers |
| rMenB_0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup A (Month 0) | 1.17 Titers |
| rMenB_0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup C (Month 2) | 31.56 Titers |
| rMenB_0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup A (Month 2) | 8.35 Titers |
| rMenB_0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | NZ98/254 strain (Month 13) | 1.93 Titers |
| rMenB_0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup C (Month 0) | 3.38 Titers |
| rMenB_0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup A (Month 3) | 68.85 Titers |
| rMenB_0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup Y (Month 13) | 18.13 Titers |
| rMenB_0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup A (Month 13) | 4.64 Titers |
| rMenB_0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup Y (Month 3) | 90.61 Titers |
| rMenB_0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup A (Month 7) | 11.49 Titers |
| rMenB_0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | M07-0241084 strain (Month 0) | 2.07 Titers |
| rMenB_0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | NZ98/254 strain (Month 7) | 2.41 Titers |
| rMenB_0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup Y (Month 0) | 1.40 Titers |
| rMenB_0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | M07-0241084 strain (Month 2) | 4.30 Titers |
| rMenB_0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | M14459 strain (Month 2) | 2.55 Titers |
| rMenB_0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | NZ98/254 strain (Month 3) | 11.46 Titers |
| rMenB_0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | M07-0241084 strain(Month 3) | 8.82 Titers |
| rMenB_0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | NZ98/254 strain (Month 2) | 2.27 Titers |
| rMenB_0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | M07-0241084 strain (Month 7) | 4.68 Titers |
| rMenB_0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | M14459 strain (Month 7) | 3.24 Titers |
| rMenB_0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | NZ98/254 strain (Month 0) | 1.22 Titers |
| rMenB_0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup W (Month 7) | 79.96 Titers |
| rMenB_0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | M07-0241084 strain(Month 13) | 4.01 Titers |
| rMenB_0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup W (Month 3) | 214.70 Titers |
| rMenB_0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | 96217 strain (Month 0) | 2.84 Titers |
| rMenB_0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | M14459 strain (Month 3) | 12.85 Titers |
| rMenB_0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup W (Month 2) | 50.71 Titers |
| rMenB_0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | 96217 strain(Month 2) | 11.62 Titers |
| rMenB_0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | M14459 strain(Month 0) | 1.22 Titers |
| rMenB_0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup W (Month 0) | 4.75 Titers |
| rMenB_0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup Y (Month 2) | 19.43 Titers |
| rMenB_0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | 96217 strain(Month 3) | 169.65 Titers |
| rMenB_0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup W (Month 13) | 45.63 Titers |
| rMenB_0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup C (Month 13) | 37.45 Titers |
| rMenB_0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | 96217 strain (Month 7) | 43.01 Titers |
| rMenB_0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup Y (Month 7) | 34.27 Titers |
| rMenB_0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | M14459 strain (Month 13) | 2.29 Titers |
| rMenB_0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | 96217 strain (Month 13) | 22.48 Titers |
| rMenB_0_2 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup C (Month 7) | 80.70 Titers |
| ABCWY_0_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | M07-0241084 strain (Month 7) | 3.36 Titers |
| ABCWY_0_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | 96217 strain (Month 7) | 37.26 Titers |
| ABCWY_0_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup A (Month 0) | 1.38 Titers |
| ABCWY_0_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | M14459 strain (Month 3) | 5.30 Titers |
| ABCWY_0_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup C (Month 2) | 163.28 Titers |
| ABCWY_0_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup Y (Month 7) | 27.86 Titers |
| ABCWY_0_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup C (Month 0) | 3.87 Titers |
| ABCWY_0_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup W (Month 7) | 74.84 Titers |
| ABCWY_0_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup A (Month 2) | 85.49 Titers |
| ABCWY_0_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | NZ98/254 strain (Month 13) | 1.81 Titers |
| ABCWY_0_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | 96217 strain (Month 13) | 24.00 Titers |
| ABCWY_0_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup A (Month 13) | 5.90 Titers |
| ABCWY_0_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | NZ98/254 strain (Month 7) | 1.88 Titers |
| ABCWY_0_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | M07-0241084 strain(Month 13) | 3.07 Titers |
| ABCWY_0_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup A (Month 3) | 52.42 Titers |
| ABCWY_0_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | M14459 strain (Month 7) | 2.19 Titers |
| ABCWY_0_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup W (Month 3) | 125.70 Titers |
| ABCWY_0_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup Y (Month 3) | 42.97 Titers |
| ABCWY_0_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | 96217 strain(Month 3) | 82.23 Titers |
| ABCWY_0_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup W (Month 2) | 175.57 Titers |
| ABCWY_0_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup A (Month 7) | 9.88 Titers |
| ABCWY_0_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup C (Month 7) | 76.97 Titers |
| ABCWY_0_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | M07-0241084 strain (Month 0) | 2.01 Titers |
| ABCWY_0_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | M14459 strain (Month 2) | 9.23 Titers |
| ABCWY_0_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | 96217 strain (Month 0) | 2.88 Titers |
| ABCWY_0_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | NZ98/254 strain (Month 3) | 3.15 Titers |
| ABCWY_0_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup C (Month 13) | 38.42 Titers |
| ABCWY_0_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | M14459 strain (Month 13) | 1.95 Titers |
| ABCWY_0_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | M07-0241084 strain (Month 2) | 6.73 Titers |
| ABCWY_0_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup W (Month 0) | 4.54 Titers |
| ABCWY_0_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup Y (Month 13) | 15.19 Titers |
| ABCWY_0_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | NZ98/254 strain (Month 2) | 6.50 Titers |
| ABCWY_0_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup Y (Month 0) | 1.68 Titers |
| ABCWY_0_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup Y (Month 2) | 63.45 Titers |
| ABCWY_0_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | M07-0241084 strain(Month 3) | 4.39 Titers |
| ABCWY_0_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup W (Month 13) | 46.83 Titers |
| ABCWY_0_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | 96217 strain(Month 2) | 124.75 Titers |
| ABCWY_0_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | NZ98/254 strain (Month 0) | 1.21 Titers |
| ABCWY_0_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | M14459 strain(Month 0) | 1.22 Titers |
| ABCWY_0_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup C (Month 3) | 119.71 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | M14459 strain (Month 2) | 2.34 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup W (Month 13) | 96.43 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | M14459 strain (Month 3) | 2.15 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | M14459 strain (Month 7) | 27.47 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | M14459 strain (Month 13) | 3.22 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | M07-0241084 strain (Month 0) | 2.06 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | M07-0241084 strain (Month 2) | 3.51 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | M07-0241084 strain(Month 3) | 3.30 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup Y (Month 0) | 1.24 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | M07-0241084 strain (Month 7) | 15.70 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | M07-0241084 strain(Month 13) | 5.42 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | 96217 strain (Month 0) | 2.39 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | 96217 strain(Month 2) | 11.61 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | 96217 strain(Month 3) | 8.61 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | 96217 strain (Month 7) | 264.85 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup Y (Month 2) | 16.41 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | 96217 strain (Month 13) | 42.27 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup A (Month 0) | 1.08 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup A (Month 2) | 7.64 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup Y (Month 13) | 42.14 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup A (Month 3) | 5.31 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup A (Month 7) | 165.14 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup A (Month 13) | 15.20 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup Y (Month 3) | 15.95 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup C (Month 0) | 3.36 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup C (Month 2) | 37.24 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup C (Month 3) | 31.50 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup C (Month 7) | 260.57 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup C (Month 13) | 57.48 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup W (Month 0) | 4.29 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup Y (Month 7) | 152.73 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup W (Month 2) | 59.37 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup W (Month 3) | 59.26 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | NZ98/254 strain (Month 0) | 1.13 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup W (Month 7) | 340.85 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | NZ98/254 strain (Month 2) | 1.92 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | NZ98/254 strain (Month 3) | 1.69 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | NZ98/254 strain (Month 7) | 14.30 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | NZ98/254 strain (Month 13) | 2.57 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | M14459 strain(Month 0) | 1.21 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | M07-0241084 strain (Month 0) | 2.59 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup Y (Month 2) | 27.00 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup C (Month 3) | 41.15 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup Y (Month 13) | 231.39 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | 96217 strain (Month 13) | 264.32 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup C (Month 7) | 24.59 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | 96217 strain (Month 7) | 5.19 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | 96217 strain(Month 3) | 7.72 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | NZ98/254 strain (Month 13) | 17.08 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup C (Month 13) | 303.63 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | 96217 strain(Month 2) | 11.94 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup W (Month 0) | 4.95 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | 96217 strain (Month 0) | 2.78 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | M14459 strain (Month 7) | 1.95 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup W (Month 2) | 94.34 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup Y (Month 7) | 14.29 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | M07-0241084 strain(Month 13) | 15.68 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup W (Month 13) | 478.73 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup W (Month 3) | 86.66 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup Y (Month 0) | 1.79 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | M07-0241084 strain (Month 7) | 2.96 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | M14459 strain (Month 2) | 3.94 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | NZ98/254 strain (Month 0) | 1.12 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | M14459 strain(Month 0) | 1.34 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | M07-0241084 strain(Month 3) | 3.55 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | NZ98/254 strain (Month 2) | 3.87 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup W (Month 7) | 58.19 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | M07-0241084 strain (Month 2) | 4.90 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | NZ98/254 strain (Month 3) | 2.38 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup C (Month 2) | 54.75 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | M14459 strain (Month 3) | 3.11 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup A (Month 7) | 3.25 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup A (Month 3) | 8.77 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | NZ98/254 strain (Month 7) | 1.75 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup A (Month 13) | 168.23 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup A (Month 2) | 22.54 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup C (Month 0) | 3.80 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup Y (Month 3) | 18.76 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup A (Month 0) | 1.19 Titers |
| ABCWY_0_11 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | M14459 strain (Month 13) | 29.01 Titers |
| ABCWY_0_2_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | M07-0241084 strain (Month 7) | 19.18 Titers |
| ABCWY_0_2_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup C (Month 2) | 40.29 Titers |
| ABCWY_0_2_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup Y (Month 3) | 97.12 Titers |
| ABCWY_0_2_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | M14459 strain (Month 13) | 3.17 Titers |
| ABCWY_0_2_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | 96217 strain (Month 13) | 47.22 Titers |
| ABCWY_0_2_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup W (Month 13) | 95.90 Titers |
| ABCWY_0_2_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | M07-0241084 strain(Month 3) | 9.29 Titers |
| ABCWY_0_2_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup C (Month 3) | 236.97 Titers |
| ABCWY_0_2_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | NZ98/254 strain (Month 7) | 18.24 Titers |
| ABCWY_0_2_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup C (Month 0) | 2.99 Titers |
| ABCWY_0_2_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | 96217 strain (Month 7) | 306.14 Titers |
| ABCWY_0_2_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | M14459 strain (Month 2) | 2.40 Titers |
| ABCWY_0_2_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | NZ98/254 strain (Month 0) | 1.06 Titers |
| ABCWY_0_2_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup C (Month 7) | 476.44 Titers |
| ABCWY_0_2_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup A (Month 7) | 140.73 Titers |
| ABCWY_0_2_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | 96217 strain(Month 3) | 162.27 Titers |
| ABCWY_0_2_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup A (Month 3) | 78.30 Titers |
| ABCWY_0_2_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | M07-0241084 strain (Month 2) | 4.20 Titers |
| ABCWY_0_2_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | M14459 strain(Month 0) | 1.17 Titers |
| ABCWY_0_2_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup C (Month 13) | 113.72 Titers |
| ABCWY_0_2_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | 96217 strain(Month 2) | 8.54 Titers |
| ABCWY_0_2_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup Y (Month 2) | 19.82 Titers |
| ABCWY_0_2_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | 96217 strain (Month 0) | 2.57 Titers |
| ABCWY_0_2_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | NZ98/254 strain (Month 13) | 2.82 Titers |
| ABCWY_0_2_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | NZ98/254 strain (Month 2) | 2.20 Titers |
| ABCWY_0_2_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup W (Month 0) | 4.46 Titers |
| ABCWY_0_2_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | M14459 strain (Month 7) | 28.56 Titers |
| ABCWY_0_2_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup A (Month 2) | 5.18 Titers |
| ABCWY_0_2_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup Y (Month 0) | 1.34 Titers |
| ABCWY_0_2_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup Y (Month 13) | 53.78 Titers |
| ABCWY_0_2_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | M07-0241084 strain (Month 0) | 1.83 Titers |
| ABCWY_0_2_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup W (Month 2) | 47.54 Titers |
| ABCWY_0_2_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | M14459 strain (Month 3) | 15.24 Titers |
| ABCWY_0_2_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | M07-0241084 strain(Month 13) | 5.80 Titers |
| ABCWY_0_2_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup A (Month 0) | 1.06 Titers |
| ABCWY_0_2_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | NZ98/254 strain (Month 3) | 12.80 Titers |
| ABCWY_0_2_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup W (Month 7) | 270.12 Titers |
| ABCWY_0_2_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup W (Month 3) | 200.91 Titers |
| ABCWY_0_2_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup Y (Month 7) | 180.33 Titers |
| ABCWY_0_2_6 Group | hSBA GMTs Against Serogroups A, C, W and Y and Serogroup B Test Strains at All the Relevant Time Points for All Schedules. | Serogroup A (Month 13) | 13.32 Titers |
Secondary
Number of Participants Reporting Any Serious AE (SAE), Medically Attended AEs (MAAEs), AEs Leading to Premature Withdrawal
The number of participants reporting any SAE, possibly or probably related SAE(s), medically-attended AEs, AEs leading to premature withdrawal, AEs leading to death, AEs leading to hospitalization and AEs leading to dose reduction, interruption and delay in study vaccination during the entire study period is reported.
Time frame: During the entire study period (Month 0 to Month 13)
Population: Analysis was done on all subjects in the Unsolicited Safety Set-all screened subjects who provided informed consent \& provided demographic \&/or other baseline screening measurements, regardless of the subject's randomization \& vaccination status, received a subject ID, received a study vaccination and have post-vaccination unsolicited AE records.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Serious AE (SAE), Medically Attended AEs (MAAEs), AEs Leading to Premature Withdrawal | AE(s) leading to premature withdrawal | 2 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Serious AE (SAE), Medically Attended AEs (MAAEs), AEs Leading to Premature Withdrawal | Any SAE(s) | 9 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Serious AE (SAE), Medically Attended AEs (MAAEs), AEs Leading to Premature Withdrawal | AE(s)leadingtodosereduction,interruption,vaccdelay | 8 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Serious AE (SAE), Medically Attended AEs (MAAEs), AEs Leading to Premature Withdrawal | AE(s) leading to Hospitalization | 9 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Serious AE (SAE), Medically Attended AEs (MAAEs), AEs Leading to Premature Withdrawal | Medically Attended AE(s) | 103 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Serious AE (SAE), Medically Attended AEs (MAAEs), AEs Leading to Premature Withdrawal | Possibly or Probably Related SAE(s) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Serious AE (SAE), Medically Attended AEs (MAAEs), AEs Leading to Premature Withdrawal | AE(s) leading to Death | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Serious AE (SAE), Medically Attended AEs (MAAEs), AEs Leading to Premature Withdrawal | AE(s) leading to Hospitalization | 1 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Serious AE (SAE), Medically Attended AEs (MAAEs), AEs Leading to Premature Withdrawal | AE(s) leading to premature withdrawal | 6 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Serious AE (SAE), Medically Attended AEs (MAAEs), AEs Leading to Premature Withdrawal | Possibly or Probably Related SAE(s) | 1 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Serious AE (SAE), Medically Attended AEs (MAAEs), AEs Leading to Premature Withdrawal | Any SAE(s) | 3 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Serious AE (SAE), Medically Attended AEs (MAAEs), AEs Leading to Premature Withdrawal | AE(s)leadingtodosereduction,interruption,vaccdelay | 8 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Serious AE (SAE), Medically Attended AEs (MAAEs), AEs Leading to Premature Withdrawal | Medically Attended AE(s) | 97 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Serious AE (SAE), Medically Attended AEs (MAAEs), AEs Leading to Premature Withdrawal | AE(s) leading to Death | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Serious AE (SAE), Medically Attended AEs (MAAEs), AEs Leading to Premature Withdrawal | AE(s)leadingtodosereduction,interruption,vaccdelay | 7 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Serious AE (SAE), Medically Attended AEs (MAAEs), AEs Leading to Premature Withdrawal | Any SAE(s) | 8 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Serious AE (SAE), Medically Attended AEs (MAAEs), AEs Leading to Premature Withdrawal | Possibly or Probably Related SAE(s) | 1 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Serious AE (SAE), Medically Attended AEs (MAAEs), AEs Leading to Premature Withdrawal | Medically Attended AE(s) | 68 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Serious AE (SAE), Medically Attended AEs (MAAEs), AEs Leading to Premature Withdrawal | AE(s) leading to premature withdrawal | 4 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Serious AE (SAE), Medically Attended AEs (MAAEs), AEs Leading to Premature Withdrawal | AE(s) leading to Death | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Serious AE (SAE), Medically Attended AEs (MAAEs), AEs Leading to Premature Withdrawal | AE(s) leading to Hospitalization | 7 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Serious AE (SAE), Medically Attended AEs (MAAEs), AEs Leading to Premature Withdrawal | AE(s) leading to premature withdrawal | 2 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Serious AE (SAE), Medically Attended AEs (MAAEs), AEs Leading to Premature Withdrawal | Medically Attended AE(s) | 57 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Serious AE (SAE), Medically Attended AEs (MAAEs), AEs Leading to Premature Withdrawal | Any SAE(s) | 7 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Serious AE (SAE), Medically Attended AEs (MAAEs), AEs Leading to Premature Withdrawal | AE(s) leading to Death | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Serious AE (SAE), Medically Attended AEs (MAAEs), AEs Leading to Premature Withdrawal | AE(s) leading to Hospitalization | 6 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Serious AE (SAE), Medically Attended AEs (MAAEs), AEs Leading to Premature Withdrawal | Possibly or Probably Related SAE(s) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Serious AE (SAE), Medically Attended AEs (MAAEs), AEs Leading to Premature Withdrawal | AE(s)leadingtodosereduction,interruption,vaccdelay | 2 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Serious AE (SAE), Medically Attended AEs (MAAEs), AEs Leading to Premature Withdrawal | AE(s) leading to Hospitalization | 1 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Serious AE (SAE), Medically Attended AEs (MAAEs), AEs Leading to Premature Withdrawal | Any SAE(s) | 2 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Serious AE (SAE), Medically Attended AEs (MAAEs), AEs Leading to Premature Withdrawal | Medically Attended AE(s) | 67 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Serious AE (SAE), Medically Attended AEs (MAAEs), AEs Leading to Premature Withdrawal | Possibly or Probably Related SAE(s) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Serious AE (SAE), Medically Attended AEs (MAAEs), AEs Leading to Premature Withdrawal | AE(s) leading to premature withdrawal | 1 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Serious AE (SAE), Medically Attended AEs (MAAEs), AEs Leading to Premature Withdrawal | AE(s)leadingtodosereduction,interruption,vaccdelay | 4 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Serious AE (SAE), Medically Attended AEs (MAAEs), AEs Leading to Premature Withdrawal | AE(s) leading to Death | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Serious AE (SAE), Medically Attended AEs (MAAEs), AEs Leading to Premature Withdrawal | AE(s)leadingtodosereduction,interruption,vaccdelay | 5 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Serious AE (SAE), Medically Attended AEs (MAAEs), AEs Leading to Premature Withdrawal | Possibly or Probably Related SAE(s) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Serious AE (SAE), Medically Attended AEs (MAAEs), AEs Leading to Premature Withdrawal | Medically Attended AE(s) | 79 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Serious AE (SAE), Medically Attended AEs (MAAEs), AEs Leading to Premature Withdrawal | AE(s) leading to Hospitalization | 6 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Serious AE (SAE), Medically Attended AEs (MAAEs), AEs Leading to Premature Withdrawal | AE(s) leading to Death | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Serious AE (SAE), Medically Attended AEs (MAAEs), AEs Leading to Premature Withdrawal | AE(s) leading to premature withdrawal | 3 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Serious AE (SAE), Medically Attended AEs (MAAEs), AEs Leading to Premature Withdrawal | Any SAE(s) | 6 Participants |
Secondary
Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7.
Number of participants reporting any solicited local or systemic AEs and other indicators of reactogenicity from Day 1 (6 hours) to Day 7 after any meningococcal vaccination is reported.
Time frame: At Day 1 (6 hours) to Day 7 after vaccination
Population: Analysis was done on all subjects in the Solicited Safety Set-all screened subjects who provided informed consent \& provided demographic \&/ other baseline screening measurements,regardless of the subject's randomization \& vaccination status in the trial,received a subject ID,provided post-vaccination reactogenicity data \& received study vaccination
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Pain/Fever treatment(3) | 38 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Erythema(4thvacc) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3AppetiteLoss(2vacc) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Arthralgia(4th vacc) | 8 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Arthralgia(5th vacc) | 8 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Fatigue (4th vacc) | 50 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Myalgia (3rd vacc) | 52 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Erythema (5th vacc) | 1 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Myalgia (1st vacc) | 62 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Garde 3 Fatigue(3rd vacc) | 4 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Fever (1st vacc) | 5 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Pain/Fever treatment(2) | 3 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Fatigue (3rd vacc) | 106 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Erythema(5thvacc) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Myalgia(4th vacc) | 1 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Fever (2nd vacc) | 2 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Pain (1st vacc) | 9 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Nausea(1stvacc) | 1 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Pain/Fever treatment(1) | 31 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | AnyInduration(1st vacc) | 21 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Chills (1st vacc) | 45 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Fatigue(2nd vacc) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | AnyAppetiteLoss(3vacc) | 28 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Pain (2nd vacc) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Nausea (3rd vacc) | 35 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Induration(1vacc) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Headache(5thvacc) | 1 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Fatigue (2nd vacc) | 61 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Fever (3rd vacc) | 6 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Pain/Fever prevention(5) | 5 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Fatigue(1st vacc) | 7 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | AnyInduration(2nd vacc) | 2 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Chills(1stvacc) | 1 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Fever (4th vacc) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Myalgia(5th vacc) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Nausea (1st vacc) | 42 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Pain/Fever prevention(4) | 6 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Induration(2vacc) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3AppetiteLoss(3vacc) | 1 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Fatigue (1st vacc) | 126 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Pain (4th vacc) | 1 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Local AE | 224 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Headache (5th vacc) | 64 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | AnyInduration(3rd vacc) | 24 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Arthralgia(5thvacc) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Induration(5th vacc) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Arthralgia(4thvacc) | 1 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Pain/Fever prevention(3) | 32 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Fever (5th vacc) | 5 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Induration(3vacc) | 2 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Headache(4thvacc) | 3 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | AnyInduration(5th vacc) | 2 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Pain (2nd vacc) | 32 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Systemic AE | 201 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Pain/Fever prevention(2) | 5 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | AnyInduration(4th vacc) | 2 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | AnyAppetiteLoss(4vacc) | 11 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Pain/Fever prevention(1) | 28 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any AE | 225 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Induration(4vacc) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Myalgia(2nd vacc) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Chills (2nd vacc) | 17 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Headache (4th vacc) | 49 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3AppetiteLoss(5vacc) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Chills(2ndvacc) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3AppetiteLoss(4vacc) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Myalgia(3rd vacc) | 2 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Headache(3rdvacc) | 3 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | AnyAppetite Loss(1vacc) | 41 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Nausea (4th vacc) | 21 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | AnyAppetiteLoss(5vacc) | 18 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Pain (5th vacc) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Nausea (5th vacc) | 16 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Pain (3rd vacc) | 11 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Headache (3rd vacc) | 90 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Arthralgia (2nd vacc) | 7 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Chills(3rd vacc) | 33 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Erythema (1st vacc) | 23 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Nausea(3rd vacc) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Arthralgia(3rdvacc) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Nausea(2nd vacc) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Myalgia (2nd vacc) | 15 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Arthralgia(1stvacc) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Erythema (1st vacc) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3AppetiteLoss(1vacc) | 2 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Headache(2ndvacc) | 1 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Chills(3rdvacc) | 1 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Headache (2nd vacc) | 67 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Nausea(4th vacc) | 1 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Erythema (2nd vacc) | 3 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Nausea(5th vacc) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Headache(1stvacc) | 4 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Arthralgia(2ndvacc) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Arthralgia(1st vacc) | 25 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Chills(4thvacc) | 11 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Erythema(2ndvacc) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Myalgia (5th vacc) | 16 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Headache (1st vacc) | 103 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Pain (1st vacc) | 213 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Nausea (2nd vacc) | 17 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Pain/Fever treatment(5) | 3 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Erythema (3rd vacc) | 32 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | AnyAppetiteLoss(2vacc) | 17 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Chills(4thvacc) | 2 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Myalgia (4th vacc) | 17 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Fatigue(5th vacc) | 1 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Myalgia(1st vacc) | 2 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Erythema(3rdvacc) | 2 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Pain (5th vacc) | 83 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Pain (3rd vacc) | 193 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Fatigue (5th vacc) | 62 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Pain/Fever treatment(4) | 7 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Chills (5th vacc) | 19 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Erythema (4th vacc) | 1 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Pain (4th vacc) | 79 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Fatigue(4th vacc) | 2 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Chills(5vacc) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Arthralgia(3rd vacc) | 16 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Arthralgia(1st vacc) | 14 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Nausea(3rd vacc) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Myalgia(4th vacc) | 1 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Pain (4th vacc) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Myalgia (5th vacc) | 26 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Nausea (3rd vacc) | 24 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Myalgia(5th vacc) | 1 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Nausea(2nd vacc) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | AnyAppetite Loss(1vacc) | 33 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Arthralgia(2ndvacc) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3AppetiteLoss(1vacc) | 3 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Nausea (2nd vacc) | 15 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | AnyAppetiteLoss(2vacc) | 11 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Nausea(1stvacc) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3AppetiteLoss(2vacc) | 1 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Pain (5th vacc) | 80 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | AnyAppetiteLoss(3vacc) | 28 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Nausea (1st vacc) | 36 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3AppetiteLoss(3vacc) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Systemic AE | 201 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3AppetiteLoss(5vacc) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | AnyAppetiteLoss(4vacc) | 10 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3AppetiteLoss(4vacc) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Arthralgia (2nd vacc) | 11 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | AnyAppetiteLoss(5vacc) | 14 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Pain (5th vacc) | 1 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Erythema (1st vacc) | 21 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any AE | 228 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Arthralgia(1stvacc) | 1 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Erythema (1st vacc) | 1 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Myalgia (4th vacc) | 20 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Erythema (2nd vacc) | 5 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Arthralgia(5th vacc) | 9 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Erythema(2ndvacc) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Pain/Fever treatment(5) | 8 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Erythema (3rd vacc) | 27 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Pain (1st vacc) | 223 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Pain/Fever treatment(4) | 4 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Erythema(3rdvacc) | 6 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Erythema (4th vacc) | 1 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Pain/Fever treatment(3) | 37 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Erythema(4thvacc) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Pain/Fever treatment(2) | 4 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Erythema (5th vacc) | 1 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Erythema(5thvacc) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Pain/Fever treatment(1) | 45 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | AnyInduration(1st vacc) | 20 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Pain (1st vacc) | 13 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Pain/Fever prevention(5) | 9 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Induration(1vacc) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | AnyInduration(2nd vacc) | 2 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Arthralgia(5thvacc) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Pain/Fever prevention(4) | 5 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Induration(2vacc) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Arthralgia(4thvacc) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Pain/Fever prevention(3) | 34 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | AnyInduration(3rd vacc) | 17 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Induration(3vacc) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Pain/Fever prevention(2) | 7 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | AnyInduration(4th vacc) | 3 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Pain/Fever prevention(1) | 34 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Induration(4vacc) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Pain (2nd vacc) | 34 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | AnyInduration(5th vacc) | 3 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Fever (5th vacc) | 1 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Induration(5th vacc) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Fever (4th vacc) | 2 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Fatigue (1st vacc) | 121 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Fatigue(1st vacc) | 7 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Arthralgia(4th vacc) | 10 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Fever (3rd vacc) | 3 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Fatigue (2nd vacc) | 64 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Fever (2nd vacc) | 6 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Fatigue(2nd vacc) | 3 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Pain (2nd vacc) | 1 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Fatigue (3rd vacc) | 96 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Fever (1st vacc) | 4 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Garde 3 Fatigue(3rd vacc) | 5 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Local AE | 227 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Chills(5vacc) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Fatigue (4th vacc) | 56 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Fatigue(4th vacc) | 3 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Chills (5th vacc) | 23 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Fatigue (5th vacc) | 59 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Chills(4thvacc) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Fatigue(5th vacc) | 2 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Pain (3rd vacc) | 185 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Headache (1st vacc) | 92 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Chills(4thvacc) | 11 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Headache(1stvacc) | 3 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Chills(3rdvacc) | 1 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Headache (2nd vacc) | 47 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Arthralgia(3rdvacc) | 1 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Headache(2ndvacc) | 2 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Chills(3rd vacc) | 33 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Headache (3rd vacc) | 76 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Chills(2ndvacc) | 1 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Headache(3rdvacc) | 4 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Pain (3rd vacc) | 7 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Headache (4th vacc) | 35 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Chills (2nd vacc) | 26 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Headache(4thvacc) | 3 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Chills(1stvacc) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Headache (5th vacc) | 40 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Headache(5thvacc) | 1 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Arthralgia(3rd vacc) | 7 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Chills (1st vacc) | 36 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Myalgia (1st vacc) | 53 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Nausea(5th vacc) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Myalgia(1st vacc) | 4 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Pain (4th vacc) | 77 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Myalgia (2nd vacc) | 20 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Nausea (5th vacc) | 15 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Myalgia(2nd vacc) | 3 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Nausea(4th vacc) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Myalgia (3rd vacc) | 40 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Myalgia(3rd vacc) | 2 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Nausea (4th vacc) | 13 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Erythema(4thvacc) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Arthralgia(5thvacc) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Chills (5th vacc) | 17 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Erythema (4th vacc) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3AppetiteLoss(2vacc) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Fatigue(4th vacc) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Arthralgia(3rdvacc) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Myalgia (3rd vacc) | 13 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Pain/Fever treatment(3) | 2 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Pain (1st vacc) | 142 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Myalgia (1st vacc) | 39 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Fatigue (5th vacc) | 37 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Erythema(3rdvacc) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Chills(4thvacc) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Nausea(1stvacc) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Pain/Fever treatment(4) | 2 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Nausea(5th vacc) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Fatigue(5th vacc) | 4 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Myalgia (5th vacc) | 19 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Erythema (3rd vacc) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Chills(4thvacc) | 10 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Erythema(2ndvacc) | 1 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | AnyAppetiteLoss(2vacc) | 15 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Headache (1st vacc) | 65 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Pain (3rd vacc) | 38 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Nausea (3rd vacc) | 10 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Pain/Fever treatment(5) | 2 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Erythema (2nd vacc) | 8 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Myalgia(1st vacc) | 2 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Headache(1stvacc) | 5 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Local AE | 148 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Chills(3rdvacc) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Nausea (4th vacc) | 9 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Arthralgia(1st vacc) | 13 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3AppetiteLoss(1vacc) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Headache (2nd vacc) | 70 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Nausea (5th vacc) | 8 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Arthralgia(5th vacc) | 8 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Chills(3rd vacc) | 9 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Erythema (1st vacc) | 1 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Nausea (2nd vacc) | 20 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Headache(2ndvacc) | 3 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Erythema (1st vacc) | 16 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Myalgia(4th vacc) | 1 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Arthralgia(1stvacc) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Systemic AE | 143 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Myalgia (2nd vacc) | 27 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Headache (3rd vacc) | 42 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Pain (5th vacc) | 1 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Chills(2ndvacc) | 1 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Pain (4th vacc) | 19 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3AppetiteLoss(4vacc) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Nausea(3rd vacc) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Headache(3rdvacc) | 1 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | AnyAppetite Loss(1vacc) | 28 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | AnyAppetiteLoss(5vacc) | 9 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Chills (2nd vacc) | 26 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Arthralgia (2nd vacc) | 10 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Nausea(2nd vacc) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Headache (4th vacc) | 26 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Pain (3rd vacc) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Pain/Fever prevention(1) | 21 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Myalgia(3rd vacc) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Induration(4vacc) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | AnyAppetiteLoss(4vacc) | 4 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | AnyInduration(4th vacc) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Fever (5th vacc) | 2 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Induration(3vacc) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3AppetiteLoss(5vacc) | 1 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | AnyInduration(5th vacc) | 1 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Pain (2nd vacc) | 122 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Myalgia(2nd vacc) | 1 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Pain/Fever prevention(2) | 18 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | AnyInduration(3rd vacc) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Headache(4thvacc) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Induration(5th vacc) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Pain/Fever prevention(3) | 3 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Fever (4th vacc) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any AE | 153 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Induration(2vacc) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Chills(1stvacc) | 1 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Fatigue (1st vacc) | 84 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Arthralgia(4th vacc) | 5 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | AnyInduration(2nd vacc) | 10 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Fever (3rd vacc) | 2 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Pain/Fever prevention(4) | 3 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Myalgia(5th vacc) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Fatigue(1st vacc) | 4 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3AppetiteLoss(3vacc) | 1 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Nausea(4th vacc) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Pain (1st vacc) | 2 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Induration(1vacc) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Headache (5th vacc) | 33 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Fatigue (2nd vacc) | 64 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Pain/Fever prevention(5) | 4 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Fever (2nd vacc) | 4 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Arthralgia(3rd vacc) | 4 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | AnyInduration(1st vacc) | 12 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Pain (5th vacc) | 58 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Fatigue(2nd vacc) | 4 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Chills (1st vacc) | 41 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Erythema(5thvacc) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Fever (1st vacc) | 5 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Pain/Fever treatment(1) | 27 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | AnyAppetiteLoss(3vacc) | 7 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Fatigue (3rd vacc) | 44 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Pain (2nd vacc) | 5 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Arthralgia(2ndvacc) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Arthralgia(4thvacc) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Erythema (5th vacc) | 1 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Headache(5thvacc) | 2 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Garde 3 Fatigue(3rd vacc) | 1 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Pain (4th vacc) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Chills(5vacc) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Myalgia (4th vacc) | 11 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Pain/Fever treatment(2) | 20 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Nausea (1st vacc) | 28 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Fatigue (4th vacc) | 37 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | AnyInduration(4th vacc) | 10 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any AE | 131 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Local AE | 129 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Systemic AE | 117 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Pain (1st vacc) | 126 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Pain (1st vacc) | 10 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Pain (2nd vacc) | 41 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Pain (2nd vacc) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Pain (3rd vacc) | 26 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Pain (3rd vacc) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Pain (4th vacc) | 106 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Pain (4th vacc) | 10 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Pain (5th vacc) | 48 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Pain (5th vacc) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Erythema (1st vacc) | 11 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Erythema (1st vacc) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Erythema (2nd vacc) | 1 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Erythema(2ndvacc) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Erythema (3rd vacc) | 2 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Erythema(3rdvacc) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Erythema (4th vacc) | 10 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Erythema(4thvacc) | 1 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Erythema (5th vacc) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Erythema(5thvacc) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | AnyInduration(1st vacc) | 13 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Induration(1vacc) | 1 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | AnyInduration(2nd vacc) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Induration(2vacc) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | AnyInduration(3rd vacc) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Induration(3vacc) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Induration(4vacc) | 1 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | AnyInduration(5th vacc) | 2 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Induration(5th vacc) | 1 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Fatigue (1st vacc) | 68 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Fatigue(1st vacc) | 3 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Fatigue (2nd vacc) | 40 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Fatigue(2nd vacc) | 2 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Fatigue (3rd vacc) | 32 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Garde 3 Fatigue(3rd vacc) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Fatigue (4th vacc) | 51 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Fatigue(4th vacc) | 5 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Fatigue (5th vacc) | 41 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Fatigue(5th vacc) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Headache (1st vacc) | 52 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Headache(1stvacc) | 2 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Headache (2nd vacc) | 36 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Headache(2ndvacc) | 2 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Headache (3rd vacc) | 28 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Headache(3rdvacc) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Headache (4th vacc) | 44 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Headache(4thvacc) | 2 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Headache (5th vacc) | 33 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Headache(5thvacc) | 1 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Myalgia (1st vacc) | 34 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Myalgia(1st vacc) | 2 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Myalgia (2nd vacc) | 15 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Myalgia(2nd vacc) | 1 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Myalgia (3rd vacc) | 10 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Myalgia(3rd vacc) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Myalgia (4th vacc) | 26 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Myalgia(4th vacc) | 2 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Myalgia (5th vacc) | 12 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Myalgia(5th vacc) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | AnyAppetite Loss(1vacc) | 22 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3AppetiteLoss(1vacc) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | AnyAppetiteLoss(2vacc) | 12 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3AppetiteLoss(2vacc) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | AnyAppetiteLoss(3vacc) | 7 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3AppetiteLoss(3vacc) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | AnyAppetiteLoss(4vacc) | 13 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3AppetiteLoss(4vacc) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | AnyAppetiteLoss(5vacc) | 9 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3AppetiteLoss(5vacc) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Nausea (1st vacc) | 17 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Nausea(1stvacc) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Nausea (2nd vacc) | 10 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Nausea(2nd vacc) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Nausea (3rd vacc) | 8 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Nausea(3rd vacc) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Nausea (4th vacc) | 11 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Nausea(4th vacc) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Nausea (5th vacc) | 11 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Nausea(5th vacc) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Chills (1st vacc) | 24 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Chills(1stvacc) | 1 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Chills (2nd vacc) | 12 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Chills(2ndvacc) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Chills(3rd vacc) | 7 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Chills(3rdvacc) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Chills(4thvacc) | 12 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Chills(4thvacc) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Chills (5th vacc) | 11 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Chills(5vacc) | 1 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Fever (1st vacc) | 1 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Fever (2nd vacc) | 2 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Fever (3rd vacc) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Fever (4th vacc) | 3 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Fever (5th vacc) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Pain/Fever prevention(1) | 26 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Pain/Fever prevention(2) | 5 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Pain/Fever prevention(3) | 2 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Pain/Fever prevention(4) | 19 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Pain/Fever prevention(5) | 1 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Pain/Fever treatment(1) | 32 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Pain/Fever treatment(2) | 3 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Pain/Fever treatment(3) | 4 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Pain/Fever treatment(4) | 22 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Pain/Fever treatment(5) | 3 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Arthralgia(1st vacc) | 17 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Arthralgia(1stvacc) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Arthralgia (2nd vacc) | 9 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Arthralgia(2ndvacc) | 1 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Arthralgia(3rd vacc) | 3 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Arthralgia(3rdvacc) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Arthralgia(4th vacc) | 10 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Arthralgia(4thvacc) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Arthralgia(5th vacc) | 6 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Arthralgia(5thvacc) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Pain (3rd vacc) | 16 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Myalgia(3rd vacc) | 2 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Arthralgia(2ndvacc) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Nausea (4th vacc) | 14 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Myalgia (3rd vacc) | 13 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Myalgia(2nd vacc) | 1 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Nausea(4th vacc) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Myalgia (2nd vacc) | 37 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Pain (4th vacc) | 44 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Nausea (5th vacc) | 21 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Myalgia(1st vacc) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Myalgia (1st vacc) | 33 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Nausea(5th vacc) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Headache(5thvacc) | 2 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Pain (3rd vacc) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Chills (1st vacc) | 27 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Headache (5th vacc) | 52 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Headache(4thvacc) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Chills(1stvacc) | 2 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Headache (4th vacc) | 26 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Arthralgia(3rd vacc) | 6 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Chills (2nd vacc) | 32 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Headache(3rdvacc) | 3 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Headache (3rd vacc) | 30 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Chills(2ndvacc) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Headache(2ndvacc) | 4 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Chills(3rd vacc) | 12 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Headache (2nd vacc) | 63 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Headache(1stvacc) | 2 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Chills(3rdvacc) | 1 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Headache (1st vacc) | 63 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Chills(4thvacc) | 9 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Fatigue(5th vacc) | 6 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Fatigue (5th vacc) | 51 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any AE | 151 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Chills(4thvacc) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Fatigue(4th vacc) | 2 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Arthralgia(3rdvacc) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Chills (5th vacc) | 22 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Fatigue (4th vacc) | 35 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Garde 3 Fatigue(3rd vacc) | 1 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Chills(5vacc) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Fatigue (3rd vacc) | 32 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Pain (2nd vacc) | 11 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Fever (1st vacc) | 2 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Fatigue(2nd vacc) | 1 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Fatigue (2nd vacc) | 64 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Fever (2nd vacc) | 9 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Fatigue(1st vacc) | 3 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Pain (2nd vacc) | 135 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Fever (3rd vacc) | 4 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Fatigue (1st vacc) | 68 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Induration(5th vacc) | 1 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Local AE | 148 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Fever (4th vacc) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | AnyInduration(5th vacc) | 16 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Arthralgia(4th vacc) | 7 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Fever (5th vacc) | 3 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Induration(4vacc) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | AnyInduration(4th vacc) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Pain/Fever prevention(1) | 5 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Induration(3vacc) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Pain/Fever prevention(2) | 24 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | AnyInduration(3rd vacc) | 1 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Induration(2vacc) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Pain (1st vacc) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Pain/Fever prevention(3) | 3 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | AnyInduration(2nd vacc) | 11 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Pain/Fever prevention(4) | 3 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Induration(1vacc) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | AnyInduration(1st vacc) | 3 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Arthralgia(5thvacc) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Pain/Fever prevention(5) | 26 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Erythema(5thvacc) | 1 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Arthralgia(4thvacc) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Pain/Fever treatment(1) | 6 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Erythema (5th vacc) | 11 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Erythema(4thvacc) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Pain/Fever treatment(2) | 29 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Erythema (4th vacc) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Pain (1st vacc) | 80 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Pain/Fever treatment(3) | 2 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Erythema(3rdvacc) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Erythema (3rd vacc) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Pain/Fever treatment(4) | 2 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Erythema(2ndvacc) | 3 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Systemic AE | 134 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Pain/Fever treatment(5) | 29 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Erythema (2nd vacc) | 17 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Erythema (1st vacc) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Arthralgia(1st vacc) | 12 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Erythema (1st vacc) | 1 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Arthralgia(5th vacc) | 11 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Arthralgia(1stvacc) | 1 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Pain (5th vacc) | 11 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3AppetiteLoss(4vacc) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Pain (5th vacc) | 119 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | AnyAppetiteLoss(5vacc) | 22 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | AnyAppetiteLoss(4vacc) | 11 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3AppetiteLoss(3vacc) | 1 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3AppetiteLoss(5vacc) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | AnyAppetiteLoss(3vacc) | 11 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Arthralgia (2nd vacc) | 8 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Nausea (1st vacc) | 26 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3AppetiteLoss(2vacc) | 2 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | AnyAppetiteLoss(2vacc) | 19 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Nausea(1stvacc) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3AppetiteLoss(1vacc) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Nausea (2nd vacc) | 26 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | AnyAppetite Loss(1vacc) | 14 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Myalgia(5th vacc) | 1 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Pain (4th vacc) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Nausea(2nd vacc) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Myalgia (5th vacc) | 21 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Nausea (3rd vacc) | 4 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Myalgia(4th vacc) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Myalgia (4th vacc) | 13 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Nausea(3rd vacc) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Arthralgia(4th vacc) | 18 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Myalgia(3rd vacc) | 2 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Arthralgia(5thvacc) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Myalgia (3rd vacc) | 34 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Pain/Fever prevention(1) | 34 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Induration(3vacc) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Nausea (4th vacc) | 23 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | AnyAppetiteLoss(2vacc) | 9 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Myalgia(2nd vacc) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | AnyInduration(3rd vacc) | 20 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Arthralgia(2ndvacc) | 1 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Pain (1st vacc) | 6 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Nausea(4th vacc) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Myalgia (2nd vacc) | 18 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Arthralgia(1st vacc) | 14 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Myalgia(1st vacc) | 3 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Pain/Fever prevention(2) | 7 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Erythema (1st vacc) | 23 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Nausea (5th vacc) | 12 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Induration(2vacc) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Myalgia (1st vacc) | 40 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Nausea (3rd vacc) | 21 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Pain (3rd vacc) | 5 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Pain (5th vacc) | 1 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Nausea(5th vacc) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Headache(5thvacc) | 2 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Arthralgia (2nd vacc) | 7 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Headache (5th vacc) | 37 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Pain/Fever prevention(3) | 21 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | AnyInduration(2nd vacc) | 2 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Chills (1st vacc) | 40 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Nausea(2nd vacc) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Headache(4thvacc) | 4 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Induration(1vacc) | 1 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any AE | 157 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Pain (1st vacc) | 146 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Chills(1stvacc) | 1 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Headache (4th vacc) | 52 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Arthralgia(1stvacc) | 2 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Headache(3rdvacc) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Pain/Fever prevention(4) | 25 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Nausea(1stvacc) | 1 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Chills (2nd vacc) | 15 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | AnyInduration(1st vacc) | 19 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Headache (3rd vacc) | 53 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Pain (5th vacc) | 64 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Arthralgia(3rd vacc) | 11 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3AppetiteLoss(4vacc) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Chills(2ndvacc) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Headache(2ndvacc) | 2 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3AppetiteLoss(1vacc) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Headache (2nd vacc) | 41 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Pain (3rd vacc) | 133 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Pain/Fever prevention(5) | 3 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Chills(3rd vacc) | 22 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Erythema(5thvacc) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Headache(1stvacc) | 3 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | AnyAppetiteLoss(4vacc) | 23 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Nausea(3rd vacc) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Erythema (5th vacc) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Chills(3rdvacc) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Headache (1st vacc) | 64 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Myalgia (5th vacc) | 19 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Fatigue(5th vacc) | 3 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Pain (2nd vacc) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | AnyAppetite Loss(1vacc) | 18 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Chills(4thvacc) | 31 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Pain/Fever treatment(1) | 31 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Fatigue (5th vacc) | 46 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | AnyAppetiteLoss(5vacc) | 7 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Erythema(4thvacc) | 4 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Pain (4th vacc) | 9 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Chills(4thvacc) | 1 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Fatigue(4th vacc) | 3 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Arthralgia(4thvacc) | 2 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Fatigue (4th vacc) | 73 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3AppetiteLoss(3vacc) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Pain/Fever treatment(2) | 4 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Chills (5th vacc) | 13 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Erythema (4th vacc) | 13 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Garde 3 Fatigue(3rd vacc) | 1 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Local AE | 156 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Arthralgia(3rdvacc) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Erythema(3rdvacc) | 1 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Chills(5vacc) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Fatigue (3rd vacc) | 55 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Arthralgia(5th vacc) | 11 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Fatigue(2nd vacc) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Nausea (2nd vacc) | 15 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Pain/Fever treatment(3) | 23 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Fever (1st vacc) | 3 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3AppetiteLoss(5vacc) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Fatigue (2nd vacc) | 49 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Erythema (3rd vacc) | 19 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Pain (2nd vacc) | 51 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | AnyAppetiteLoss(3vacc) | 17 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Fever (2nd vacc) | 3 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Fatigue(1st vacc) | 4 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Systemic AE | 143 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Fatigue (1st vacc) | 76 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Myalgia(4th vacc) | 2 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Pain/Fever treatment(4) | 27 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Fever (3rd vacc) | 4 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Erythema(2ndvacc) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Induration(5th vacc) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3AppetiteLoss(2vacc) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Erythema (2nd vacc) | 2 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Myalgia(5th vacc) | 1 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Fever (4th vacc) | 7 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | AnyInduration(5th vacc) | 1 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Pain (4th vacc) | 138 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade3Induration(4vacc) | 1 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Pain/Fever treatment(5) | 2 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Nausea (1st vacc) | 21 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Fever (5th vacc) | 1 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Grade 3 Erythema (1st vacc) | 2 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | AnyInduration(4th vacc) | 14 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic Adverse Events (AEs) and Other Indicators of Reactogenicity From Day 1 to Day 7. | Any Myalgia (4th vacc) | 39 Participants |
Secondary
Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination.
Number of participants reporting any solicited local or systemic AEs and other indicators of reactogenicity within 30 minutes after each vaccination. Assessed solicited symptoms were Pain, erythema and induration. Assessed solicited systemic symptoms were Fatigue, headache, myalgia, arthralgia, loss of appetite, nausea, chills, and fever (body temperature ≥38.0°C).
Time frame: Within 30 minutes after vaccination
Population: Analysis was done on subjects in Solicited Safety Set - all screened subjects who provided informed consent \& provided demographic \&/or other baseline screening measurements, regardless of the subject's randomization \& vaccination status in the trial, received a subject ID,provided post-vaccination reactogenicity data \& received a study vaccination
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Induration(3rd vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Pain(1st vaccination) | 19 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Induration(5th vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Induration(5th vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Pain(4th vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Induration(4th vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Induration(3rd vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Erythema(5th vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Induration(4th vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Induration(1st vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Erythema(3rd vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Pain(2nd vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Pain(3rd vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Pain(4th vaccination) | 28 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Induration(1st vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Erythema(5th vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Erythema(4th vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Pain(3rd vaccination) | 10 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Induration(2nd vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Erythema(4th vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Erythema(3rd vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Erythema(1st vaccination) | 1 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Induration(2nd vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Pain(5th vaccination) | 19 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Headache(3rd vaccination) | 2 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Pain/Fever prevention(1st vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Nausea(5th vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Nausea(1st vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Appetite Loss(4th vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Chills(5th vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Myalgia(2nd vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Chills(3rd vaccination) | 1 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Fatigue (1st vaccination) | 4 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Arthralgia(4th vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Myalgia(1st vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Appetite Loss(4th vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Fever(5th vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Pain(2nd vaccination) | 10 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Fatigue(1st vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Chills(1st vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Myalgia(1st vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Erythema(1st vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Headache(3rd vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Fever(4th vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Fatigue (2nd vaccination) | 4 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Headache(1st vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | AnyAppetiteLoss(5th vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Pain/Fever treatment(4th vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Pain/Fever treatment(3rd vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Arthralgia(2nd vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Fatigue(2nd vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Appetite Loss(1st vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Fatigue(5th vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Fatigue (5th vaccination) | 1 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Fever(3rd vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Appetite Loss(5th vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Fatigue (3rd vaccination) | 2 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Nausea(1st vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Fatigue(4th vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Pain(1st vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Arthralgia(5th vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Fever(2nd vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Fatigue(3rd vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Headache(4th vaccination) | 3 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Fever(1st vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Arthralgia(4th vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Fatigue (4th vaccination) | 2 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Arthralgia(1st vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Pain/Fever treatment(1st vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Chills(1st vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Pain/Fever treatment(2nd vaccination) | 1 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Headache(4th vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Arthralgia(5th vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Arthralgia(1st vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Gradec3 Chills(2nd vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Headache(2nd vaccination) | 3 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Headache(5th vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Headache(5th vaccination) | 2 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Headache(1st vaccination) | 2 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Appetite Loss(1st vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Pain/Fever prevention(5th vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Nausea(2nd vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Chills(4th vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Myalgia(5th vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Pain/Fever treatment(5th vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Appetite Loss(2nd vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Arthralgia(3rd vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Nausea(3rd vaccination) | 2 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Chills(5th vaccination) | 1 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Erythema(2nd vaccination) | 2 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Myalgia(5th vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Pain/Fever prevention(4th vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Myalgia(4th vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Nausea(3rd vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Chills(3rd vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Appetite Loss(2nd vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Erythema(2nd vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Headache(2nd vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Pain/Fever prevention(3rd vaccination) | 1 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Nausea(4th vaccination) | 2 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Chills(4th vaccination) | 1 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Myalgia(4th vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Arthralgia(3rd vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Appetite Loss(3rd vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Nausea(2nd vaccination) | 2 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Nausea(4th vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Chills(2nd vaccination) | 1 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Pain(5th vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Myalgia(3rd vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Pain/Fever prevention(2nd vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Myalgia(3rd vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Nausea(5th vaccination) | 1 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Arthralgia(2nd vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Appetite Loss(3rd vaccination) | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Myalgia(2nd vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Arthralgia(5th vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Chills(3rd vaccination) | 1 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Headache(1st vaccination) | 3 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Headache(1st vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Gradec3 Chills(2nd vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Headache(2nd vaccination) | 1 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Chills(2nd vaccination) | 1 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Headache(2nd vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Headache(3rd vaccination) | 1 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Nausea(2nd vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Chills(1st vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Headache(3rd vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Chills(1st vaccination) | 1 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Headache(4th vaccination) | 2 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Erythema(1st vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Headache(4th vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Pain/Fever prevention(5th vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Headache(5th vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Headache(5th vaccination) | 1 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Nausea(2nd vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Pain/Fever prevention(4th vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Nausea(3rd vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Nausea(3rd vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Pain/Fever prevention(3rd vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Nausea(4th vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Erythema(2nd vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Pain/Fever prevention(2nd vaccination) | 2 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Nausea(4th vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Nausea(5th vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Pain/Fever prevention(1st vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Nausea(5th vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Pain/Fever treatment(4th vaccination) | 1 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Fever(5th vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Fatigue (1st vaccination) | 6 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Fatigue(1st vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Fever(4th vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Fatigue (2nd vaccination) | 3 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Fever(3rd vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Fatigue(2nd vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Fatigue (3rd vaccination) | 4 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Fever(2nd vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Fatigue(3rd vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Pain(1st vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Fever(1st vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Fatigue (4th vaccination) | 1 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Fatigue(4th vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Appetite Loss(5th vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Fatigue (5th vaccination) | 2 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Pain/Fever treatment(3rd vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | AnyAppetiteLoss(5th vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Fatigue(5th vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Myalgia(1st vaccination) | 1 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Appetite Loss(4th vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Myalgia(1st vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Pain(2nd vaccination) | 12 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Appetite Loss(4th vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Myalgia(2nd vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Myalgia(2nd vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Pain/Fever treatment(5th vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Appetite Loss(3rd vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Myalgia(3rd vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Appetite Loss(3rd vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Myalgia(3rd vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Myalgia(4th vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Pain(5th vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Appetite Loss(2nd vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Myalgia(4th vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Appetite Loss(2nd vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Myalgia(5th vaccination) | 4 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Myalgia(5th vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Pain/Fever treatment(2nd vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Appetite Loss(1st vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Arthralgia(1st vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Appetite Loss(1st vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Arthralgia(1st vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Arthralgia(2nd vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Nausea(1st vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Chills(5th vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Arthralgia(2nd vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Chills(5th vaccination) | 1 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Arthralgia(3rd vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Erythema(2nd vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Arthralgia(3rd vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Chills(4th vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Arthralgia(4th vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Pain/Fever treatment(1st vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Chills(4th vaccination) | 1 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Arthralgia(4th vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Arthralgia(5th vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Nausea(1st vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Chills(3rd vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Induration(2nd vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Erythema(5th vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Pain(1st vaccination) | 4 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Pain(2nd vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Pain(5th vaccination) | 16 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Pain(3rd vaccination) | 11 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Induration(2nd vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Induration(1st vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Induration(3rd vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Induration(3rd vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Induration(4th vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Induration(1st vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Pain(4th vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Induration(4th vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Induration(5th vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Induration(5th vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Erythema(1st vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Pain(4th vaccination) | 22 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Erythema(3rd vaccination) | 1 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Erythema(3rd vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Erythema(4th vaccination) | 1 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Erythema(4th vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Pain(3rd vaccination) | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Erythema(5th vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Pain(2nd vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Pain(3rd vaccination) | 8 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Erythema(5th vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Erythema(3rd vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Induration(5th vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Erythema(4th vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Erythema(1st vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Induration(5th vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Erythema(5th vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Pain(5th vaccination) | 12 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Pain(4th vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Induration(3rd vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Erythema(4th vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Induration(4th vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Induration(3rd vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Induration(2nd vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Induration(2nd vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Erythema(3rd vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Pain(3rd vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Induration(4th vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Induration(1st vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Induration(1st vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Pain(4th vaccination) | 7 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Nausea(5th vaccination) | 3 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Pain/Fever prevention(1st vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Headache(2nd vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Myalgia(3rd vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Pain/Fever treatment(2nd vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Appetite Loss(3rd vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Arthralgia(4th vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Erythema(2nd vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Arthralgia(3rd vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Myalgia(3rd vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Nausea(4th vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Pain/Fever prevention(2nd vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Appetite Loss(2nd vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Nausea(4th vaccination) | 2 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Erythema(2nd vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Myalgia(4th vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Chills(2nd vaccination) | 1 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Chills(4th vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Nausea(3rd vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Pain/Fever prevention(3rd vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Pain/Fever prevention(5th vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Myalgia(4th vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Pain(5th vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Appetite Loss(2nd vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Headache(1st vaccination) | 1 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Pain/Fever treatment(4th vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Arthralgia(3rd vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Myalgia(5th vaccination) | 1 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Nausea(3rd vaccination) | 2 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Pain/Fever prevention(4th vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Appetite Loss(1st vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Nausea(2nd vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Pain/Fever treatment(1st vaccination) | 1 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Myalgia(5th vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Chills(3rd vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Headache(2nd vaccination) | 2 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Headache(5th vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Headache(4th vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Headache(1st vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Arthralgia(1st vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Headache(5th vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Appetite Loss(1st vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Chills(3rd vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Headache(4th vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Arthralgia(4th vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Fever(1st vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Arthralgia(1st vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Fatigue (4th vaccination) | 1 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Pain(1st vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Fatigue(3rd vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Appetite Loss(5th vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Fatigue (3rd vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Chills(1st vaccination) | 1 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Fatigue(4th vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Pain/Fever treatment(5th vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Nausea(2nd vaccination) | 1 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Fever(2nd vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Pain/Fever treatment(3rd vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Chills(5th vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Fatigue (5th vaccination) | 1 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Headache(3rd vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | AnyAppetiteLoss(5th vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Arthralgia(5th vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Fatigue(2nd vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Arthralgia(2nd vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Fatigue(5th vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Fever(3rd vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Fatigue (2nd vaccination) | 1 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Appetite Loss(4th vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Fatigue(1st vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Chills(4th vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Myalgia(1st vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Fever(4th vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Arthralgia(5th vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Pain(1st vaccination) | 12 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Fatigue (1st vaccination) | 6 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Headache(3rd vaccination) | 2 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Myalgia(1st vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Chills(1st vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Appetite Loss(4th vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Gradec3 Chills(2nd vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Fever(5th vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Arthralgia(2nd vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Myalgia(2nd vaccination) | 1 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Pain(2nd vaccination) | 11 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Nausea(5th vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Appetite Loss(3rd vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Erythema(1st vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Nausea(1st vaccination) | 2 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Myalgia(2nd vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Chills(5th vaccination) | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Nausea(1st vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Fever(4th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Erythema(1st vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Erythema(2nd vaccination) | 1 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Erythema(2nd vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Pain(1st vaccination) | 8 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Pain(1st vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Pain(2nd vaccination) | 9 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Pain(5th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Nausea(1st vaccination) | 1 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Nausea(1st vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Nausea(2nd vaccination) | 1 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Nausea(2nd vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Nausea(3rd vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Nausea(3rd vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Nausea(4th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Nausea(4th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Nausea(5th vaccination) | 1 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Nausea(5th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Fatigue (1st vaccination) | 1 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Fatigue(1st vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Fatigue (2nd vaccination) | 1 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Fatigue(2nd vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Fatigue (3rd vaccination) | 1 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Fatigue(3rd vaccination) | 1 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Fatigue (4th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Fatigue(4th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Fatigue (5th vaccination) | 3 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Fatigue(5th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Myalgia(1st vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Myalgia(1st vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Myalgia(2nd vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Myalgia(2nd vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Myalgia(3rd vaccination) | 1 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Myalgia(3rd vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Myalgia(4th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Myalgia(4th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Myalgia(5th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Myalgia(5th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Arthralgia(1st vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Arthralgia(1st vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Arthralgia(2nd vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Arthralgia(2nd vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Arthralgia(3rd vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Arthralgia(3rd vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Arthralgia(4th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Arthralgia(4th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Arthralgia(5th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Arthralgia(5th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Headache(1st vaccination) | 1 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Headache(1st vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Headache(2nd vaccination) | 1 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Headache(2nd vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Headache(3rd vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Headache(3rd vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Headache(4th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Headache(4th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Headache(5th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Headache(5th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Chills(1st vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Chills(1st vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Chills(2nd vaccination) | 1 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Gradec3 Chills(2nd vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Chills(3rd vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Chills(3rd vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Chills(4th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Chills(4th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Chills(5th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Chills(5th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Appetite Loss(1st vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Appetite Loss(1st vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Appetite Loss(2nd vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Appetite Loss(2nd vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Appetite Loss(3rd vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Appetite Loss(3rd vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Appetite Loss(4th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Appetite Loss(4th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | AnyAppetiteLoss(5th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Appetite Loss(5th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Fever(1st vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Fever(2nd vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Fever(3rd vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Fever(5th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Pain/Fever prevention(1st vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Pain/Fever prevention(2nd vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Pain/Fever prevention(3rd vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Pain/Fever prevention(4th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Pain/Fever prevention(5th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Pain/Fever treatment(1st vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Pain/Fever treatment(2nd vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Pain/Fever treatment(3rd vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Pain/Fever treatment(4th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Pain/Fever treatment(5th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Pain(5th vaccination) | 15 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Erythema(5th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Induration(5th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Induration(1st vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Pain(4th vaccination) | 14 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Erythema(5th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Induration(5th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Induration(2nd vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Erythema(1st vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Erythema(4th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Erythema(3rd vaccination) | 1 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Pain(2nd vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Erythema(3rd vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Pain(3rd vaccination) | 7 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Pain(3rd vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Induration(1st vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Induration(3rd vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Induration(4th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Erythema(4th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Induration(2nd vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Pain(4th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Induration(4th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Induration(3rd vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Erythema(3rd vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Induration(1st vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Induration(1st vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Induration(2nd vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Induration(2nd vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Induration(3rd vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Induration(3rd vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Induration(4th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Induration(4th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Induration(5th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Induration(5th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Erythema(1st vaccination) | 1 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Erythema(3rd vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Erythema(4th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Erythema(4th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Erythema(5th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Erythema(5th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Pain(2nd vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Pain(3rd vaccination) | 5 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Pain(3rd vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Pain(4th vaccination) | 8 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Pain(4th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Pain(5th vaccination) | 13 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Arthralgia(5th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Chills(3rd vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Arthralgia(5th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Chills(3rd vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Arthralgia(4th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Arthralgia(4th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Nausea(1st vaccination) | 2 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Chills(4th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Arthralgia(3rd vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Chills(4th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Arthralgia(3rd vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Arthralgia(2nd vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Pain/Fever treatment(1st vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Chills(5th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Arthralgia(2nd vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Chills(5th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Arthralgia(1st vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Arthralgia(1st vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Appetite Loss(1st vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Myalgia(5th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Pain(5th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Appetite Loss(1st vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Myalgia(5th vaccination) | 1 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Myalgia(4th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Pain(2nd vaccination) | 14 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Appetite Loss(2nd vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Myalgia(4th vaccination) | 1 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Erythema(1st vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Appetite Loss(2nd vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Myalgia(3rd vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Myalgia(3rd vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Pain/Fever treatment(2nd vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Appetite Loss(3rd vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Myalgia(2nd vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Appetite Loss(3rd vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Myalgia(2nd vaccination) | 3 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Myalgia(1st vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Appetite Loss(4th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Myalgia(1st vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Pain(1st vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Appetite Loss(4th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Fatigue(5th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Fatigue (5th vaccination) | 1 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | AnyAppetiteLoss(5th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Fatigue(4th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Appetite Loss(5th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Fatigue (4th vaccination) | 1 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Fatigue(3rd vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Pain/Fever treatment(3rd vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Fever(1st vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Fatigue (3rd vaccination) | 1 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Fever(2nd vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Fatigue(2nd vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Fatigue (2nd vaccination) | 2 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Pain(1st vaccination) | 17 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Fever(3rd vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Fatigue(1st vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Fever(4th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Fatigue (1st vaccination) | 2 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Nausea(5th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Erythema(2nd vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Fever(5th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Nausea(5th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Pain/Fever prevention(1st vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Nausea(4th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Nausea(4th vaccination) | 1 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Pain/Fever treatment(5th vaccination) | 1 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Pain/Fever prevention(2nd vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Nausea(3rd vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Pain/Fever treatment(4th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Pain/Fever prevention(3rd vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Nausea(3rd vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Nausea(2nd vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Pain/Fever prevention(4th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Headache(5th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Headache(4th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Nausea(2nd vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Headache(5th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Headache(4th vaccination) | 1 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Headache(3rd vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Chills(1st vaccination) | 2 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Headache(3rd vaccination) | 1 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Erythema(2nd vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Chills(1st vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Headache(2nd vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Headache(2nd vaccination) | 1 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Pain/Fever prevention(5th vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Chills(2nd vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Headache(1st vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Gradec3 Chills(2nd vaccination) | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Headache(1st vaccination) | 1 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Nausea(1st vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Appetite Loss(5th vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Chills(3rd vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Arthralgia(5th vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Nausea(3rd vaccination) | 1 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Arthralgia(4th vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Nausea(1st vaccination) | 2 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Fatigue(3rd vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Chills(3rd vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Pain/Fever prevention(5th vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Arthralgia(4th vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Chills(1st vaccination) | 2 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Pain/Fever prevention(3rd vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Fever(1st vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Chills(4th vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Arthralgia(3rd vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Fatigue (3rd vaccination) | 2 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Arthralgia(3rd vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Erythema(1st vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Headache(3rd vaccination) | 1 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Chills(4th vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Fatigue(2nd vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Arthralgia(2nd vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Pain/Fever treatment(3rd vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Nausea(2nd vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Fever(2nd vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Chills(5th vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Arthralgia(2nd vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Arthralgia(5th vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Arthralgia(1st vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Pain/Fever treatment(1st vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Fatigue (2nd vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Chills(5th vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Pain/Fever treatment(4th vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Arthralgia(1st vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Headache(2nd vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Pain(5th vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Pain/Fever prevention(4th vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Appetite Loss(1st vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Myalgia(5th vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Fever(3rd vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Myalgia(5th vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Fatigue(1st vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Nausea(2nd vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Appetite Loss(1st vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Fatigue (1st vaccination) | 1 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Myalgia(4th vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Erythema(1st vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Chills(2nd vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Fever(4th vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Appetite Loss(2nd vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Myalgia(4th vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Headache(5th vaccination) | 1 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Myalgia(3rd vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Nausea(5th vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Headache(4th vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Appetite Loss(2nd vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Headache(1st vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Myalgia(3rd vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Headache(4th vaccination) | 1 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Fever(5th vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Nausea(5th vaccination) | 1 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Appetite Loss(3rd vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Myalgia(2nd vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Chills(1st vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Myalgia(2nd vaccination) | 1 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Pain/Fever treatment(2nd vaccination) | 1 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Nausea(4th vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Appetite Loss(3rd vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Erythema(2nd vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Myalgia(1st vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Gradec3 Chills(2nd vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Pain(1st vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Pain/Fever prevention(1st vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Appetite Loss(4th vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Myalgia(1st vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Headache(5th vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Fatigue(5th vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Nausea(4th vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Headache(2nd vaccination) | 1 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Appetite Loss(4th vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Headache(3rd vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Fatigue (5th vaccination) | 1 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Headache(1st vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Pain(1st vaccination) | 13 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Pain/Fever prevention(2nd vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | AnyAppetiteLoss(5th vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Fatigue(4th vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Nausea(3rd vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Fatigue (4th vaccination) | 3 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Pain/Fever treatment(5th vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Nausea(1st vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Erythema(5th vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Erythema(4th vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Erythema(4th vaccination) | 1 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Erythema(3rd vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Induration(1st vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Pain(3rd vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Erythema(3rd vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Erythema(2nd vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Induration(5th vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Induration(5th vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Induration(1st vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Pain(4th vaccination) | 17 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Induration(4th vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Induration(4th vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Induration(3rd vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Induration(3rd vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Pain(5th vaccination) | 12 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Pain(4th vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Induration(2nd vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Pain(2nd vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Pain(2nd vaccination) | 9 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Grade 3 Erythema(5th vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Induration(2nd vaccination) | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Solicited Local or Systemic AEs and Other Indicators of Reactogenicity Within 30 Minutes After Vaccination. | Any Pain(3rd vaccination) | 13 Participants |
Secondary
Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination.
An unsolicited adverse event is an adverse event that was not solicited and that was spontaneously communicated by a participant and/or parent/legal guardian who has signed the informed consent. Number of participants reporting any unsolicited AE within 30 minutes after each vaccination.
Time frame: Within 30 minutes after vaccination
Population: Analysis was done on subjects in the Unsolicited Safety Set-all screened subjects who provided informed consent \& demographic \&/or other baseline screening measurements, regardless of the subject's randomization \& vaccination status, received a subject ID, received a study vaccination \& have either post-vaccination reactogenicity data or records.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Asthenia | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Headache | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Syncope | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Injection site bruising | 1 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Pain | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Hypoaesthesia | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Paraesthesia | 1 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Injection site pain | 1 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Injection site warmth | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Fatigue | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Presyncope | 2 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Pruritus allergic | 0 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Dyspnoea | 1 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Dizziness | 3 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Pain | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Headache | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Injection site bruising | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Hypoaesthesia | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Presyncope | 1 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Paraesthesia | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Syncope | 1 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Dizziness | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Injection site pain | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Asthenia | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Dyspnoea | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Injection site warmth | 1 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Fatigue | 0 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Pruritus allergic | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Paraesthesia | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Hypoaesthesia | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Asthenia | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Presyncope | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Headache | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Dyspnoea | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Pruritus allergic | 1 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Injection site warmth | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Pain | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Fatigue | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Injection site pain | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Dizziness | 1 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Injection site bruising | 0 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Syncope | 1 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Hypoaesthesia | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Injection site warmth | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Asthenia | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Dizziness | 2 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Presyncope | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Syncope | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Injection site pain | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Dyspnoea | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Fatigue | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Headache | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Injection site bruising | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Pain | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Paraesthesia | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Pruritus allergic | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Headache | 1 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Asthenia | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Injection site bruising | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Fatigue | 1 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Dyspnoea | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Injection site warmth | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Injection site pain | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Pain | 1 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Syncope | 1 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Presyncope | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Pruritus allergic | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Paraesthesia | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Dizziness | 0 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Hypoaesthesia | 1 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Paraesthesia | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Fatigue | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Pain | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Dizziness | 1 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Injection site bruising | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Presyncope | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Dyspnoea | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Hypoaesthesia | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Asthenia | 1 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Injection site warmth | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Injection site pain | 1 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Headache | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Syncope | 0 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Any Unsolicited AEs Within 30 Minutes After Vaccination. | Pruritus allergic | 0 Participants |
Secondary
Number of Participants Reporting Unsolicited AEs From Day 1 to Day 30 After Any Vaccination.
The number of participants reporting unsolicited AEs and possibly or probably related unsolicited AEs were assessed.
Time frame: Day 1 through Day 30 after any vaccination
Population: Analysis was done on subjects in the Unsolicited Safety Set -all screened subjects who provided informed consent \& provided demographic \&/or other baseline screening measurements, regardless of the subject's randomization \& vaccination status, received a subject ID, received a study vaccination \& have either post-vaccination reactogenicity records.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| ABCWY_ 0_2 Group | Number of Participants Reporting Unsolicited AEs From Day 1 to Day 30 After Any Vaccination. | Any AE(s) | 146 Participants |
| ABCWY_ 0_2 Group | Number of Participants Reporting Unsolicited AEs From Day 1 to Day 30 After Any Vaccination. | Possibly or Probably Related AE(s) | 25 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Unsolicited AEs From Day 1 to Day 30 After Any Vaccination. | Any AE(s) | 148 Participants |
| rMenB_0_2 Group | Number of Participants Reporting Unsolicited AEs From Day 1 to Day 30 After Any Vaccination. | Possibly or Probably Related AE(s) | 31 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Unsolicited AEs From Day 1 to Day 30 After Any Vaccination. | Any AE(s) | 93 Participants |
| ABCWY_0_6 Group | Number of Participants Reporting Unsolicited AEs From Day 1 to Day 30 After Any Vaccination. | Possibly or Probably Related AE(s) | 23 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Unsolicited AEs From Day 1 to Day 30 After Any Vaccination. | Any AE(s) | 76 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Unsolicited AEs From Day 1 to Day 30 After Any Vaccination. | Possibly or Probably Related AE(s) | 16 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Unsolicited AEs From Day 1 to Day 30 After Any Vaccination. | Any AE(s) | 97 Participants |
| ABCWY_0_11 Group | Number of Participants Reporting Unsolicited AEs From Day 1 to Day 30 After Any Vaccination. | Possibly or Probably Related AE(s) | 18 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Unsolicited AEs From Day 1 to Day 30 After Any Vaccination. | Any AE(s) | 104 Participants |
| ABCWY_0_2_6 Group | Number of Participants Reporting Unsolicited AEs From Day 1 to Day 30 After Any Vaccination. | Possibly or Probably Related AE(s) | 27 Participants |
Secondary
Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules.
The kinetic of immune response (at Months 0, 2, 3, 7 and 13) following different vaccination schedules as measured by the percentages of subjects with hSBA titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 against 96217 B strain was assessed.
Time frame: At Month 0, Month 2, Month 3, Month 7 and Month 13.
Population: Analysis was done on the FAS Month 13 which included all screened subjects who received a study vaccination \& provided evaluable serum samples at month 0 and atleast from month 2 to 13 and provided results for atleast one serogroup or serogroup B test strain.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 13) ≥ 16 | 76 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 0) ≥ 128 | 1 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 7) ≥ 16 | 93 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 0) ≥ 8 | 24 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 7) ≥ 5 | 96 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 0) ≥ LLQ (8.6) | 23 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 2) ≥ 32 | 27 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 2) ≥ LLQ (8.6) | 69 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 3) ≥ 128 | 74 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 13) ≥ LLQ (8.6) | 87 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 2) ≥ 16 | 48 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 3) ≥ 32 | 98 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 13) ≥ 8 | 88 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 2) ≥ 5 | 75 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 0) ≥ 16 | 16 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 13) ≥ 5 | 90 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 13) ≥ 128 | 4 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 2) ≥ 8 | 70 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 3) ≥ 5 | 99 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 3) ≥ LLQ (8.6) | 99 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 7) ≥ 8 | 95 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 7) ≥ LLQ (8.6) | 95 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 7) ≥ 64 | 43 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 13) ≥ 64 | 23 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 0) ≥ 32 | 6 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 3) ≥ 64 | 90 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 2) ≥ 128 | 7 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 3) ≥ 16 | 99 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 13) ≥ 32 | 52 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 7) ≥ 128 | 11 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 0) ≥ 64 | 2 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 3) ≥ 8 | 99 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 2) ≥ 64 | 11 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 0) ≥ 5 | 26 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 7) ≥ 32 | 75 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 3) ≥ 5 | 97 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 7) ≥ 8 | 91 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 3) ≥ 32 | 89 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 0) ≥ 16 | 17 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 3) ≥ 64 | 81 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 7) ≥ 5 | 93 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 3) ≥ 128 | 63 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 7) ≥ LLQ (8.6) | 91 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 13) ≥ 32 | 40 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 0) ≥ 32 | 8 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 13) ≥ 128 | 3 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 0) ≥ 64 | 2 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 13) ≥ 16 | 69 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 0) ≥ 128 | 1 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 0) ≥ 5 | 35 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 2) ≥ LLQ (8.6) | 64 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 13) ≥ 8 | 83 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 2) ≥ 5 | 67 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 13) ≥ 5 | 85 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 2) ≥ 8 | 64 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 2) ≥ 16 | 48 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 13) ≥ LLQ (8.6) | 83 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 2) ≥ 32 | 21 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 7) ≥ 128 | 7 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 2) ≥ 64 | 15 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 0) ≥ 8 | 30 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 2) ≥ 128 | 4 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 7) ≥ 64 | 34 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 3) ≥ LLQ (8.6) | 97 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 0) ≥ LLQ (8.6) | 29 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 7) ≥ 32 | 65 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 13) ≥ 64 | 13 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 3) ≥ 8 | 97 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 7) ≥ 16 | 85 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 3) ≥ 16 | 95 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 7) ≥ 128 | 12 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 3) ≥ 32 | 83 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 0) ≥ 64 | 3 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 0) ≥ 16 | 22 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 2) ≥ 64 | 73 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 7) ≥ 16 | 76 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 13) ≥ 16 | 66 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 7) ≥ 64 | 32 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 0) ≥ 32 | 8 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 3) ≥ 64 | 62 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 2) ≥ 128 | 45 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 0) ≥ 8 | 31 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 7) ≥ 8 | 88 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 13) ≥ 32 | 41 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 7) ≥ LLQ (8.6) | 88 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 3) ≥ 8 | 95 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 3) ≥ LLQ (8.6) | 94 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 7) ≥ 5 | 91 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 7) ≥ 32 | 57 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 13) ≥ 5 | 83 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 3) ≥ 16 | 91 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 2) ≥ 8 | 97 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 0) ≥ LLQ (8.6) | 29 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 2) ≥ 5 | 97 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 13) ≥ LLQ (8.6) | 81 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 0) ≥ 5 | 35 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 13) ≥ 128 | 8 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 2) ≥ 16 | 94 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 13) ≥ 64 | 23 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 3) ≥ 128 | 34 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 2) ≥ LLQ (8.6) | 97 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 13) ≥ 8 | 81 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 3) ≥ 5 | 96 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 2) ≥ 32 | 84 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 0) ≥ 128 | 0 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 13) ≥ 8 | 90 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 0) ≥ LLQ (8.6) | 28 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 0) ≥ 5 | 29 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 0) ≥ 8 | 28 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 0) ≥ 16 | 19 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 0) ≥ 32 | 4 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 0) ≥ 64 | 0 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 0) ≥ 128 | 0 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 2) ≥ LLQ (8.6) | 62 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 2) ≥ 5 | 66 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 2) ≥ 8 | 63 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 2) ≥ 16 | 48 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 2) ≥ 32 | 20 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 2) ≥ 64 | 9 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 2) ≥ 128 | 4 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 3) ≥ LLQ (8.6) | 58 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 3) ≥ 5 | 61 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 3) ≥ 8 | 58 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 3) ≥ 16 | 40 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 3) ≥ 32 | 21 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 3) ≥ 64 | 6 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 3) ≥ 128 | 4 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 7) ≥ LLQ (8.6) | 97 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 7) ≥ 5 | 97 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 7) ≥ 8 | 97 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 7) ≥ 16 | 96 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 7) ≥ 32 | 96 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 7) ≥ 64 | 87 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 7) ≥ 128 | 73 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 13) ≥ LLQ (8.6) | 90 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 13) ≥ 5 | 92 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 13) ≥ 16 | 79 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 13) ≥ 32 | 57 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 13) ≥ 64 | 30 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 13) ≥ 128 | 13 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 2) ≥ 128 | 9 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 2) ≥ 5 | 66 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 3) ≥ 8 | 52 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 13) ≥ 5 | 98 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 13) ≥ 64 | 85 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 7) ≥ 64 | 7 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 2) ≥ LLQ (8.6) | 58 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 3) ≥ 5 | 56 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 0) ≥ 128 | 1 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 13) ≥ 8 | 98 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 2) ≥ 64 | 14 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 0) ≥ 8 | 25 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 0) ≥ 64 | 2 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 2) ≥ 32 | 26 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 0) ≥ LLQ (8.6) | 25 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 13) ≥ 16 | 98 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 3) ≥ LLQ (8.6) | 47 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 0) ≥ 32 | 8 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 7) ≥ 128 | 2 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 0) ≥ 16 | 18 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 13) ≥ 128 | 73 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 13) ≥ 32 | 96 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 7) ≥ 32 | 18 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 3) ≥ 128 | 4 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 2) ≥ 16 | 42 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 7) ≥ LLQ (8.6) | 39 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 7) ≥ 8 | 40 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 0) ≥ 5 | 35 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 3) ≥ 64 | 11 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 13) ≥ LLQ (8.6) | 98 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 7) ≥ 16 | 30 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 7) ≥ 5 | 44 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 2) ≥ 8 | 59 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 3) ≥ 32 | 23 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 3) ≥ 16 | 36 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 3) ≥ 16 | 95 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 7) ≥ 8 | 99 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 3) ≥ 8 | 97 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 3) ≥ 5 | 98 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 0) ≥ 5 | 29 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 7) ≥ 16 | 99 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 3) ≥ LLQ (8.6) | 97 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 7) ≥ 32 | 98 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 2) ≥ 128 | 7 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 2) ≥ 64 | 12 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 7) ≥ 64 | 98 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 2) ≥ 32 | 24 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 13) ≥ 64 | 36 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 7) ≥ 128 | 85 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 2) ≥ 16 | 39 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 2) ≥ 8 | 51 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 13) ≥ LLQ (8.6) | 93 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 2) ≥ 5 | 53 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 0) ≥ LLQ (8.6) | 27 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 13) ≥ 5 | 93 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 2) ≥ LLQ (8.6) | 50 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 0) ≥ 128 | 2 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 13) ≥ 8 | 93 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 0) ≥ 64 | 5 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 0) ≥ 32 | 7 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 13) ≥ 16 | 88 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 0) ≥ 16 | 16 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 13) ≥ 128 | 12 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 3) ≥ 128 | 60 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 13) ≥ 32 | 64 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 7) ≥ LLQ (8.6) | 99 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 3) ≥ 64 | 84 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 3) ≥ 32 | 92 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 0) ≥ 8 | 27 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against 96217 B Strain for All Schedules. | 96217 Strain (At Month 7) ≥ 5 | 99 Percentages of subjects |
Secondary
Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules.
The kinetic of immune response (at Months 0, 2, 3, 7 and 13) following different vaccination schedules as measured by the percentages of subjects with hSBA titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 against A human serogroup was assessed.
Time frame: At Month 0, Month 2, Month 3, Month 7 and Month 13.
Population: Analysis was done on the FAS Month 13 which included all screened subjects who received a study vaccination \& provided evaluable serum samples at month 0 and atleast from month 2 to 13 and provided results for atleast one serogroup or serogroup B test strain.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 13) ≥ 16 | 38 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 0) ≥ 128 | 1 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 7) ≥ 16 | 61 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 0) ≥ 8 | 10 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 7) ≥ 5 | 70 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 0) ≥ LLQ (22.7) | 6 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 2) ≥ 32 | 19 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 2) ≥ LLQ (22.7) | 22 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 3) ≥ 128 | 45 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 13) ≥ LLQ (22.7) | 33 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 2) ≥ 16 | 28 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 3) ≥ 32 | 91 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 13) ≥ 8 | 48 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 2) ≥ 5 | 37 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 0) ≥ 16 | 7 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 13) ≥ 5 | 51 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 13) ≥ 128 | 4 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 2) ≥ 8 | 37 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 3) ≥ 5 | 97 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 3) ≥ LLQ (22.7) | 94 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 7) ≥ 8 | 68 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 7) ≥ LLQ (22.7) | 53 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 7) ≥ 64 | 19 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 13) ≥ 64 | 13 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 0) ≥ 32 | 4 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 3) ≥ 64 | 71 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 2) ≥ 128 | 4 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 3) ≥ 16 | 95 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 13) ≥ 32 | 24 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 7) ≥ 128 | 5 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 0) ≥ 64 | 1 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 3) ≥ 8 | 97 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 2) ≥ 64 | 12 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 0) ≥ 5 | 10 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 7) ≥ 32 | 42 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 3) ≥ 5 | 94 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 7) ≥ 8 | 58 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 3) ≥ 32 | 83 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 0) ≥ 16 | 4 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 3) ≥ 64 | 57 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 7) ≥ 5 | 62 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 3) ≥ 128 | 30 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 7) ≥ LLQ (22.7) | 46 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 13) ≥ 32 | 20 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 0) ≥ 32 | 2 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 13) ≥ 128 | 2 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 0) ≥ 64 | 1 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 13) ≥ 16 | 30 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 0) ≥ 128 | 1 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 0) ≥ 5 | 6 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 2) ≥ LLQ (22.7) | 35 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 13) ≥ 8 | 39 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 2) ≥ 5 | 53 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 13) ≥ 5 | 42 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 2) ≥ 8 | 51 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 2) ≥ 16 | 44 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 13) ≥ LLQ (22.7) | 26 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 2) ≥ 32 | 33 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 7) ≥ 128 | 6 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 2) ≥ 64 | 19 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 0) ≥ 8 | 6 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 2) ≥ 128 | 10 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 7) ≥ 64 | 19 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 3) ≥ LLQ (22.7) | 87 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 0) ≥ LLQ (22.7) | 3 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 7) ≥ 32 | 37 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 13) ≥ 64 | 8 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 3) ≥ 8 | 93 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 7) ≥ 16 | 51 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 3) ≥ 16 | 91 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 7) ≥ 128 | 10 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 3) ≥ 32 | 74 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 0) ≥ 64 | 2 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 0) ≥ 16 | 7 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 2) ≥ 64 | 69 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 7) ≥ 16 | 49 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 13) ≥ 16 | 41 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 7) ≥ 64 | 18 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 0) ≥ 32 | 3 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 3) ≥ 64 | 46 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 2) ≥ 128 | 34 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 0) ≥ 8 | 10 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 7) ≥ 8 | 58 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 13) ≥ 32 | 27 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 7) ≥ LLQ (22.7) | 41 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 3) ≥ 8 | 91 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 3) ≥ LLQ (22.7) | 80 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 7) ≥ 5 | 60 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 7) ≥ 32 | 35 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 13) ≥ 5 | 48 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 3) ≥ 16 | 86 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 2) ≥ 8 | 94 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 0) ≥ LLQ (22.7) | 5 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 2) ≥ 5 | 95 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 13) ≥ LLQ (22.7) | 34 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 0) ≥ 5 | 10 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 13) ≥ 128 | 6 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 2) ≥ 16 | 93 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 13) ≥ 64 | 13 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 3) ≥ 128 | 21 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 2) ≥ LLQ (22.7) | 93 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 13) ≥ 8 | 47 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 3) ≥ 5 | 92 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 2) ≥ 32 | 88 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 0) ≥ 128 | 1 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 13) ≥ 8 | 66 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 0) ≥ LLQ (22.7) | 2 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 0) ≥ 5 | 4 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 0) ≥ 8 | 3 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 0) ≥ 16 | 2 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 0) ≥ 32 | 1 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 0) ≥ 64 | 1 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 0) ≥ 128 | 0 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 2) ≥ LLQ (22.7) | 33 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 2) ≥ 5 | 48 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 2) ≥ 8 | 46 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 2) ≥ 16 | 41 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 2) ≥ 32 | 30 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 2) ≥ 64 | 18 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 2) ≥ 128 | 9 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 3) ≥ LLQ (22.7) | 30 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 3) ≥ 5 | 40 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 3) ≥ 8 | 39 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 3) ≥ 16 | 33 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 3) ≥ 32 | 27 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 3) ≥ 64 | 12 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 3) ≥ 128 | 6 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 7) ≥ LLQ (22.7) | 95 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 7) ≥ 5 | 97 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 7) ≥ 8 | 97 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 7) ≥ 16 | 97 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 7) ≥ 32 | 91 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 7) ≥ 64 | 76 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 7) ≥ 128 | 63 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 13) ≥ LLQ (22.7) | 51 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 13) ≥ 5 | 68 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 13) ≥ 16 | 59 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 13) ≥ 32 | 44 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 13) ≥ 64 | 27 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 13) ≥ 128 | 8 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 2) ≥ 128 | 14 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 2) ≥ 5 | 75 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 3) ≥ 8 | 53 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 13) ≥ 5 | 98 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 13) ≥ 64 | 81 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 7) ≥ 64 | 7 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 2) ≥ LLQ (22.7) | 54 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 3) ≥ 5 | 55 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 0) ≥ 128 | 0 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 13) ≥ 8 | 98 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 2) ≥ 64 | 33 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 0) ≥ 8 | 5 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 0) ≥ 64 | 0 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 2) ≥ 32 | 42 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 0) ≥ LLQ (22.7) | 3 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 13) ≥ 16 | 95 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 3) ≥ LLQ (22.7) | 38 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 0) ≥ 32 | 2 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 7) ≥ 128 | 3 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 0) ≥ 16 | 4 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 13) ≥ 128 | 61 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 13) ≥ 32 | 88 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 7) ≥ 32 | 14 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 3) ≥ 128 | 10 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 2) ≥ 16 | 67 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 7) ≥ LLQ (22.7) | 21 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 7) ≥ 8 | 28 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 0) ≥ 5 | 8 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 3) ≥ 64 | 19 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 13) ≥ LLQ (22.7) | 93 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 7) ≥ 16 | 22 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 7) ≥ 5 | 29 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 2) ≥ 8 | 74 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 3) ≥ 32 | 31 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 3) ≥ 16 | 42 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 3) ≥ 16 | 92 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 7) ≥ 8 | 98 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 3) ≥ 8 | 94 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 3) ≥ 5 | 94 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 0) ≥ 5 | 3 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 7) ≥ 16 | 97 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 3) ≥ LLQ (22.7) | 92 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 7) ≥ 32 | 93 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 2) ≥ 128 | 6 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 2) ≥ 64 | 14 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 7) ≥ 64 | 80 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 2) ≥ 32 | 22 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 13) ≥ 64 | 16 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 7) ≥ 128 | 54 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 2) ≥ 16 | 31 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 2) ≥ 8 | 38 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 13) ≥ LLQ (22.7) | 54 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 2) ≥ 5 | 39 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 0) ≥ LLQ (22.7) | 1 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 13) ≥ 5 | 65 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 2) ≥ LLQ (22.7) | 28 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 0) ≥ 128 | 1 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 13) ≥ 8 | 64 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 0) ≥ 64 | 1 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 0) ≥ 32 | 1 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 13) ≥ 16 | 60 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 0) ≥ 16 | 2 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 13) ≥ 128 | 6 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 3) ≥ 128 | 29 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 13) ≥ 32 | 41 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 7) ≥ LLQ (22.7) | 94 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 3) ≥ 64 | 61 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 3) ≥ 32 | 90 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 0) ≥ 8 | 2 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against A Human Serogroup for All Schedules. | A human Serogroup (At Month 7) ≥ 5 | 98 Percentages of subjects |
Secondary
Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules.
The kinetic of immune response (at Months 0, 2, 3, 7 and 13) following different vaccination schedules as measured by the percentages of subjects with hSBA titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 against C human serogroup was assessed.
Time frame: At Month 0, Month 2, Month 3, Month 7 and Month 13.
Population: Analysis was done on the FAS Month 13 which included all screened subjects who received a study vaccination \& provided evaluable serum samples at month 0 and atleast from month 2 to 13 and provided results for atleast one serogroup or serogroup B test strain.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 3) ≥ 128 | 11 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 0) ≥ 32 | 5 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 0) ≥ 16 | 19 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 3) ≥ LLQ (5.2) | 97 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 2) ≥ LLQ (5.2) | 61 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 2) ≥ 16 | 35 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 7) ≥ 32 | 23 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 0) ≥ 5 | 46 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 2) ≥ 128 | 3 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 2) ≥ 64 | 8 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 13) ≥ 64 | 9 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 2) ≥ 32 | 18 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 13) ≥ 5 | 61 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 0) ≥ 128 | 1 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 13) ≥ 32 | 15 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 3) ≥ 64 | 26 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 3) ≥ 32 | 56 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 13) ≥ LLQ (5.2) | 60 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 7) ≥ 64 | 9 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 7) ≥ 16 | 38 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 13) ≥ 8 | 48 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 3) ≥ 16 | 78 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 13) ≥ 128 | 2 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 3) ≥ 8 | 94 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 7) ≥ 128 | 3 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 7) ≥ 5 | 69 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 0) ≥ 8 | 34 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 3) ≥ 5 | 97 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 2) ≥ 5 | 62 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 7) ≥ LLQ (5.2) | 69 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 13) ≥ 16 | 30 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 7) ≥ 8 | 58 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 0) ≥ LLQ (5.2) | 43 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 0) ≥ 64 | 2 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 2) ≥ 8 | 53 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 0) ≥ 128 | 2 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 7) ≥ 8 | 96 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 2) ≥ LLQ (5.2) | 84 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 7) ≥ 16 | 90 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 13) ≥ LLQ (5.2) | 92 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 7) ≥ 32 | 74 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 7) ≥ 64 | 53 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 7) ≥ 128 | 30 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 2) ≥ 5 | 84 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 0) ≥ LLQ (5.2) | 45 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 2) ≥ 8 | 78 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 13) ≥ 64 | 28 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 2) ≥ 16 | 65 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 2) ≥ 32 | 40 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 2) ≥ 64 | 23 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 2) ≥ 128 | 16 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 3) ≥ LLQ (5.2) | 99 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 0) ≥ 5 | 45 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 13) ≥ 32 | 51 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 0) ≥ 16 | 14 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 0) ≥ 32 | 6 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 13) ≥ 16 | 78 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 0) ≥ 64 | 2 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 3) ≥ 5 | 99 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 3) ≥ 8 | 98 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 0) ≥ 8 | 30 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 13) ≥ 8 | 88 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 3) ≥ 16 | 96 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 3) ≥ 32 | 90 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 3) ≥ 64 | 78 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 3) ≥ 128 | 58 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 13) ≥ 5 | 92 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 7) ≥ LLQ (5.2) | 96 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 13) ≥ 128 | 16 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 7) ≥ 5 | 96 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 3) ≥ 16 | 95 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 0) ≥ 16 | 20 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 0) ≥ 8 | 36 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 7) ≥ 64 | 53 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 2) ≥ 5 | 100 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 13) ≥ LLQ (5.2) | 94 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 3) ≥ 32 | 86 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 13) ≥ 128 | 16 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 0) ≥ 128 | 0 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 0) ≥ 32 | 9 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 3) ≥ 128 | 40 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 7) ≥ 32 | 77 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 7) ≥ 16 | 91 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 3) ≥ 64 | 67 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 3) ≥ 5 | 98 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 2) ≥ 32 | 89 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 0) ≥ 5 | 49 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 7) ≥ 128 | 25 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 13) ≥ 8 | 89 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 2) ≥ 64 | 79 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 13) ≥ 16 | 79 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 13) ≥ 64 | 25 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 3) ≥ 8 | 98 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 7) ≥ 5 | 97 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 7) ≥ LLQ (5.2) | 97 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 2) ≥ 128 | 53 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 0) ≥ 64 | 2 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 2) ≥ 16 | 95 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 13) ≥ 32 | 57 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 0) ≥ LLQ (5.2) | 48 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 13) ≥ 5 | 94 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 3) ≥ LLQ (5.2) | 98 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 2) ≥ 8 | 98 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 7) ≥ 8 | 96 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 2) ≥ LLQ (5.2) | 100 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 2) ≥ 128 | 17 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 2) ≥ 8 | 80 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 0) ≥ 16 | 14 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 3) ≥ 128 | 18 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 0) ≥ 32 | 4 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 0) ≥ 5 | 43 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 7) ≥ 16 | 98 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 0) ≥ 64 | 3 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 2) ≥ 5 | 84 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 13) ≥ 8 | 91 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 13) ≥ 64 | 38 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 3) ≥ 5 | 81 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 7) ≥ 128 | 74 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 7) ≥ 5 | 99 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 3) ≥ 8 | 77 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 7) ≥ LLQ (5.2) | 99 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 7) ≥ 64 | 86 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 3) ≥ 16 | 62 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 2) ≥ LLQ (5.2) | 84 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 3) ≥ 32 | 43 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 13) ≥ 5 | 98 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 7) ≥ 32 | 95 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 7) ≥ 8 | 99 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 2) ≥ 32 | 44 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 13) ≥ 32 | 61 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 0) ≥ LLQ (5.2) | 41 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 3) ≥ 64 | 25 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 2) ≥ 64 | 29 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 13) ≥ 128 | 25 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 13) ≥ 16 | 83 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 2) ≥ 16 | 64 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 0) ≥ 128 | 1 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 13) ≥ LLQ (5.2) | 97 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 3) ≥ LLQ (5.2) | 81 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 0) ≥ 8 | 30 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 2) ≥ LLQ (5.2) | 89 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 0) ≥ LLQ (5.2) | 48 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 0) ≥ 5 | 49 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 0) ≥ 128 | 1 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 2) ≥ 5 | 89 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 2) ≥ 8 | 86 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 2) ≥ 16 | 72 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 2) ≥ 32 | 55 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 2) ≥ 64 | 39 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 2) ≥ 128 | 26 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 0) ≥ 8 | 36 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 0) ≥ 16 | 24 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 0) ≥ 32 | 7 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 0) ≥ 64 | 3 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 3) ≥ LLQ (5.2) | 88 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 3) ≥ 5 | 88 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 3) ≥ 8 | 84 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 3) ≥ 16 | 63 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 3) ≥ 32 | 46 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 3) ≥ 64 | 30 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 3) ≥ 128 | 21 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 7) ≥ LLQ (5.2) | 82 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 7) ≥ 5 | 82 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 7) ≥ 8 | 73 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 7) ≥ 16 | 55 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 7) ≥ 32 | 35 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 7) ≥ 64 | 26 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 7) ≥ 128 | 16 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 13) ≥ LLQ (5.2) | 100 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 13) ≥ 5 | 100 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 13) ≥ 8 | 98 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 13) ≥ 16 | 98 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 13) ≥ 32 | 97 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 13) ≥ 64 | 93 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 13) ≥ 128 | 85 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 13) ≥ LLQ (5.2) | 99 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 7) ≥ LLQ (5.2) | 100 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 3) ≥ 128 | 60 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 3) ≥ 64 | 85 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 3) ≥ 32 | 94 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 0) ≥ 64 | 1 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 13) ≥ 5 | 99 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 3) ≥ 16 | 98 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 3) ≥ 8 | 99 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 3) ≥ 5 | 100 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 3) ≥ LLQ (5.2) | 99 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 0) ≥ 128 | 0 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 13) ≥ 8 | 98 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 13) ≥ 16 | 94 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 0) ≥ 32 | 3 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 0) ≥ 16 | 8 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 0) ≥ 8 | 30 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 2) ≥ 128 | 19 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 2) ≥ 64 | 25 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 0) ≥ 5 | 42 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 2) ≥ 32 | 44 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 0) ≥ LLQ (5.2) | 41 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 13) ≥ 32 | 81 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 2) ≥ 16 | 61 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 2) ≥ 8 | 78 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 2) ≥ 5 | 88 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 2) ≥ LLQ (5.2) | 88 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 7) ≥ 64 | 96 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 13) ≥ 128 | 40 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 7) ≥ 128 | 85 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 7) ≥ 32 | 98 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 7) ≥ 16 | 99 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 7) ≥ 8 | 99 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 7) ≥ 5 | 100 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against C Human Serogroup for All Schedules. | C human Serogroup (At Month 13) ≥ 64 | 58 Percentages of subjects |
Secondary
Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules.
The kinetic of immune response (at Months 0, 2, 3, 7 and 13) following different vaccination schedules as measured by the percentages of subjects with hSBA titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 against M07-0241084 B strain was assessed.
Time frame: At Month 0, Month 2, Month 3, Month 7 and Month 13.
Population: Analysis was done on the FAS Month 13 which included all screened subjects who received a study vaccination \& provided evaluable serum samples at month 0 and atleast from month 2 to 13 and provided results for atleast one serogroup or serogroup B test strain.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 13) ≥ 16 | 26 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 0) ≥ 128 | 0 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 7) ≥ 16 | 29 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 0) ≥ 8 | 22 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 7) ≥ 5 | 50 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 0) ≥ LLQ (8.9) | 21 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 2) ≥ 32 | 20 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 2) ≥ LLQ (8.9) | 38 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 3) ≥ 128 | 5 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 13) ≥ LLQ (8.9) | 34 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 2) ≥ 16 | 31 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 3) ≥ 32 | 33 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 13) ≥ 8 | 37 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 2) ≥ 5 | 47 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 0) ≥ 16 | 13 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 13) ≥ 5 | 46 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 13) ≥ 128 | 2 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 2) ≥ 8 | 42 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 3) ≥ 5 | 79 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 3) ≥ LLQ (8.9) | 66 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 7) ≥ 8 | 42 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 7) ≥ LLQ (8.9) | 40 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 7) ≥ 64 | 6 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 13) ≥ 64 | 6 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 0) ≥ 32 | 8 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 3) ≥ 64 | 18 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 2) ≥ 128 | 3 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 3) ≥ 16 | 52 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 13) ≥ 32 | 16 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 7) ≥ 128 | 1 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 0) ≥ 64 | 3 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 3) ≥ 8 | 69 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 2) ≥ 64 | 10 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 0) ≥ 5 | 30 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 7) ≥ 32 | 21 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 3) ≥ 5 | 69 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 7) ≥ 8 | 32 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 3) ≥ 32 | 18 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 0) ≥ 16 | 14 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 3) ≥ 64 | 11 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 7) ≥ 5 | 44 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 3) ≥ 128 | 3 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 7) ≥ LLQ (8.9) | 30 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 13) ≥ 32 | 13 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 0) ≥ 32 | 6 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 13) ≥ 128 | 1 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 0) ≥ 64 | 2 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 13) ≥ 16 | 23 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 0) ≥ 128 | 0 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 0) ≥ 5 | 28 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 2) ≥ LLQ (8.9) | 29 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 13) ≥ 8 | 34 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 2) ≥ 5 | 43 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 13) ≥ 5 | 39 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 2) ≥ 8 | 32 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 2) ≥ 16 | 22 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 13) ≥ LLQ (8.9) | 27 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 2) ≥ 32 | 15 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 7) ≥ 128 | 2 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 2) ≥ 64 | 7 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 0) ≥ 8 | 20 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 2) ≥ 128 | 2 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 7) ≥ 64 | 8 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 3) ≥ LLQ (8.9) | 47 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 0) ≥ LLQ (8.9) | 18 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 7) ≥ 32 | 14 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 13) ≥ 64 | 3 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 3) ≥ 8 | 55 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 7) ≥ 16 | 24 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 3) ≥ 16 | 33 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 7) ≥ 128 | 1 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 3) ≥ 32 | 15 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 0) ≥ 64 | 3 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 0) ≥ 16 | 12 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 2) ≥ 64 | 9 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 7) ≥ 16 | 19 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 13) ≥ 16 | 17 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 7) ≥ 64 | 6 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 0) ≥ 32 | 7 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 3) ≥ 64 | 5 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 2) ≥ 128 | 3 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 0) ≥ 8 | 18 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 7) ≥ 8 | 27 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 13) ≥ 32 | 11 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 7) ≥ LLQ (8.9) | 26 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 3) ≥ 8 | 34 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 3) ≥ LLQ (8.9) | 28 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 7) ≥ 5 | 32 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 7) ≥ 32 | 9 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 13) ≥ 5 | 36 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 3) ≥ 16 | 21 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 2) ≥ 8 | 43 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 0) ≥ LLQ (8.9) | 17 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 2) ≥ 5 | 54 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 13) ≥ LLQ (8.9) | 23 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 0) ≥ 5 | 25 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 13) ≥ 128 | 2 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 2) ≥ 16 | 29 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 13) ≥ 64 | 4 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 3) ≥ 128 | 3 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 2) ≥ LLQ (8.9) | 37 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 13) ≥ 8 | 27 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 3) ≥ 5 | 43 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 2) ≥ 32 | 17 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 0) ≥ 128 | 0 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 13) ≥ 8 | 39 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 0) ≥ LLQ (8.9) | 14 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 0) ≥ 5 | 27 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 0) ≥ 8 | 19 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 0) ≥ 16 | 6 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 0) ≥ 32 | 4 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 0) ≥ 64 | 2 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 0) ≥ 128 | 2 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 2) ≥ LLQ (8.9) | 28 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 2) ≥ 5 | 40 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 2) ≥ 8 | 31 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 2) ≥ 16 | 16 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 2) ≥ 32 | 7 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 2) ≥ 64 | 2 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 2) ≥ 128 | 1 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 3) ≥ LLQ (8.9) | 28 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 3) ≥ 5 | 40 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 3) ≥ 8 | 31 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 3) ≥ 16 | 12 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 3) ≥ 32 | 5 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 3) ≥ 64 | 1 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 3) ≥ 128 | 1 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 7) ≥ LLQ (8.9) | 66 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 7) ≥ 5 | 83 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 7) ≥ 8 | 70 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 7) ≥ 16 | 53 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 7) ≥ 32 | 28 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 7) ≥ 64 | 10 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 7) ≥ 128 | 3 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 13) ≥ LLQ (8.9) | 34 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 13) ≥ 5 | 57 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 13) ≥ 16 | 19 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 13) ≥ 32 | 12 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 13) ≥ 64 | 5 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 13) ≥ 128 | 1 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 2) ≥ 128 | 5 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 2) ≥ 5 | 54 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 3) ≥ 8 | 34 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 13) ≥ 5 | 82 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 13) ≥ 64 | 20 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 7) ≥ 64 | 4 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 2) ≥ LLQ (8.9) | 39 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 3) ≥ 5 | 43 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 0) ≥ 128 | 1 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 13) ≥ 8 | 74 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 2) ≥ 64 | 9 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 0) ≥ 8 | 24 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 0) ≥ 64 | 3 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 2) ≥ 32 | 19 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 0) ≥ LLQ (8.9) | 21 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 13) ≥ 16 | 55 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 3) ≥ LLQ (8.9) | 30 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 0) ≥ 32 | 9 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 7) ≥ 128 | 1 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 0) ≥ 16 | 16 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 13) ≥ 128 | 9 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 13) ≥ 32 | 35 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 7) ≥ 32 | 8 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 3) ≥ 128 | 2 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 2) ≥ 16 | 30 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 7) ≥ LLQ (8.9) | 26 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 7) ≥ 8 | 28 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 0) ≥ 5 | 30 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 3) ≥ 64 | 4 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 13) ≥ LLQ (8.9) | 69 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 7) ≥ 16 | 18 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 7) ≥ 5 | 36 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 2) ≥ 8 | 43 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 3) ≥ 32 | 15 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 3) ≥ 16 | 21 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 3) ≥ 16 | 40 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 7) ≥ 8 | 77 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 3) ≥ 8 | 56 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 3) ≥ 5 | 62 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 0) ≥ 5 | 21 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 7) ≥ 16 | 58 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 3) ≥ LLQ (8.9) | 53 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 7) ≥ 32 | 34 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 2) ≥ 128 | 0 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 2) ≥ 64 | 5 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 7) ≥ 64 | 17 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 2) ≥ 32 | 9 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 13) ≥ 64 | 5 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 7) ≥ 128 | 4 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 2) ≥ 16 | 19 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 2) ≥ 8 | 35 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 13) ≥ LLQ (8.9) | 37 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 2) ≥ 5 | 41 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 0) ≥ LLQ (8.9) | 19 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 13) ≥ 5 | 51 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 2) ≥ LLQ (8.9) | 30 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 0) ≥ 128 | 1 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 13) ≥ 8 | 42 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 0) ≥ 64 | 3 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 0) ≥ 32 | 6 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 13) ≥ 16 | 26 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 0) ≥ 16 | 15 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 13) ≥ 128 | 1 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 3) ≥ 128 | 2 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 13) ≥ 32 | 12 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 7) ≥ LLQ (8.9) | 70 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 3) ≥ 64 | 13 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 3) ≥ 32 | 23 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 0) ≥ 8 | 20 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M07-0241084 B Strain for All Schedules. | M07-0241084 Strain (At Month 7) ≥ 5 | 80 Percentages of subjects |
Secondary
Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules.
The kinetic of immune response (at Months 0, 2, 3, 7 and 13) following different vaccination schedules as measured by the percentages of subjects with hSBA titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 against M14459 B strain was assessed.
Time frame: At Month 0, Month 2, Month 3, Month 7 and Month 13.
Population: Analysis was done on the FAS Month 13 which included all screened subjects who received a study vaccination \& provided evaluable serum samples at month 0 and atleast from month 2 to 13 and provided results for atleast one serogroup or serogroup B test strain.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 13) ≥ 16 | 15 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 0) ≥ 128 | 0 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 7) ≥ 16 | 19 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 0) ≥ 8 | 7 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 7) ≥ 5 | 44 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 0) ≥ LLQ (8.0) | 7 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 2) ≥ 32 | 9 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 2) ≥ LLQ (8.0) | 28 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 3) ≥ 128 | 7 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 13) ≥ LLQ (8.0) | 23 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 2) ≥ 16 | 17 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 3) ≥ 32 | 39 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 13) ≥ 8 | 23 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 2) ≥ 5 | 38 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 0) ≥ 16 | 3 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 13) ≥ 5 | 30 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 13) ≥ 128 | 0 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 2) ≥ 8 | 28 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 3) ≥ 5 | 84 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 3) ≥ LLQ (8.0) | 82 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 7) ≥ 8 | 34 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 7) ≥ LLQ (8.0) | 34 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 7) ≥ 64 | 3 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 13) ≥ 64 | 2 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 0) ≥ 32 | 2 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 3) ≥ 64 | 18 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 2) ≥ 128 | 1 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 3) ≥ 16 | 66 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 13) ≥ 32 | 5 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 7) ≥ 128 | 0 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 0) ≥ 64 | 1 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 3) ≥ 8 | 82 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 2) ≥ 64 | 4 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 0) ≥ 5 | 12 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 7) ≥ 32 | 11 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 3) ≥ 5 | 74 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 7) ≥ 8 | 30 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 3) ≥ 32 | 30 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 0) ≥ 16 | 2 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 3) ≥ 64 | 11 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 7) ≥ 5 | 35 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 3) ≥ 128 | 2 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 7) ≥ LLQ (8.0) | 30 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 13) ≥ 32 | 4 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 0) ≥ 32 | 0 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 13) ≥ 128 | 1 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 0) ≥ 64 | 0 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 13) ≥ 16 | 9 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 0) ≥ 128 | 0 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 0) ≥ 5 | 7 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 2) ≥ LLQ (8.0) | 24 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 13) ≥ 8 | 20 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 2) ≥ 5 | 30 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 13) ≥ 5 | 26 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 2) ≥ 8 | 24 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 2) ≥ 16 | 13 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 13) ≥ LLQ (8.0) | 20 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 2) ≥ 32 | 6 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 7) ≥ 128 | 1 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 2) ≥ 64 | 2 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 0) ≥ 8 | 5 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 2) ≥ 128 | 2 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 7) ≥ 64 | 4 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 3) ≥ LLQ (8.0) | 68 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 0) ≥ LLQ (8.0) | 5 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 7) ≥ 32 | 7 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 13) ≥ 64 | 2 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 3) ≥ 8 | 68 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 7) ≥ 16 | 14 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 3) ≥ 16 | 51 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 7) ≥ 128 | 1 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 3) ≥ 32 | 6 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 0) ≥ 64 | 0 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 0) ≥ 16 | 2 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 2) ≥ 64 | 4 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 7) ≥ 16 | 10 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 13) ≥ 16 | 7 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 7) ≥ 64 | 3 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 0) ≥ 32 | 1 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 3) ≥ 64 | 3 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 2) ≥ 128 | 2 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 0) ≥ 8 | 6 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 7) ≥ 8 | 17 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 13) ≥ 32 | 4 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 7) ≥ LLQ (8.0) | 17 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 3) ≥ 8 | 44 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 3) ≥ LLQ (8.0) | 44 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 7) ≥ 5 | 21 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 7) ≥ 32 | 5 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 13) ≥ 5 | 20 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 3) ≥ 16 | 24 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 2) ≥ 8 | 61 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 0) ≥ LLQ (8.0) | 6 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 2) ≥ 5 | 75 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 13) ≥ LLQ (8.0) | 13 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 0) ≥ 5 | 6 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 13) ≥ 128 | 2 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 2) ≥ 16 | 34 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 13) ≥ 64 | 3 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 3) ≥ 128 | 2 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 2) ≥ LLQ (8.0) | 61 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 13) ≥ 8 | 13 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 3) ≥ 5 | 54 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 2) ≥ 32 | 19 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 0) ≥ 128 | 0 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 13) ≥ 8 | 23 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 0) ≥ LLQ (8.0) | 4 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 0) ≥ 5 | 6 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 0) ≥ 8 | 4 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 0) ≥ 16 | 3 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 0) ≥ 32 | 1 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 0) ≥ 64 | 0 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 0) ≥ 128 | 0 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 2) ≥ LLQ (8.0) | 17 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 2) ≥ 5 | 26 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 2) ≥ 8 | 17 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 2) ≥ 16 | 11 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 2) ≥ 32 | 6 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 2) ≥ 64 | 2 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 2) ≥ 128 | 1 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 3) ≥ LLQ (8.0) | 16 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 3) ≥ 5 | 20 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 3) ≥ 8 | 16 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 3) ≥ 16 | 9 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 3) ≥ 32 | 4 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 3) ≥ 64 | 1 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 3) ≥ 128 | 1 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 7) ≥ LLQ (8.0) | 86 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 7) ≥ 5 | 92 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 7) ≥ 8 | 86 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 7) ≥ 16 | 69 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 7) ≥ 32 | 50 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 7) ≥ 64 | 23 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 7) ≥ 128 | 10 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 13) ≥ LLQ (8.0) | 23 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 13) ≥ 5 | 37 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 13) ≥ 16 | 13 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 13) ≥ 32 | 7 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 13) ≥ 64 | 1 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 13) ≥ 128 | 1 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 2) ≥ 128 | 5 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 2) ≥ 5 | 42 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 3) ≥ 8 | 28 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 13) ≥ 5 | 93 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 13) ≥ 64 | 29 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 7) ≥ 64 | 4 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 2) ≥ LLQ (8.0) | 34 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 3) ≥ 5 | 35 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 0) ≥ 128 | 0 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 13) ≥ 8 | 89 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 2) ≥ 64 | 8 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 0) ≥ 8 | 7 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 0) ≥ 64 | 0 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 2) ≥ 32 | 13 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 0) ≥ LLQ (8.0) | 7 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 13) ≥ 16 | 76 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 3) ≥ LLQ (8.0) | 28 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 0) ≥ 32 | 0 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 7) ≥ 128 | 2 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 0) ≥ 16 | 2 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 13) ≥ 128 | 11 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 13) ≥ 32 | 54 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 7) ≥ 32 | 6 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 3) ≥ 128 | 3 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 2) ≥ 16 | 25 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 7) ≥ LLQ (8.0) | 15 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 7) ≥ 8 | 15 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 0) ≥ 5 | 11 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 3) ≥ 64 | 4 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 13) ≥ LLQ (8.0) | 89 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 7) ≥ 16 | 8 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 7) ≥ 5 | 20 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 2) ≥ 8 | 34 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 3) ≥ 32 | 9 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 3) ≥ 16 | 18 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 3) ≥ 16 | 51 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 7) ≥ 8 | 89 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 3) ≥ 8 | 73 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 3) ≥ 5 | 80 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 0) ≥ 5 | 4 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 7) ≥ 16 | 72 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 3) ≥ LLQ (8.0) | 73 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 7) ≥ 32 | 49 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 2) ≥ 128 | 1 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 2) ≥ 64 | 2 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 7) ≥ 64 | 22 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 2) ≥ 32 | 5 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 13) ≥ 64 | 1 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 7) ≥ 128 | 7 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 2) ≥ 16 | 12 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 2) ≥ 8 | 17 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 13) ≥ LLQ (8.0) | 27 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 2) ≥ 5 | 22 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 0) ≥ LLQ (8.0) | 2 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 13) ≥ 5 | 38 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 2) ≥ LLQ (8.0) | 17 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 0) ≥ 128 | 0 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 13) ≥ 8 | 27 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 0) ≥ 64 | 1 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 0) ≥ 32 | 1 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 13) ≥ 16 | 13 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 0) ≥ 16 | 1 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 13) ≥ 128 | 1 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 3) ≥ 128 | 3 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 13) ≥ 32 | 6 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 7) ≥ LLQ (8.0) | 89 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 3) ≥ 64 | 10 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 3) ≥ 32 | 28 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 0) ≥ 8 | 2 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against M14459 B Strain for All Schedules. | M14459 Strain (At Month 7) ≥ 5 | 93 Percentages of subjects |
Secondary
Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules.
The kinetic of immune response (at Months 0, 2, 3, 7 and 13) following different vaccination schedules as measured by the percentages of subjects with hSBA titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 against NZ98/254 B strain was assessed.
Time frame: At Month 0, Month 2, Month 3, Month 7 and Month 13.
Population: Analysis was done on the FAS Month 13 which included all screened subjects who received a study vaccination \& provided evaluable serum samples at month 0 and atleast from month 2 to 13 and provided results for atleast one serogroup or serogroup B test strain.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 7) ≥ 64 | 6 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 0) ≥ 5 | 9 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 3) ≥ 64 | 29 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 13) ≥ 32 | 7 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 3) ≥ 16 | 74 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 13) ≥ 8 | 21 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 0) ≥ 128 | 0 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 0) ≥ 8 | 7 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 3) ≥ 5 | 94 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 7) ≥ 8 | 27 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 0) ≥ 64 | 0 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 2) ≥ 128 | 2 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 7) ≥ 32 | 12 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 0) ≥ 16 | 4 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 13) ≥ 64 | 3 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 7) ≥ 16 | 21 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 13) ≥ 5 | 27 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 0) ≥ 32 | 2 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 2) ≥ 16 | 19 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 2) ≥ 8 | 23 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 3) ≥ 32 | 50 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 3) ≥ 8 | 88 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 7) ≥ LLQ (8.2) | 27 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 13) ≥ LLQ (8.2) | 21 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 13) ≥ 128 | 2 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 3) ≥ LLQ (8.2) | 88 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 2) ≥ 5 | 29 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 2) ≥ 64 | 9 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 7) ≥ 128 | 2 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 7) ≥ 5 | 33 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 0) ≥ LLQ (8.2) | 7 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 2) ≥ 32 | 15 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 2) ≥ LLQ (8.2) | 23 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 13) ≥ 16 | 15 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 3) ≥ 128 | 12 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 2) ≥ 16 | 15 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 3) ≥ 32 | 23 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 2) ≥ 128 | 5 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 13) ≥ 64 | 5 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 3) ≥ LLQ (8.2) | 61 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 3) ≥ 16 | 44 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 3) ≥ 5 | 76 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 3) ≥ 8 | 63 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 7) ≥ 128 | 4 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 13) ≥ 128 | 3 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 13) ≥ 5 | 19 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 0) ≥ LLQ (8.2) | 6 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 7) ≥ 64 | 6 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 0) ≥ 5 | 7 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 13) ≥ 16 | 12 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 0) ≥ 8 | 6 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 7) ≥ 32 | 10 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 0) ≥ 16 | 5 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 7) ≥ 16 | 14 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 0) ≥ 32 | 3 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 0) ≥ 64 | 3 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 7) ≥ 8 | 20 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 0) ≥ 128 | 0 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 7) ≥ 5 | 27 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 2) ≥ LLQ (8.2) | 20 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 13) ≥ 32 | 7 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 2) ≥ 5 | 24 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 7) ≥ LLQ (8.2) | 19 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 2) ≥ 8 | 20 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 13) ≥ 8 | 16 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 3) ≥ 128 | 6 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 13) ≥ LLQ (8.2) | 16 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 2) ≥ 32 | 10 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 3) ≥ 64 | 12 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 2) ≥ 64 | 7 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 7) ≥ 5 | 18 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 2) ≥ 128 | 5 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 0) ≥ LLQ (8.2) | 6 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 13) ≥ 64 | 5 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 2) ≥ LLQ (8.2) | 43 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 3) ≥ 64 | 6 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 7) ≥ 64 | 6 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 7) ≥ LLQ (8.2) | 14 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 13) ≥ 128 | 3 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 3) ≥ LLQ (8.2) | 30 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 2) ≥ 5 | 58 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 13) ≥ 32 | 8 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 3) ≥ 32 | 13 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 7) ≥ 128 | 5 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 3) ≥ 8 | 30 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 2) ≥ 32 | 20 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 2) ≥ 8 | 43 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 3) ≥ 16 | 18 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 3) ≥ 128 | 4 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 7) ≥ 16 | 12 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 2) ≥ 64 | 12 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 0) ≥ 32 | 3 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 13) ≥ 8 | 15 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 0) ≥ 16 | 4 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 7) ≥ 8 | 14 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 13) ≥ 16 | 8 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 13) ≥ 5 | 16 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 0) ≥ 64 | 0 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 13) ≥ LLQ (8.2) | 15 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 3) ≥ 5 | 38 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 0) ≥ 8 | 6 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 7) ≥ 32 | 9 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 2) ≥ 16 | 28 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 0) ≥ 128 | 0 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 0) ≥ 5 | 7 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 7) ≥ 32 | 26 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 13) ≥ 8 | 18 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 13) ≥ 16 | 12 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 13) ≥ 32 | 8 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 13) ≥ 64 | 5 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 13) ≥ 128 | 3 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 0) ≥ LLQ (8.2) | 5 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 0) ≥ 5 | 5 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 0) ≥ 8 | 5 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 0) ≥ 16 | 4 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 0) ≥ 32 | 1 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 0) ≥ 64 | 1 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 0) ≥ 128 | 0 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 2) ≥ LLQ (8.2) | 17 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 2) ≥ 5 | 18 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 2) ≥ 8 | 17 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 2) ≥ 16 | 11 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 2) ≥ 32 | 9 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 2) ≥ 64 | 4 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 2) ≥ 128 | 3 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 3) ≥ LLQ (8.2) | 14 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 3) ≥ 5 | 17 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 3) ≥ 8 | 14 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 3) ≥ 16 | 11 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 3) ≥ 32 | 5 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 3) ≥ 64 | 4 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 3) ≥ 128 | 2 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 7) ≥ LLQ (8.2) | 63 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 7) ≥ 5 | 80 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 7) ≥ 8 | 69 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 7) ≥ 16 | 46 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 7) ≥ 64 | 13 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 7) ≥ 128 | 7 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 13) ≥ LLQ (8.2) | 18 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 13) ≥ 5 | 28 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 2) ≥ 5 | 36 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 0) ≥ 16 | 2 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 2) ≥ 32 | 17 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 7) ≥ 16 | 10 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 13) ≥ LLQ (8.2) | 73 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 7) ≥ LLQ (8.2) | 13 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 0) ≥ 8 | 4 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 2) ≥ 16 | 23 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 0) ≥ 5 | 6 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 7) ≥ 32 | 4 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 2) ≥ LLQ (8.2) | 27 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 13) ≥ 32 | 30 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 0) ≥ LLQ (8.2) | 4 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 0) ≥ 128 | 0 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 13) ≥ 8 | 74 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 7) ≥ 64 | 2 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 2) ≥ 8 | 28 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 13) ≥ 128 | 6 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 7) ≥ 5 | 17 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 13) ≥ 64 | 13 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 13) ≥ 5 | 85 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 7) ≥ 128 | 1 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 3) ≥ 128 | 4 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 3) ≥ 5 | 27 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 0) ≥ 64 | 0 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 3) ≥ 8 | 21 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 3) ≥ 32 | 10 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 13) ≥ 16 | 49 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 3) ≥ LLQ (8.2) | 20 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 7) ≥ 8 | 13 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 3) ≥ 64 | 6 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 3) ≥ 16 | 14 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 0) ≥ 32 | 0 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 2) ≥ 128 | 6 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 2) ≥ 64 | 13 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 2) ≥ 64 | 2 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 3) ≥ 32 | 19 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 2) ≥ 32 | 7 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 2) ≥ 16 | 13 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 13) ≥ 16 | 14 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 3) ≥ 64 | 14 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 2) ≥ 8 | 18 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 3) ≥ 128 | 4 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 2) ≥ 5 | 20 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 2) ≥ LLQ (8.2) | 18 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 7) ≥ LLQ (8.2) | 72 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 0) ≥ 128 | 0 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 13) ≥ LLQ (8.2) | 19 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 7) ≥ 5 | 82 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 0) ≥ 64 | 0 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 0) ≥ 32 | 0 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 7) ≥ 8 | 74 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 0) ≥ 16 | 1 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 13) ≥ 8 | 19 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 7) ≥ 16 | 55 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 0) ≥ 8 | 2 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 0) ≥ 5 | 3 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 7) ≥ 32 | 34 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 0) ≥ LLQ (8.2) | 2 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 13) ≥ 128 | 2 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 7) ≥ 64 | 16 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 13) ≥ 64 | 3 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 13) ≥ 5 | 25 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 3) ≥ 5 | 78 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 7) ≥ 128 | 5 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 3) ≥ 8 | 69 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 3) ≥ LLQ (8.2) | 68 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 2) ≥ 128 | 1 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 13) ≥ 32 | 4 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against NZ98/254 B Strain for All Schedules. | NZ98/254 Strain (At Month 3) ≥ 16 | 46 Percentages of subjects |
Secondary
Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules.
The kinetic of immune response (at Months 0, 2, 3, 7 and 13) following different vaccination schedules as measured by the percentages of subjects with hSBA titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 against W human serogroup was assessed.
Time frame: At Month 0, Month 2, Month 3, Month 7 and Month 13.
Population: Analysis was done on the FAS Month 13 which included all screened subjects who received a study vaccination \& provided evaluable serum samples at month 0 and atleast from month 2 to 13 and provided results for atleast one serogroup or serogroup B test strain.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 13) ≥ 16 | 57 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 0) ≥ 128 | 8 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 7) ≥ 16 | 69 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 0) ≥ 8 | 49 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 7) ≥ 5 | 71 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 0) ≥ LLQ (39.6) | 30 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 2) ≥ 32 | 52 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 2) ≥ LLQ (39.6) | 48 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 3) ≥ 128 | 61 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 13) ≥ LLQ (39.6) | 47 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 2) ≥ 16 | 60 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 3) ≥ 32 | 91 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 13) ≥ 8 | 60 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 2) ≥ 5 | 66 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 0) ≥ 16 | 44 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 13) ≥ 5 | 62 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 13) ≥ 128 | 21 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 2) ≥ 8 | 64 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 3) ≥ 5 | 96 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 3) ≥ LLQ (39.6) | 89 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 7) ≥ 8 | 70 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 7) ≥ LLQ (39.6) | 60 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 7) ≥ 64 | 49 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 13) ≥ 64 | 35 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 0) ≥ 32 | 35 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 3) ≥ 64 | 80 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 2) ≥ 128 | 29 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 3) ≥ 16 | 96 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 13) ≥ 32 | 50 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 7) ≥ 128 | 31 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 0) ≥ 64 | 21 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 3) ≥ 8 | 96 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 2) ≥ 64 | 44 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 0) ≥ 5 | 51 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 7) ≥ 32 | 63 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 3) ≥ 5 | 99 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 7) ≥ 8 | 95 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 3) ≥ 32 | 98 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 0) ≥ 16 | 39 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 3) ≥ 64 | 93 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 7) ≥ 5 | 97 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 3) ≥ 128 | 74 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 7) ≥ LLQ (39.6) | 82 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 13) ≥ 32 | 71 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 0) ≥ 32 | 31 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 13) ≥ 128 | 22 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 0) ≥ 64 | 19 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 13) ≥ 16 | 84 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 0) ≥ 128 | 9 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 0) ≥ 5 | 43 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 2) ≥ LLQ (39.6) | 65 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 13) ≥ 8 | 90 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 2) ≥ 5 | 90 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 13) ≥ 5 | 93 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 2) ≥ 8 | 86 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 2) ≥ 16 | 82 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 13) ≥ LLQ (39.6) | 64 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 2) ≥ 32 | 69 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 7) ≥ 128 | 41 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 2) ≥ 64 | 50 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 0) ≥ 8 | 41 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 2) ≥ 128 | 31 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 7) ≥ 64 | 68 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 3) ≥ LLQ (39.6) | 97 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 0) ≥ LLQ (39.6) | 26 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 7) ≥ 32 | 84 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 13) ≥ 64 | 44 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 3) ≥ 8 | 99 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 7) ≥ 16 | 92 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 3) ≥ 16 | 99 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 7) ≥ 128 | 34 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 3) ≥ 32 | 91 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 0) ≥ 64 | 20 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 0) ≥ 16 | 39 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 2) ≥ 64 | 84 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 7) ≥ 16 | 91 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 13) ≥ 16 | 81 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 7) ≥ 64 | 67 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 0) ≥ 32 | 31 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 3) ≥ 64 | 77 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 2) ≥ 128 | 62 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 0) ≥ 8 | 40 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 7) ≥ 8 | 95 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 13) ≥ 32 | 72 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 7) ≥ LLQ (39.6) | 79 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 3) ≥ 8 | 97 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 3) ≥ LLQ (39.6) | 85 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 7) ≥ 5 | 96 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 7) ≥ 32 | 84 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 13) ≥ 5 | 90 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 3) ≥ 16 | 96 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 2) ≥ 8 | 99 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 0) ≥ LLQ (39.6) | 29 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 2) ≥ 5 | 99 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 13) ≥ LLQ (39.6) | 66 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 0) ≥ 5 | 41 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 13) ≥ 128 | 28 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 2) ≥ 16 | 99 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 13) ≥ 64 | 48 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 3) ≥ 128 | 50 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 2) ≥ LLQ (39.6) | 96 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 13) ≥ 8 | 90 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 3) ≥ 5 | 98 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 2) ≥ 32 | 98 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 0) ≥ 128 | 10 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 13) ≥ 8 | 98 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 0) ≥ LLQ (39.6) | 20 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 0) ≥ 5 | 42 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 0) ≥ 8 | 41 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 0) ≥ 16 | 34 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 0) ≥ 32 | 24 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 0) ≥ 64 | 13 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 0) ≥ 128 | 10 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 2) ≥ LLQ (39.6) | 67 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 2) ≥ 5 | 92 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 2) ≥ 8 | 92 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 2) ≥ 16 | 81 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 2) ≥ 32 | 72 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 2) ≥ 64 | 52 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 2) ≥ 128 | 33 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 3) ≥ LLQ (39.6) | 68 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 3) ≥ 5 | 94 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 3) ≥ 8 | 90 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 3) ≥ 16 | 81 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 3) ≥ 32 | 73 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 3) ≥ 64 | 50 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 3) ≥ 128 | 33 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 7) ≥ LLQ (39.6) | 99 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 7) ≥ 5 | 100 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 7) ≥ 8 | 100 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 7) ≥ 16 | 100 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 7) ≥ 32 | 100 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 7) ≥ 64 | 97 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 7) ≥ 128 | 87 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 13) ≥ LLQ (39.6) | 82 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 13) ≥ 5 | 99 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 13) ≥ 16 | 94 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 13) ≥ 32 | 85 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 13) ≥ 64 | 73 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 13) ≥ 128 | 43 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 2) ≥ 128 | 49 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 2) ≥ 5 | 93 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 3) ≥ 8 | 90 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 13) ≥ 5 | 99 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 13) ≥ 64 | 98 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 7) ≥ 64 | 59 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 2) ≥ LLQ (39.6) | 77 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 3) ≥ 5 | 92 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 0) ≥ 128 | 7 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 13) ≥ 8 | 99 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 2) ≥ 64 | 67 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 0) ≥ 8 | 45 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 0) ≥ 64 | 21 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 2) ≥ 32 | 78 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 0) ≥ LLQ (39.6) | 29 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 13) ≥ 16 | 99 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 3) ≥ LLQ (39.6) | 77 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 0) ≥ 32 | 33 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 7) ≥ 128 | 34 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 0) ≥ 16 | 41 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 13) ≥ 128 | 94 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 13) ≥ 32 | 98 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 7) ≥ 32 | 76 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 3) ≥ 128 | 44 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 2) ≥ 16 | 89 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 7) ≥ LLQ (39.6) | 74 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 7) ≥ 8 | 91 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 0) ≥ 5 | 45 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 3) ≥ 64 | 64 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 13) ≥ LLQ (39.6) | 98 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 7) ≥ 16 | 87 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 7) ≥ 5 | 93 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 2) ≥ 8 | 93 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 3) ≥ 32 | 78 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 3) ≥ 16 | 86 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 3) ≥ 16 | 99 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 7) ≥ 8 | 100 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 3) ≥ 8 | 100 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 3) ≥ 5 | 100 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 0) ≥ 5 | 45 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 7) ≥ 16 | 100 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 3) ≥ LLQ (39.6) | 97 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 7) ≥ 32 | 99 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 2) ≥ 128 | 27 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 2) ≥ 64 | 44 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 7) ≥ 64 | 98 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 2) ≥ 32 | 65 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 13) ≥ 64 | 68 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 7) ≥ 128 | 82 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 2) ≥ 16 | 80 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 2) ≥ 8 | 89 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 13) ≥ LLQ (39.6) | 84 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 2) ≥ 5 | 93 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 0) ≥ LLQ (39.6) | 22 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 13) ≥ 5 | 98 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 2) ≥ LLQ (39.6) | 60 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 0) ≥ 128 | 4 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 13) ≥ 8 | 98 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 0) ≥ 64 | 12 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 0) ≥ 32 | 26 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 13) ≥ 16 | 96 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 0) ≥ 16 | 38 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 13) ≥ 128 | 45 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 3) ≥ 128 | 70 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 13) ≥ 32 | 89 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 7) ≥ LLQ (39.6) | 99 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 3) ≥ 64 | 91 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 3) ≥ 32 | 98 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 0) ≥ 8 | 43 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against W Human Serogroup for All Schedules. | W human Serogroup (At Month 7) ≥ 5 | 100 Percentages of subjects |
Secondary
Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules.
The kinetic of immune response (at Months 0, 2, 3, 7 and 13) following different vaccination schedules as measured by the percentages of subjects with hSBA titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 against Y human serogroup was assessed.
Time frame: At Month 0, Month 2, Month 3, Month 7 and Month 13.
Population: Analysis was done on the FAS Month 13 which included all screened subjects who received a study vaccination \& provided evaluable serum samples at month 0 and atleast from month 2 to 13 and provided results for at least one serogroup or serogroup B test strain.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 13) ≥ 32 | 10 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 3) ≥ 16 | 26 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 2) ≥ 64 | 5 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 0) ≥ 8 | 16 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 3) ≥ 8 | 30 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 2) ≥ 128 | 1 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 3) ≥ 5 | 33 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 3) ≥ LLQ (14.7) | 27 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 0) ≥ LLQ (14.7) | 15 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 13) ≥ 16 | 18 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 0) ≥ 16 | 15 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 13) ≥ 8 | 24 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 13) ≥ 5 | 25 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 0) ≥ 32 | 9 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 13) ≥ 128 | 1 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 13) ≥ LLQ (14.7) | 19 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 0) ≥ 64 | 2 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 7) ≥ 128 | 1 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 7) ≥ 64 | 3 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 0) ≥ 128 | 0 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 0) ≥ 5 | 16 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 7) ≥ 32 | 13 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 2) ≥ LLQ (14.7) | 21 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 7) ≥ 16 | 22 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 7) ≥ 8 | 26 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 2) ≥ 5 | 27 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 7) ≥ 5 | 26 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 2) ≥ 8 | 26 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 13) ≥ 64 | 3 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 7) ≥ LLQ (14.7) | 23 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 3) ≥ 128 | 2 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 2) ≥ 16 | 20 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 3) ≥ 64 | 9 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 2) ≥ 32 | 13 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 3) ≥ 32 | 18 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 7) ≥ 64 | 37 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 3) ≥ 16 | 92 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 3) ≥ 32 | 84 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 7) ≥ LLQ (14.7) | 78 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 2) ≥ 64 | 31 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 0) ≥ 128 | 1 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 3) ≥ 8 | 93 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 2) ≥ 16 | 64 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 3) ≥ 5 | 94 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 7) ≥ 32 | 63 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 2) ≥ 128 | 14 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 0) ≥ 8 | 11 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 2) ≥ 8 | 70 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 3) ≥ LLQ (14.7) | 92 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 7) ≥ 16 | 74 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 13) ≥ 32 | 43 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 13) ≥ 16 | 61 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 2) ≥ LLQ (14.7) | 66 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 13) ≥ 8 | 71 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 0) ≥ 5 | 11 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 0) ≥ 16 | 10 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 13) ≥ 128 | 9 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 3) ≥ 64 | 68 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 13) ≥ 5 | 76 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 7) ≥ 8 | 84 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 3) ≥ 128 | 39 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 0) ≥ 32 | 3 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 2) ≥ 32 | 47 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 13) ≥ LLQ (14.7) | 64 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 2) ≥ 5 | 72 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 7) ≥ 128 | 14 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 0) ≥ LLQ (14.7) | 10 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 0) ≥ 64 | 2 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 13) ≥ 64 | 21 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 7) ≥ 5 | 86 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 13) ≥ 8 | 63 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 0) ≥ LLQ (14.7) | 13 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 0) ≥ 5 | 15 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 0) ≥ 8 | 14 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 0) ≥ 16 | 13 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 0) ≥ 32 | 8 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 0) ≥ 64 | 4 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 0) ≥ 128 | 1 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 2) ≥ LLQ (14.7) | 85 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 2) ≥ 5 | 90 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 2) ≥ 8 | 89 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 2) ≥ 16 | 85 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 2) ≥ 32 | 75 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 2) ≥ 64 | 59 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 2) ≥ 128 | 39 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 3) ≥ LLQ (14.7) | 80 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 3) ≥ 5 | 84 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 3) ≥ 8 | 83 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 3) ≥ 16 | 79 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 3) ≥ 32 | 68 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 3) ≥ 64 | 47 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 3) ≥ 128 | 28 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 7) ≥ LLQ (14.7) | 72 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 7) ≥ 5 | 80 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 7) ≥ 8 | 77 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 7) ≥ 16 | 69 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 7) ≥ 32 | 54 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 7) ≥ 64 | 35 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 7) ≥ 128 | 22 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 13) ≥ LLQ (14.7) | 58 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 13) ≥ 5 | 73 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 13) ≥ 16 | 55 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 13) ≥ 32 | 40 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 13) ≥ 64 | 23 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 13) ≥ 128 | 11 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 2) ≥ 16 | 58 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 0) ≥ 5 | 7 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 7) ≥ 8 | 95 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 2) ≥ 128 | 12 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 7) ≥ 128 | 57 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 2) ≥ LLQ (14.7) | 60 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 0) ≥ 64 | 0 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 7) ≥ 64 | 79 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 7) ≥ 16 | 94 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 3) ≥ 64 | 24 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 13) ≥ 64 | 41 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 2) ≥ 64 | 30 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 0) ≥ 128 | 0 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 13) ≥ 128 | 21 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 7) ≥ 32 | 87 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 3) ≥ LLQ (14.7) | 58 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 13) ≥ 16 | 76 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 3) ≥ 16 | 57 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 13) ≥ 32 | 60 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 3) ≥ 128 | 16 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 3) ≥ 32 | 44 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 0) ≥ LLQ (14.7) | 6 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 2) ≥ 8 | 62 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 0) ≥ 8 | 7 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 3) ≥ 8 | 60 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 7) ≥ LLQ (14.7) | 95 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 13) ≥ 8 | 84 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 0) ≥ 16 | 6 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 3) ≥ 5 | 65 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 2) ≥ 5 | 65 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 13) ≥ 5 | 91 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 7) ≥ 5 | 95 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 2) ≥ 32 | 47 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 13) ≥ LLQ (14.7) | 78 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 0) ≥ 32 | 3 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 7) ≥ LLQ (14.7) | 54 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 3) ≥ 16 | 59 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 0) ≥ 5 | 17 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 3) ≥ 32 | 44 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 2) ≥ 16 | 69 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 3) ≥ 64 | 31 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 2) ≥ 8 | 76 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 3) ≥ 128 | 23 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 13) ≥ 32 | 93 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 2) ≥ 5 | 78 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 7) ≥ 5 | 69 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 2) ≥ LLQ (14.7) | 72 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 7) ≥ 8 | 64 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 7) ≥ 16 | 52 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 0) ≥ 128 | 1 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 7) ≥ 32 | 40 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 0) ≥ 64 | 5 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 7) ≥ 64 | 27 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 13) ≥ 64 | 92 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 7) ≥ 128 | 13 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 0) ≥ 32 | 8 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 13) ≥ LLQ (14.7) | 97 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 0) ≥ 16 | 12 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 0) ≥ LLQ (14.7) | 13 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 13) ≥ 5 | 97 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 13) ≥ 128 | 73 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 13) ≥ 8 | 97 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 0) ≥ 8 | 16 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 2) ≥ 128 | 23 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 3) ≥ LLQ (14.7) | 62 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 13) ≥ 16 | 97 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 3) ≥ 5 | 70 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 2) ≥ 64 | 39 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 3) ≥ 8 | 67 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 2) ≥ 32 | 54 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 0) ≥ 16 | 6 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 2) ≥ 64 | 39 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 3) ≥ 16 | 90 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 13) ≥ 32 | 69 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 3) ≥ 32 | 83 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 13) ≥ 5 | 91 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 7) ≥ LLQ (14.7) | 97 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 0) ≥ 8 | 9 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 2) ≥ 32 | 50 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 0) ≥ 5 | 9 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 3) ≥ 5 | 93 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 13) ≥ 8 | 87 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 3) ≥ 8 | 93 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 2) ≥ 5 | 65 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 3) ≥ 128 | 47 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 2) ≥ 128 | 23 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 7) ≥ 32 | 91 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 0) ≥ 64 | 3 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 2) ≥ 16 | 60 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 7) ≥ 16 | 97 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 0) ≥ LLQ (14.7) | 7 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 2) ≥ 8 | 64 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 7) ≥ 64 | 75 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 0) ≥ 128 | 1 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 0) ≥ 32 | 4 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 3) ≥ 64 | 65 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 7) ≥ 8 | 98 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 13) ≥ 16 | 81 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 7) ≥ 128 | 57 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 3) ≥ LLQ (14.7) | 90 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 2) ≥ LLQ (14.7) | 61 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 13) ≥ 64 | 46 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 7) ≥ 5 | 99 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 13) ≥ 128 | 28 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With hSBA Titers ≥LLQ, ≥5, ≥8, ≥16, ≥32, ≥64, ≥128 Against Y Human Serogroup for All Schedules. | Y human Serogroup (At Month 13) ≥ LLQ (14.7) | 82 Percentages of subjects |
Secondary
Percentages of Subjects With hSBA Titers ≥ LLQ Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_1 Month, 0_2 Month, 0_6 Month and 0_11 Month Schedule.
The immunogenicity of MenABCWY vaccine, administered according to 0, 2 month schedule, was compared with those, administered according to 0, 1 month, 0, 6 month and 0, 11 month schedules, as measured by the percentages of subjects with hSBA titers ≥ LLQ against N. meningitidis serogroups A, C, W and Y and serogroup B test strains at 1 month after the second meningococcal vaccination.
Time frame: At 1 month after second vaccination (Month 2 for ABCWY_0_1 Group, Month 3 for ABCWY_0_2 Group , Month 7 for ABCWY_0_6 Group and Month 13 for ABCWY_0_11 Group)
Population: Analysis was done on the FAS- 1 month after last meningococcal vaccination, which included all screened subjects who provided informed consent, received a study vaccination \& provided evaluable serum samples at 1 month after last vaccination whose results were available for atleast 1 serogroup or B strain
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥ LLQ Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_1 Month, 0_2 Month, 0_6 Month and 0_11 Month Schedule. | NZ98/254 strain (LLQ=8.2) | 63 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥ LLQ Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_1 Month, 0_2 Month, 0_6 Month and 0_11 Month Schedule. | M14459 strain (LLQ=8.0) | 70 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥ LLQ Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_1 Month, 0_2 Month, 0_6 Month and 0_11 Month Schedule. | M07-0241084 strain (LLQ=8.9) | 49 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥ LLQ Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_1 Month, 0_2 Month, 0_6 Month and 0_11 Month Schedule. | 96217 strain (LLQ=8.6) | 97 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥ LLQ Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_1 Month, 0_2 Month, 0_6 Month and 0_11 Month Schedule. | Serogroup A (LLQ=22.7) | 88 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥ LLQ Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_1 Month, 0_2 Month, 0_6 Month and 0_11 Month Schedule. | Serogroup C (LLQ=5.2) | 99 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥ LLQ Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_1 Month, 0_2 Month, 0_6 Month and 0_11 Month Schedule. | Serogroup W (LLQ=39.6) | 97 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥ LLQ Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_1 Month, 0_2 Month, 0_6 Month and 0_11 Month Schedule. | Serogroup Y (LLQ=14.7) | 92 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥ LLQ Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_1 Month, 0_2 Month, 0_6 Month and 0_11 Month Schedule. | Serogroup C (LLQ=5.2) | 100 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥ LLQ Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_1 Month, 0_2 Month, 0_6 Month and 0_11 Month Schedule. | Serogroup A (LLQ=22.7) | 92 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥ LLQ Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_1 Month, 0_2 Month, 0_6 Month and 0_11 Month Schedule. | M14459 strain (LLQ=8.0) | 62 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥ LLQ Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_1 Month, 0_2 Month, 0_6 Month and 0_11 Month Schedule. | Serogroup Y (LLQ=14.7) | 85 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥ LLQ Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_1 Month, 0_2 Month, 0_6 Month and 0_11 Month Schedule. | Serogroup W (LLQ=39.6) | 96 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥ LLQ Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_1 Month, 0_2 Month, 0_6 Month and 0_11 Month Schedule. | 96217 strain (LLQ=8.6) | 97 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥ LLQ Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_1 Month, 0_2 Month, 0_6 Month and 0_11 Month Schedule. | M07-0241084 strain (LLQ=8.9) | 40 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥ LLQ Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_1 Month, 0_2 Month, 0_6 Month and 0_11 Month Schedule. | NZ98/254 strain (LLQ=8.2) | 44 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥ LLQ Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_1 Month, 0_2 Month, 0_6 Month and 0_11 Month Schedule. | Serogroup W (LLQ=39.6) | 99 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥ LLQ Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_1 Month, 0_2 Month, 0_6 Month and 0_11 Month Schedule. | M07-0241084 strain (LLQ=8.9) | 66 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥ LLQ Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_1 Month, 0_2 Month, 0_6 Month and 0_11 Month Schedule. | 96217 strain (LLQ=8.6) | 98 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥ LLQ Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_1 Month, 0_2 Month, 0_6 Month and 0_11 Month Schedule. | Serogroup A (LLQ=22.7) | 94 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥ LLQ Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_1 Month, 0_2 Month, 0_6 Month and 0_11 Month Schedule. | Serogroup C (LLQ=5.2) | 99 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥ LLQ Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_1 Month, 0_2 Month, 0_6 Month and 0_11 Month Schedule. | Serogroup Y (LLQ=14.7) | 94 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥ LLQ Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_1 Month, 0_2 Month, 0_6 Month and 0_11 Month Schedule. | NZ98/254 strain (LLQ=8.2) | 64 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With hSBA Titers ≥ LLQ Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_1 Month, 0_2 Month, 0_6 Month and 0_11 Month Schedule. | M14459 strain (LLQ=8.0) | 87 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥ LLQ Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_1 Month, 0_2 Month, 0_6 Month and 0_11 Month Schedule. | M07-0241084 strain (LLQ=8.9) | 69 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥ LLQ Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_1 Month, 0_2 Month, 0_6 Month and 0_11 Month Schedule. | 96217 strain (LLQ=8.6) | 98 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥ LLQ Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_1 Month, 0_2 Month, 0_6 Month and 0_11 Month Schedule. | M14459 strain (LLQ=8.0) | 89 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥ LLQ Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_1 Month, 0_2 Month, 0_6 Month and 0_11 Month Schedule. | NZ98/254 strain (LLQ=8.2) | 73 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥ LLQ Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_1 Month, 0_2 Month, 0_6 Month and 0_11 Month Schedule. | Serogroup A (LLQ=22.7) | 94 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥ LLQ Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_1 Month, 0_2 Month, 0_6 Month and 0_11 Month Schedule. | Serogroup Y (LLQ=14.7) | 97 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥ LLQ Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_1 Month, 0_2 Month, 0_6 Month and 0_11 Month Schedule. | Serogroup W (LLQ=39.6) | 98 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With hSBA Titers ≥ LLQ Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_1 Month, 0_2 Month, 0_6 Month and 0_11 Month Schedule. | Serogroup C (LLQ=5.2) | 100 Percentages of subjects |
Secondary
Percentages of Subjects With hSBA Titers ≥LLQ Against N. Meningitidis Serogroups A, C, W and y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_2 Month Schedule.
The immunogenicity of MenABCWY vaccine, administered according to 0, 2, 6 month schedule, was compared with those, administered according to 0, 2 month schedule, as measured by the percentages of subjects with hSBA titers ≥ LLQ against N. meningitidis serogroup B test strains at 1 month after the last meningococcal vaccination.
Time frame: At baseline (Month 0) and 1 month after the last meningococcal vaccination (Month 3 for ABCWY_ 0_2 Group and Month 7 for ABCWY_0_2_6 Group)
Population: Analysis was done on the FAS-1 month after the last meningococcal vaccination.All subjects in All Enrolled Set who received a study meningococcal vaccination \& provided evaluable serum samples at pre- \& at one month after the last meningococcal vaccination whose result is available for at least one A,C,W,or Y serogroup or serogroup B test strain.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ Against N. Meningitidis Serogroups A, C, W and y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_2 Month Schedule. | M07-0241084 strain (Month 0) | 18 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ Against N. Meningitidis Serogroups A, C, W and y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_2 Month Schedule. | M07-0241084 strain (Month 3/7) | 49 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ Against N. Meningitidis Serogroups A, C, W and y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_2 Month Schedule. | 96217 strain (Month 0) | 28 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ Against N. Meningitidis Serogroups A, C, W and y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_2 Month Schedule. | 96217 strain (Month 3/7) | 97 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ Against N. Meningitidis Serogroups A, C, W and y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_2 Month Schedule. | Serogroup A (Month 0) | 3 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ Against N. Meningitidis Serogroups A, C, W and y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_2 Month Schedule. | Serogroup A (Month 3/7) | 88 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ Against N. Meningitidis Serogroups A, C, W and y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_2 Month Schedule. | Serogroup C (Month 0) | 44 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ Against N. Meningitidis Serogroups A, C, W and y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_2 Month Schedule. | Serogroup C (Month 3/7) | 99 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ Against N. Meningitidis Serogroups A, C, W and y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_2 Month Schedule. | Serogroup W (Month 0) | 27 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ Against N. Meningitidis Serogroups A, C, W and y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_2 Month Schedule. | Serogroup W (Month 3/7) | 97 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ Against N. Meningitidis Serogroups A, C, W and y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_2 Month Schedule. | Serogroup Y (Month 0) | 9 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ Against N. Meningitidis Serogroups A, C, W and y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_2 Month Schedule. | Serogroup Y (Month 3/7) | 92 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ Against N. Meningitidis Serogroups A, C, W and y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_2 Month Schedule. | NZ98/254 strain (Month 0) | 6 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ Against N. Meningitidis Serogroups A, C, W and y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_2 Month Schedule. | NZ98/254 strain (Month 3/7) | 63 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ Against N. Meningitidis Serogroups A, C, W and y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_2 Month Schedule. | M14459 strain (Month 0) | 5 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ Against N. Meningitidis Serogroups A, C, W and y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_2 Month Schedule. | M14459 strain (Month 3/Month 7) | 70 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ Against N. Meningitidis Serogroups A, C, W and y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_2 Month Schedule. | M14459 strain (Month 3/Month 7) | 89 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ Against N. Meningitidis Serogroups A, C, W and y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_2 Month Schedule. | M07-0241084 strain (Month 0) | 18 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ Against N. Meningitidis Serogroups A, C, W and y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_2 Month Schedule. | Serogroup W (Month 0) | 22 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ Against N. Meningitidis Serogroups A, C, W and y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_2 Month Schedule. | M07-0241084 strain (Month 3/7) | 72 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ Against N. Meningitidis Serogroups A, C, W and y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_2 Month Schedule. | NZ98/254 strain (Month 0) | 2 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ Against N. Meningitidis Serogroups A, C, W and y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_2 Month Schedule. | 96217 strain (Month 0) | 27 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ Against N. Meningitidis Serogroups A, C, W and y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_2 Month Schedule. | Serogroup W (Month 3/7) | 99 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ Against N. Meningitidis Serogroups A, C, W and y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_2 Month Schedule. | 96217 strain (Month 3/7) | 99 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ Against N. Meningitidis Serogroups A, C, W and y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_2 Month Schedule. | M14459 strain (Month 0) | 2 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ Against N. Meningitidis Serogroups A, C, W and y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_2 Month Schedule. | Serogroup A (Month 0) | 1 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ Against N. Meningitidis Serogroups A, C, W and y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_2 Month Schedule. | Serogroup Y (Month 0) | 6 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ Against N. Meningitidis Serogroups A, C, W and y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_2 Month Schedule. | Serogroup A (Month 3/7) | 95 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ Against N. Meningitidis Serogroups A, C, W and y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_2 Month Schedule. | NZ98/254 strain (Month 3/7) | 74 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ Against N. Meningitidis Serogroups A, C, W and y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_2 Month Schedule. | Serogroup C (Month 0) | 41 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ Against N. Meningitidis Serogroups A, C, W and y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_2 Month Schedule. | Serogroup Y (Month 3/7) | 97 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥LLQ Against N. Meningitidis Serogroups A, C, W and y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_2 Month Schedule. | Serogroup C (Month 3/7) | 100 Percentages of subjects |
Secondary
Percentages of Subjects With hSBA Titers ≥ Lower Limit of Quantitation (LLQ) Against N. Meningitidis Serogroup B Test Strains When Administered According to 0_2 Month Schedule.
A sufficient immune response following Bexsero vaccine, administered according to 0, 2 month schedule, as measured by the percentage of subjects with hSBA titers ≥ Lower Limit of Quantitation (LLQ) against N. meningitidis serogroup B test strains at 1 month after the last meningococcal vaccination, was to be demonstrated. Criterion: the immune response was to be considered sufficient if the lower limit of the two-sided 95% CI for the percentage of subjects with hSBA titers ≥ LLQ was greater than 75% for each of the four serogroup B test strains. The test strains assessed were Meningitis B NZ98/254 Ab, Meningitis B M14459 Ab, Meningitis B M07-0241084 Ab and Meningitis B 96217 Ab.
Time frame: At baseline (Month 0) and 1 month after the last meningococcal vaccination (Month 3)
Population: Analysis was done on Full Analysis Set(FAS)- 1 month post meningococcal vaccination. Subjects in All Enrolled Set who received a study meningococcal vaccination \& provided evaluable serum samples at pre- \& at 1 month post last meningococcal vaccination whose result is available for at least one A,C,W or Y serogroup or serogroup B test strain.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥ Lower Limit of Quantitation (LLQ) Against N. Meningitidis Serogroup B Test Strains When Administered According to 0_2 Month Schedule. | NZ98/254 strain - month 0 (LLQ = 8.2) | 7 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥ Lower Limit of Quantitation (LLQ) Against N. Meningitidis Serogroup B Test Strains When Administered According to 0_2 Month Schedule. | NZ98/254 strain - month 3 (LLQ = 8.2) | 88 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥ Lower Limit of Quantitation (LLQ) Against N. Meningitidis Serogroup B Test Strains When Administered According to 0_2 Month Schedule. | M14459 strain - month 0 (LLQ = 8.0) | 7 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥ Lower Limit of Quantitation (LLQ) Against N. Meningitidis Serogroup B Test Strains When Administered According to 0_2 Month Schedule. | M14459 strain - month 3 (LLQ = 8.0) | 82 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥ Lower Limit of Quantitation (LLQ) Against N. Meningitidis Serogroup B Test Strains When Administered According to 0_2 Month Schedule. | M07-0241084 strain - month 0 (LLQ = 8.9) | 21 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥ Lower Limit of Quantitation (LLQ) Against N. Meningitidis Serogroup B Test Strains When Administered According to 0_2 Month Schedule. | M07-0241084 strain - month 3 (LLQ = 8.9) | 66 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥ Lower Limit of Quantitation (LLQ) Against N. Meningitidis Serogroup B Test Strains When Administered According to 0_2 Month Schedule. | 96217 strain - month 0 (LLQ = 8.6) | 23 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥ Lower Limit of Quantitation (LLQ) Against N. Meningitidis Serogroup B Test Strains When Administered According to 0_2 Month Schedule. | 96217 strain - month 3 (LLQ = 8.6) | 99 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥ Lower Limit of Quantitation (LLQ) Against N. Meningitidis Serogroup B Test Strains When Administered According to 0_2 Month Schedule. | 96217 strain - month 3 (LLQ = 8.6) | 97 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥ Lower Limit of Quantitation (LLQ) Against N. Meningitidis Serogroup B Test Strains When Administered According to 0_2 Month Schedule. | NZ98/254 strain - month 0 (LLQ = 8.2) | 6 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥ Lower Limit of Quantitation (LLQ) Against N. Meningitidis Serogroup B Test Strains When Administered According to 0_2 Month Schedule. | M07-0241084 strain - month 0 (LLQ = 8.9) | 18 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥ Lower Limit of Quantitation (LLQ) Against N. Meningitidis Serogroup B Test Strains When Administered According to 0_2 Month Schedule. | NZ98/254 strain - month 3 (LLQ = 8.2) | 61 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥ Lower Limit of Quantitation (LLQ) Against N. Meningitidis Serogroup B Test Strains When Administered According to 0_2 Month Schedule. | 96217 strain - month 0 (LLQ = 8.6) | 29 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥ Lower Limit of Quantitation (LLQ) Against N. Meningitidis Serogroup B Test Strains When Administered According to 0_2 Month Schedule. | M14459 strain - month 0 (LLQ = 8.0) | 5 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥ Lower Limit of Quantitation (LLQ) Against N. Meningitidis Serogroup B Test Strains When Administered According to 0_2 Month Schedule. | M07-0241084 strain - month 3 (LLQ = 8.9) | 47 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥ Lower Limit of Quantitation (LLQ) Against N. Meningitidis Serogroup B Test Strains When Administered According to 0_2 Month Schedule. | M14459 strain - month 3 (LLQ = 8.0) | 68 Percentages of subjects |
Secondary
Percentages of Subjects With hSBA Titers ≥ Lower Limit of Quantitation (LLQ) Against Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_6 Month Schedule.
The immunogenicity of MenABCWY vaccine, administered according to 0, 2, 6 month schedule, was compared with those, administered according to 0, 6 month schedule, as measured by the percentages of subjects with hSBA titers ≥ LLQ against serogroups A, C, W and Y and serogroup B test strains at 1 month after the last meningococcal vaccination.
Time frame: At baseline (Month 0) and 1 month after the last meningococcal vaccination (Month 7)
Population: Analysis was done on the FAS- 1 month after last meningococcal vaccination, which included all screened subjects who provided informed consent, received a study vaccination \& provided evaluable serum samples at 1 month after last vaccination whose results were available for atleast 1 serogroup or B strain
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥ Lower Limit of Quantitation (LLQ) Against Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_6 Month Schedule. | NZ98/254 strain - month 0 (LLQ=8.2) | 5 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥ Lower Limit of Quantitation (LLQ) Against Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_6 Month Schedule. | NZ98/254 strain - month 7 (LLQ=8.2) | 64 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥ Lower Limit of Quantitation (LLQ) Against Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_6 Month Schedule. | M14459 strain - month 0 (LLQ=8.0) | 5 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥ Lower Limit of Quantitation (LLQ) Against Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_6 Month Schedule. | M14459 strain - month 7 (LLQ=8.0) | 87 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥ Lower Limit of Quantitation (LLQ) Against Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_6 Month Schedule. | M07-0241084 strain - month 0 (LLQ=8.9) | 14 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥ Lower Limit of Quantitation (LLQ) Against Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_6 Month Schedule. | M07-0241084 strain - month 7 (LLQ=8.9) | 66 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥ Lower Limit of Quantitation (LLQ) Against Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_6 Month Schedule. | 96217 strain - month 0 (LLQ=8.6) | 27 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥ Lower Limit of Quantitation (LLQ) Against Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_6 Month Schedule. | 996217 strain - month 7 (LLQ=8.6) | 98 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥ Lower Limit of Quantitation (LLQ) Against Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_6 Month Schedule. | A human serogroup - month 0 (LLQ=22.7) | 2 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥ Lower Limit of Quantitation (LLQ) Against Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_6 Month Schedule. | A human serogroup - month 7 (LLQ=22.7) | 94 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥ Lower Limit of Quantitation (LLQ) Against Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_6 Month Schedule. | C human serogroup - month 0 (LLQ=5.2) | 42 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥ Lower Limit of Quantitation (LLQ) Against Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_6 Month Schedule. | C human serogroup - month 7 (LLQ=5.2) | 99 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥ Lower Limit of Quantitation (LLQ) Against Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_6 Month Schedule. | W human serogroup - month 0 (LLQ=39.6) | 20 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥ Lower Limit of Quantitation (LLQ) Against Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_6 Month Schedule. | W human serogroup -month 7 (LLQ=39.6) | 99 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥ Lower Limit of Quantitation (LLQ) Against Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_6 Month Schedule. | Y human serogroup - month 0 (LLQ=14.7) | 7 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With hSBA Titers ≥ Lower Limit of Quantitation (LLQ) Against Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_6 Month Schedule. | Y human serogroup - month 7 (LLQ=14.7) | 94 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥ Lower Limit of Quantitation (LLQ) Against Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_6 Month Schedule. | Y human serogroup - month 7 (LLQ=14.7) | 97 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥ Lower Limit of Quantitation (LLQ) Against Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_6 Month Schedule. | NZ98/254 strain - month 0 (LLQ=8.2) | 2 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥ Lower Limit of Quantitation (LLQ) Against Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_6 Month Schedule. | A human serogroup - month 0 (LLQ=22.7) | 1 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥ Lower Limit of Quantitation (LLQ) Against Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_6 Month Schedule. | NZ98/254 strain - month 7 (LLQ=8.2) | 74 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥ Lower Limit of Quantitation (LLQ) Against Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_6 Month Schedule. | W human serogroup - month 0 (LLQ=39.6) | 22 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥ Lower Limit of Quantitation (LLQ) Against Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_6 Month Schedule. | M14459 strain - month 0 (LLQ=8.0) | 2 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥ Lower Limit of Quantitation (LLQ) Against Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_6 Month Schedule. | A human serogroup - month 7 (LLQ=22.7) | 95 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥ Lower Limit of Quantitation (LLQ) Against Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_6 Month Schedule. | M14459 strain - month 7 (LLQ=8.0) | 89 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥ Lower Limit of Quantitation (LLQ) Against Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_6 Month Schedule. | Y human serogroup - month 0 (LLQ=14.7) | 6 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥ Lower Limit of Quantitation (LLQ) Against Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_6 Month Schedule. | M07-0241084 strain - month 0 (LLQ=8.9) | 18 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥ Lower Limit of Quantitation (LLQ) Against Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_6 Month Schedule. | C human serogroup - month 0 (LLQ=5.2) | 41 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥ Lower Limit of Quantitation (LLQ) Against Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_6 Month Schedule. | M07-0241084 strain - month 7 (LLQ=8.9) | 72 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥ Lower Limit of Quantitation (LLQ) Against Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_6 Month Schedule. | W human serogroup -month 7 (LLQ=39.6) | 99 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥ Lower Limit of Quantitation (LLQ) Against Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_6 Month Schedule. | 96217 strain - month 0 (LLQ=8.6) | 27 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥ Lower Limit of Quantitation (LLQ) Against Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_6 Month Schedule. | C human serogroup - month 7 (LLQ=5.2) | 100 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With hSBA Titers ≥ Lower Limit of Quantitation (LLQ) Against Serogroups A, C, W and Y and Serogroup B Test Strains When Administered According to 0_2_6 Month and 0_6 Month Schedule. | 996217 strain - month 7 (LLQ=8.6) | 99 Percentages of subjects |
Secondary
Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules.
The kinetic of immune response (at Months 2, 3, 7 and 13) following different vaccination schedules as measured by the percentages of subjects with two-, three- and four-fold titer rise against serogroups A, C, W and Y and serogroup B test strains was assessed. The two/three/four fold titer rise is defined as: a) for subjects with prevaccination hSBA titers ≤ LLQ, a postvaccination hSBA ≥ 2/3/4 LLQ; b) for subjects with a prevaccination hSBA titers ≥ LLQ, an increase of at least 2/3/4 times of the prevaccination hSBA titer.
Time frame: At Month 2, Month 3, Month 7 and Month 13
Population: Analysis was done on the FAS Month 13 which included all screened subjects who received a study vaccination \& provided evaluable serum samples at month 0 and atleast from month 2 to 13 and provided results for atleast one serogroup or serogroup B test strain.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | NZ98/254 Strain ≥ 2-fold (At Month 13) | 11 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | A human Serogroup ≥ 3-fold (At Month 2) | 9 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | NZ98/254 Strain ≥ 4-fold (At Month 3) | 47 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | C human Serogroup ≥ 2-fold (At Month 3) | 80 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | A human Serogroup ≥ 4-fold (At Month 2) | 6 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | C human Serogroup ≥ 4-fold (At Month 2) | 9 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | A human Serogroup ≥ 2-fold (At Month 3) | 80 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | 96217 Strain ≥ 2-fold (At Month 13) | 65 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | A human Serogroup ≥ 3-fold (At Month 13) | 9 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | 96217 Strain ≥ 3-fold (At Month 13) | 53 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | C human Serogroup ≥ 2-fold (At Month 2) | 24 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | A human Serogroup ≥ 3-fold (At Month 3) | 66 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | A human Serogroup ≥ 2-fold (At Month 13) | 16 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | A human Serogroup ≥ 4-fold (At Month 3) | 56 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | A human Serogroup ≥ 4-fold (At Month 7) | 11 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | A human Serogroup ≥ 2-fold (At Month 7) | 27 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | 96217 Strain ≥ 4-fold (At Month 13) | 35 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | NZ98/254 Strain ≥ 2-fold (At Month 7) | 19 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | A human Serogroup ≥ 2-fold (At Month 2) | 12 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | A human Serogroup ≥ 3-fold (At Month 7) | 17 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | Y human Serogroup ≥ 2-fold (At Month 7) | 5 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | NZ98/254 Strain ≥ 3-fold (At Month 7) | 11 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | Y human Serogroup ≥ 4-fold (At Month 3) | 4 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | NZ98/254 Strain ≥ 4-fold (At Month 7) | 9 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | A human Serogroup ≥ 4-fold (At Month 13) | 5 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | Y human Serogroup ≥ 3-fold (At Month 7) | 3 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | Y human Serogroup ≥ 3-fold (At Month 3) | 7 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | NZ98/254 Strain ≥ 3-fold (At Month 13) | 5 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | Y human Serogroup ≥ 2-fold (At Month 3) | 10 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | NZ98/254 Strain ≥ 4-fold (At Month 13) | 4 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | C human Serogroup ≥ 3-fold (At Month 2) | 15 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M14459 Strain ≥ 2-fold (At Month 2) | 14 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | Y human Serogroup ≥ 4-fold (At Month 2) | 2 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M14459 Strain ≥ 3-fold (At Month 2) | 10 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | Y human Serogroup ≥ 3-fold (At Month 2) | 4 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M14459 Strain ≥ 4-fold (At Month 2) | 7 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M14459 Strain ≥ 2-fold (At Month 3) | 65 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | NZ98/254 Strain ≥ 2-fold (At Month 2) | 18 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | Y human Serogroup ≥ 2-fold (At Month 2) | 6 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M07-0241084 Strain ≥ 4-fold (At Month 7) | 7 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | W human Serogroup ≥ 4-fold (At Month 13) | 7 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M07-0241084 Strain ≥ 2-fold (At Month 13) | 13 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M07-0241084 Strain ≥ 3-fold (At Month 13) | 9 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | W human Serogroup ≥ 3-fold (At Month 13) | 9 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M07-0241084 Strain ≥ 4-fold (At Month 13) | 5 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | Y human Serogroup ≥ 3-fold (At Month 13) | 3 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | W human Serogroup ≥ 2-fold (At Month 13) | 20 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M14459 Strain ≥ 3-fold (At Month 13) | 8 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | W human Serogroup ≥ 4-fold (At Month 7) | 13 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M14459 Strain ≥ 4-fold (At Month 13) | 3 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | NZ98/254 Strain ≥ 3-fold (At Month 2) | 14 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | W human Serogroup ≥ 3-fold (At Month 7) | 22 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M07-0241084 Strain ≥ 2-fold (At Month 2) | 16 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M07-0241084 Strain ≥ 3-fold (At Month 2) | 12 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | W human Serogroup ≥ 2-fold (At Month 7) | 31 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M07-0241084 Strain ≥ 4-fold (At Month 2) | 8 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | W human Serogroup ≥ 4-fold (At Month 3) | 43 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M07-0241084 Strain ≥ 2-fold (At Month 3) | 37 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M07-0241084 Strain ≥ 3-fold (At Month 3) | 28 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | Y human Serogroup ≥ 2-fold (At Month 13) | 5 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | W human Serogroup ≥ 3-fold (At Month 3) | 54 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M07-0241084 Strain ≥ 4-fold (At Month 3) | 19 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | NZ98/254 Strain ≥ 4-fold (At Month 2) | 11 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | W human Serogroup ≥ 2-fold (At Month 3) | 67 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M07-0241084 Strain ≥ 2-fold (At Month 7) | 19 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M07-0241084 Strain ≥ 3-fold (At Month 7) | 11 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | W human Serogroup ≥ 4-fold (At Month 2) | 11 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | 96217 Strain ≥ 2-fold (At Month 3) | 97 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | W human Serogroup ≥ 3-fold (At Month 2) | 17 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | 96217 Strain ≥ 3-fold (At Month 3) | 96 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M14459 Strain ≥ 3-fold (At Month 3) | 49 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | W human Serogroup ≥ 2-fold (At Month 2) | 24 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M14459 Strain ≥ 4-fold (At Month 3) | 38 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | NZ98/254 Strain ≥ 2-fold (At Month 3) | 73 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | C human Serogroup ≥ 4-fold (At Month 13) | 10 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M14459 Strain ≥ 2-fold (At Month 7) | 16 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M14459 Strain ≥ 3-fold (At Month 7) | 12 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | C human Serogroup ≥ 3-fold (At Month 13) | 13 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M14459 Strain ≥ 4-fold (At Month 7) | 8 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | C human Serogroup ≥ 2-fold (At Month 13) | 19 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M14459 Strain ≥ 2-fold (At Month 13) | 11 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | 96217 Strain ≥ 2-fold (At Month 2) | 34 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | Y human Serogroup ≥ 4-fold (At Month 7) | 3 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | C human Serogroup ≥ 4-fold (At Month 7) | 10 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | 96217 Strain ≥ 3-fold (At Month 2) | 26 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | 96217 Strain ≥ 4-fold (At Month 2) | 18 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | C human Serogroup ≥ 3-fold (At Month 7) | 16 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | NZ98/254 Strain ≥ 3-fold (At Month 3) | 61 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | C human Serogroup ≥ 2-fold (At Month 7) | 29 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | 96217 Strain ≥ 4-fold (At Month 3) | 94 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | C human Serogroup ≥ 4-fold (At Month 3) | 49 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | 96217 Strain ≥ 2-fold (At Month 7) | 81 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | Y human Serogroup ≥ 4-fold (At Month 13) | 2 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | 96217 Strain ≥ 3-fold (At Month 7) | 73 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | C human Serogroup ≥ 3-fold (At Month 3) | 64 Percentages of subjects |
| ABCWY_ 0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | 96217 Strain ≥ 4-fold (At Month 7) | 61 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | NZ98/254 Strain ≥ 4-fold (At Month 2) | 8 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | W human Serogroup ≥ 4-fold (At Month 7) | 21 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | A human Serogroup ≥ 3-fold (At Month 2) | 16 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M14459 Strain ≥ 2-fold (At Month 13) | 9 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | W human Serogroup ≥ 4-fold (At Month 2) | 16 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | C human Serogroup ≥ 2-fold (At Month 3) | 94 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M14459 Strain ≥ 3-fold (At Month 7) | 7 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M07-0241084 Strain ≥ 2-fold (At Month 13) | 11 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | A human Serogroup ≥ 4-fold (At Month 2) | 11 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M14459 Strain ≥ 4-fold (At Month 13) | 4 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M14459 Strain ≥ 2-fold (At Month 3) | 50 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | NZ98/254 Strain ≥ 4-fold (At Month 3) | 22 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | C human Serogroup ≥ 4-fold (At Month 2) | 42 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | C human Serogroup ≥ 3-fold (At Month 3) | 90 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | 96217 Strain ≥ 4-fold (At Month 7) | 50 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | A human Serogroup ≥ 2-fold (At Month 3) | 71 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | W human Serogroup ≥ 3-fold (At Month 7) | 30 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | 96217 Strain ≥ 2-fold (At Month 2) | 29 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | C human Serogroup ≥ 3-fold (At Month 13) | 64 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M07-0241084 Strain ≥ 2-fold (At Month 2) | 11 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | 96217 Strain ≥ 2-fold (At Month 13) | 54 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | NZ98/254 Strain ≥ 3-fold (At Month 3) | 32 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | NZ98/254 Strain ≥ 3-fold (At Month 2) | 9 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | A human Serogroup ≥ 3-fold (At Month 13) | 8 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | 96217 Strain ≥ 2-fold (At Month 3) | 92 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | W human Serogroup ≥ 3-fold (At Month 13) | 13 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | 96217 Strain ≥ 3-fold (At Month 13) | 39 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | W human Serogroup ≥ 2-fold (At Month 7) | 51 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | 96217 Strain ≥ 2-fold (At Month 7) | 74 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | A human Serogroup ≥ 2-fold (At Month 13) | 12 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | W human Serogroup ≥ 3-fold (At Month 2) | 19 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | A human Serogroup ≥ 3-fold (At Month 3) | 52 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M07-0241084 Strain ≥ 3-fold (At Month 2) | 7 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M14459 Strain ≥ 4-fold (At Month 7) | 6 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | 96217 Strain ≥ 3-fold (At Month 3) | 89 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M07-0241084 Strain ≥ 3-fold (At Month 13) | 7 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | C human Serogroup ≥ 4-fold (At Month 7) | 71 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | A human Serogroup ≥ 4-fold (At Month 3) | 42 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M14459 Strain ≥ 4-fold (At Month 2) | 6 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | Y human Serogroup ≥ 2-fold (At Month 7) | 60 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | A human Serogroup ≥ 4-fold (At Month 7) | 10 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | A human Serogroup ≥ 4-fold (At Month 13) | 4 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M07-0241084 Strain ≥ 4-fold (At Month 2) | 5 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | A human Serogroup ≥ 2-fold (At Month 7) | 28 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | W human Serogroup ≥ 2-fold (At Month 2) | 32 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | 96217 Strain ≥ 4-fold (At Month 13) | 22 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M14459 Strain ≥ 3-fold (At Month 2) | 10 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M07-0241084 Strain ≥ 3-fold (At Month 7) | 7 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | W human Serogroup ≥ 4-fold (At Month 3) | 57 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | A human Serogroup ≥ 3-fold (At Month 7) | 16 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | Y human Serogroup ≥ 4-fold (At Month 13) | 25 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M14459 Strain ≥ 3-fold (At Month 3) | 39 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | A human Serogroup ≥ 2-fold (At Month 2) | 23 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M07-0241084 Strain ≥ 4-fold (At Month 13) | 6 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | NZ98/254 Strain ≥ 2-fold (At Month 7) | 12 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M07-0241084 Strain ≥ 2-fold (At Month 3) | 22 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M07-0241084 Strain ≥ 4-fold (At Month 7) | 6 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | C human Serogroup ≥ 2-fold (At Month 2) | 64 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | Y human Serogroup ≥ 4-fold (At Month 7) | 41 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | Y human Serogroup ≥ 2-fold (At Month 13) | 43 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | C human Serogroup ≥ 2-fold (At Month 7) | 86 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | NZ98/254 Strain ≥ 3-fold (At Month 7) | 10 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | C human Serogroup ≥ 2-fold (At Month 13) | 73 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | W human Serogroup ≥ 3-fold (At Month 3) | 65 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | Y human Serogroup ≥ 4-fold (At Month 3) | 68 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | 96217 Strain ≥ 3-fold (At Month 2) | 20 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | 96217 Strain ≥ 3-fold (At Month 7) | 63 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | NZ98/254 Strain ≥ 4-fold (At Month 7) | 8 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M07-0241084 Strain ≥ 3-fold (At Month 3) | 12 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M14459 Strain ≥ 4-fold (At Month 3) | 28 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | W human Serogroup ≥ 2-fold (At Month 13) | 26 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | Y human Serogroup ≥ 3-fold (At Month 3) | 80 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | Y human Serogroup ≥ 3-fold (At Month 2) | 39 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | NZ98/254 Strain ≥ 2-fold (At Month 13) | 9 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | NZ98/254 Strain ≥ 2-fold (At Month 2) | 13 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | C human Serogroup ≥ 4-fold (At Month 3) | 87 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | W human Serogroup ≥ 4-fold (At Month 13) | 11 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M07-0241084 Strain ≥ 4-fold (At Month 3) | 9 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | C human Serogroup ≥ 4-fold (At Month 13) | 51 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | NZ98/254 Strain ≥ 3-fold (At Month 13) | 7 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | Y human Serogroup ≥ 3-fold (At Month 7) | 48 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | Y human Serogroup ≥ 3-fold (At Month 13) | 34 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | Y human Serogroup ≥ 2-fold (At Month 3) | 84 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | 96217 Strain ≥ 4-fold (At Month 3) | 83 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | C human Serogroup ≥ 3-fold (At Month 7) | 80 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | NZ98/254 Strain ≥ 4-fold (At Month 13) | 5 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | W human Serogroup ≥ 2-fold (At Month 3) | 78 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M14459 Strain ≥ 2-fold (At Month 7) | 14 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M14459 Strain ≥ 3-fold (At Month 13) | 4 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | Y human Serogroup ≥ 4-fold (At Month 2) | 32 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | 96217 Strain ≥ 4-fold (At Month 2) | 13 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M14459 Strain ≥ 2-fold (At Month 2) | 13 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M07-0241084 Strain ≥ 2-fold (At Month 7) | 13 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | C human Serogroup ≥ 3-fold (At Month 2) | 50 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | NZ98/254 Strain ≥ 2-fold (At Month 3) | 42 Percentages of subjects |
| rMenB_0_2 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | Y human Serogroup ≥ 2-fold (At Month 2) | 49 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | Y human Serogroup ≥ 3-fold (At Month 2) | 64 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M14459 Strain ≥ 3-fold (At Month 2) | 23 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M14459 Strain ≥ 4-fold (At Month 2) | 15 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M07-0241084 Strain ≥ 3-fold (At Month 7) | 6 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | Y human Serogroup ≥ 2-fold (At Month 2) | 74 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M14459 Strain ≥ 2-fold (At Month 3) | 24 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M14459 Strain ≥ 3-fold (At Month 7) | 6 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | NZ98/254 Strain ≥ 2-fold (At Month 3) | 18 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | W human Serogroup ≥ 4-fold (At Month 13) | 13 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | NZ98/254 Strain ≥ 3-fold (At Month 3) | 13 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M07-0241084 Strain ≥ 4-fold (At Month 7) | 3 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | C human Serogroup ≥ 2-fold (At Month 13) | 74 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | C human Serogroup ≥ 4-fold (At Month 3) | 83 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M07-0241084 Strain ≥ 2-fold (At Month 13) | 8 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | NZ98/254 Strain ≥ 2-fold (At Month 2) | 28 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | W human Serogroup ≥ 3-fold (At Month 13) | 17 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M07-0241084 Strain ≥ 3-fold (At Month 13) | 5 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M14459 Strain ≥ 4-fold (At Month 7) | 4 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | W human Serogroup ≥ 2-fold (At Month 13) | 32 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M07-0241084 Strain ≥ 4-fold (At Month 13) | 4 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M14459 Strain ≥ 2-fold (At Month 13) | 6 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | Y human Serogroup ≥ 2-fold (At Month 13) | 38 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | W human Serogroup ≥ 4-fold (At Month 7) | 17 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M14459 Strain ≥ 3-fold (At Month 13) | 4 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | W human Serogroup ≥ 3-fold (At Month 7) | 29 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | C human Serogroup ≥ 4-fold (At Month 7) | 72 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M14459 Strain ≥ 4-fold (At Month 13) | 3 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | 96217 Strain ≥ 2-fold (At Month 2) | 88 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M07-0241084 Strain ≥ 2-fold (At Month 2) | 20 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | W human Serogroup ≥ 2-fold (At Month 7) | 43 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M07-0241084 Strain ≥ 3-fold (At Month 2) | 9 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | NZ98/254 Strain ≥ 3-fold (At Month 2) | 19 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | W human Serogroup ≥ 4-fold (At Month 3) | 30 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | 96217 Strain ≥ 2-fold (At Month 7) | 64 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M07-0241084 Strain ≥ 4-fold (At Month 2) | 7 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | A human Serogroup ≥ 4-fold (At Month 13) | 9 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | C human Serogroup ≥ 2-fold (At Month 3) | 93 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | 96217 Strain ≥ 3-fold (At Month 13) | 34 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M07-0241084 Strain ≥ 2-fold (At Month 3) | 11 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | W human Serogroup ≥ 3-fold (At Month 3) | 39 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M07-0241084 Strain ≥ 3-fold (At Month 3) | 7 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | 96217 Strain ≥ 3-fold (At Month 2) | 81 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | Y human Serogroup ≥ 3-fold (At Month 7) | 44 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | W human Serogroup ≥ 2-fold (At Month 3) | 55 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | C human Serogroup ≥ 3-fold (At Month 7) | 79 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M07-0241084 Strain ≥ 4-fold (At Month 3) | 4 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | C human Serogroup ≥ 3-fold (At Month 3) | 90 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M07-0241084 Strain ≥ 2-fold (At Month 7) | 8 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | W human Serogroup ≥ 4-fold (At Month 2) | 42 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | A human Serogroup ≥ 3-fold (At Month 2) | 64 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | 96217 Strain ≥ 4-fold (At Month 2) | 76 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | NZ98/254 Strain ≥ 4-fold (At Month 2) | 17 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | A human Serogroup ≥ 4-fold (At Month 2) | 50 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | C human Serogroup ≥ 4-fold (At Month 2) | 88 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | W human Serogroup ≥ 3-fold (At Month 2) | 52 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | A human Serogroup ≥ 2-fold (At Month 3) | 61 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | C human Serogroup ≥ 3-fold (At Month 2) | 91 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | A human Serogroup ≥ 3-fold (At Month 13) | 11 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | C human Serogroup ≥ 2-fold (At Month 7) | 89 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | 96217 Strain ≥ 2-fold (At Month 13) | 52 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | NZ98/254 Strain ≥ 4-fold (At Month 3) | 9 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | 96217 Strain ≥ 2-fold (At Month 3) | 85 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | Y human Serogroup ≥ 4-fold (At Month 13) | 23 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | A human Serogroup ≥ 2-fold (At Month 13) | 18 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | A human Serogroup ≥ 3-fold (At Month 3) | 41 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | Y human Serogroup ≥ 2-fold (At Month 7) | 51 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | A human Serogroup ≥ 4-fold (At Month 7) | 13 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | 96217 Strain ≥ 3-fold (At Month 3) | 76 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | A human Serogroup ≥ 4-fold (At Month 3) | 31 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | Y human Serogroup ≥ 4-fold (At Month 7) | 38 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | W human Serogroup ≥ 2-fold (At Month 2) | 65 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | 96217 Strain ≥ 4-fold (At Month 13) | 28 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | 96217 Strain ≥ 4-fold (At Month 7) | 42 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | A human Serogroup ≥ 3-fold (At Month 7) | 16 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | A human Serogroup ≥ 2-fold (At Month 7) | 25 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | A human Serogroup ≥ 2-fold (At Month 2) | 78 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | NZ98/254 Strain ≥ 2-fold (At Month 7) | 11 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M14459 Strain ≥ 3-fold (At Month 3) | 10 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | Y human Serogroup ≥ 4-fold (At Month 3) | 48 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | NZ98/254 Strain ≥ 3-fold (At Month 7) | 7 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | C human Serogroup ≥ 2-fold (At Month 2) | 95 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | C human Serogroup ≥ 4-fold (At Month 13) | 53 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | NZ98/254 Strain ≥ 4-fold (At Month 7) | 6 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | Y human Serogroup ≥ 3-fold (At Month 3) | 55 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M14459 Strain ≥ 4-fold (At Month 3) | 4 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | NZ98/254 Strain ≥ 2-fold (At Month 13) | 7 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | Y human Serogroup ≥ 3-fold (At Month 13) | 28 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | 96217 Strain ≥ 3-fold (At Month 7) | 52 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | Y human Serogroup ≥ 2-fold (At Month 3) | 66 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | NZ98/254 Strain ≥ 3-fold (At Month 13) | 6 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | 96217 Strain ≥ 4-fold (At Month 3) | 69 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | NZ98/254 Strain ≥ 4-fold (At Month 13) | 5 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | Y human Serogroup ≥ 4-fold (At Month 2) | 58 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M14459 Strain ≥ 2-fold (At Month 7) | 9 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M14459 Strain ≥ 2-fold (At Month 2) | 34 Percentages of subjects |
| ABCWY_0_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | C human Serogroup ≥ 3-fold (At Month 13) | 61 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M14459 Strain ≥ 3-fold (At Month 13) | 7 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | A human Serogroup ≥ 4-fold (At Month 13) | 15 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | C human Serogroup ≥ 2-fold (At Month 2) | 55 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | NZ98/254 Strain ≥ 2-fold (At Month 2) | 9 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | NZ98/254 Strain ≥ 3-fold (At Month 2) | 9 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | NZ98/254 Strain ≥ 4-fold (At Month 2) | 7 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | NZ98/254 Strain ≥ 2-fold (At Month 3) | 9 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | NZ98/254 Strain ≥ 3-fold (At Month 3) | 5 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | NZ98/254 Strain ≥ 4-fold (At Month 3) | 4 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | NZ98/254 Strain ≥ 2-fold (At Month 7) | 45 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | NZ98/254 Strain ≥ 3-fold (At Month 7) | 33 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | NZ98/254 Strain ≥ 4-fold (At Month 7) | 24 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | NZ98/254 Strain ≥ 2-fold (At Month 13) | 10 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | NZ98/254 Strain ≥ 3-fold (At Month 13) | 9 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | NZ98/254 Strain ≥ 4-fold (At Month 13) | 6 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M14459 Strain ≥ 2-fold (At Month 2) | 8 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M14459 Strain ≥ 3-fold (At Month 2) | 6 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M14459 Strain ≥ 4-fold (At Month 2) | 4 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M07-0241084 Strain ≥ 3-fold (At Month 7) | 31 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M07-0241084 Strain ≥ 4-fold (At Month 7) | 19 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M07-0241084 Strain ≥ 2-fold (At Month 13) | 13 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M07-0241084 Strain ≥ 3-fold (At Month 13) | 9 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M07-0241084 Strain ≥ 4-fold (At Month 13) | 6 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M14459 Strain ≥ 2-fold (At Month 13) | 10 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M14459 Strain ≥ 4-fold (At Month 13) | 6 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M07-0241084 Strain ≥ 2-fold (At Month 2) | 5 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M07-0241084 Strain ≥ 3-fold (At Month 2) | 2 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M07-0241084 Strain ≥ 4-fold (At Month 2) | 2 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M07-0241084 Strain ≥ 2-fold (At Month 3) | 2 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M07-0241084 Strain ≥ 3-fold (At Month 3) | 1 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M07-0241084 Strain ≥ 4-fold (At Month 3) | 0 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M07-0241084 Strain ≥ 2-fold (At Month 7) | 43 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | 96217 Strain ≥ 4-fold (At Month 2) | 12 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | 96217 Strain ≥ 2-fold (At Month 3) | 28 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M14459 Strain ≥ 2-fold (At Month 3) | 6 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M14459 Strain ≥ 3-fold (At Month 3) | 3 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M14459 Strain ≥ 4-fold (At Month 3) | 3 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M14459 Strain ≥ 2-fold (At Month 7) | 69 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M14459 Strain ≥ 3-fold (At Month 7) | 55 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M14459 Strain ≥ 4-fold (At Month 7) | 48 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | 96217 Strain ≥ 2-fold (At Month 2) | 32 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | 96217 Strain ≥ 3-fold (At Month 2) | 19 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | 96217 Strain ≥ 3-fold (At Month 3) | 14 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | 96217 Strain ≥ 4-fold (At Month 3) | 11 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | 96217 Strain ≥ 3-fold (At Month 13) | 54 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | 96217 Strain ≥ 2-fold (At Month 7) | 96 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | 96217 Strain ≥ 3-fold (At Month 7) | 96 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | 96217 Strain ≥ 4-fold (At Month 7) | 95 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | A human Serogroup ≥ 3-fold (At Month 2) | 14 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | A human Serogroup ≥ 4-fold (At Month 2) | 11 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | 96217 Strain ≥ 2-fold (At Month 13) | 72 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | A human Serogroup ≥ 2-fold (At Month 3) | 20 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | A human Serogroup ≥ 3-fold (At Month 3) | 12 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | A human Serogroup ≥ 4-fold (At Month 3) | 7 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | 96217 Strain ≥ 4-fold (At Month 13) | 45 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | A human Serogroup ≥ 2-fold (At Month 2) | 21 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | A human Serogroup ≥ 2-fold (At Month 7) | 87 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | A human Serogroup ≥ 3-fold (At Month 7) | 76 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | A human Serogroup ≥ 4-fold (At Month 7) | 70 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | A human Serogroup ≥ 2-fold (At Month 13) | 31 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | A human Serogroup ≥ 3-fold (At Month 13) | 25 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | C human Serogroup ≥ 3-fold (At Month 2) | 48 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | C human Serogroup ≥ 4-fold (At Month 2) | 44 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | C human Serogroup ≥ 2-fold (At Month 3) | 58 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | C human Serogroup ≥ 3-fold (At Month 3) | 47 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | C human Serogroup ≥ 4-fold (At Month 3) | 41 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | C human Serogroup ≥ 2-fold (At Month 7) | 97 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | C human Serogroup ≥ 3-fold (At Month 7) | 94 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | C human Serogroup ≥ 4-fold (At Month 7) | 92 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | C human Serogroup ≥ 2-fold (At Month 13) | 82 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | C human Serogroup ≥ 3-fold (At Month 13) | 70 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | C human Serogroup ≥ 4-fold (At Month 13) | 56 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | W human Serogroup ≥ 2-fold (At Month 2) | 35 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | W human Serogroup ≥ 3-fold (At Month 2) | 25 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | W human Serogroup ≥ 4-fold (At Month 2) | 18 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | W human Serogroup ≥ 2-fold (At Month 3) | 34 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | W human Serogroup ≥ 3-fold (At Month 3) | 23 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | W human Serogroup ≥ 4-fold (At Month 3) | 19 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | W human Serogroup ≥ 2-fold (At Month 7) | 90 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | W human Serogroup ≥ 3-fold (At Month 7) | 81 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | W human Serogroup ≥ 4-fold (At Month 7) | 73 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | W human Serogroup ≥ 2-fold (At Month 13) | 56 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | W human Serogroup ≥ 3-fold (At Month 13) | 38 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | W human Serogroup ≥ 4-fold (At Month 13) | 27 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | Y human Serogroup ≥ 2-fold (At Month 2) | 47 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | Y human Serogroup ≥ 3-fold (At Month 2) | 40 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | Y human Serogroup ≥ 4-fold (At Month 2) | 33 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | Y human Serogroup ≥ 2-fold (At Month 3) | 45 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | Y human Serogroup ≥ 3-fold (At Month 3) | 35 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | Y human Serogroup ≥ 4-fold (At Month 3) | 29 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | Y human Serogroup ≥ 2-fold (At Month 7) | 90 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | Y human Serogroup ≥ 3-fold (At Month 7) | 83 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | Y human Serogroup ≥ 4-fold (At Month 7) | 79 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | Y human Serogroup ≥ 2-fold (At Month 13) | 60 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | Y human Serogroup ≥ 3-fold (At Month 13) | 48 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | Y human Serogroup ≥ 4-fold (At Month 13) | 45 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | 96217 Strain ≥ 3-fold (At Month 7) | 9 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | 96217 Strain ≥ 2-fold (At Month 7) | 16 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | Y human Serogroup ≥ 2-fold (At Month 7) | 39 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | C human Serogroup ≥ 3-fold (At Month 3) | 50 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | 96217 Strain ≥ 4-fold (At Month 3) | 13 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | 96217 Strain ≥ 3-fold (At Month 13) | 95 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | C human Serogroup ≥ 4-fold (At Month 3) | 42 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | 96217 Strain ≥ 3-fold (At Month 3) | 17 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | C human Serogroup ≥ 2-fold (At Month 7) | 50 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | A human Serogroup ≥ 2-fold (At Month 2) | 38 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | 96217 Strain ≥ 3-fold (At Month 2) | 18 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | NZ98/254 Strain ≥ 3-fold (At Month 3) | 10 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | C human Serogroup ≥ 3-fold (At Month 7) | 37 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | 96217 Strain ≥ 2-fold (At Month 2) | 31 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | C human Serogroup ≥ 4-fold (At Month 7) | 28 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M14459 Strain ≥ 4-fold (At Month 7) | 5 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | A human Serogroup ≥ 4-fold (At Month 13) | 78 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | C human Serogroup ≥ 2-fold (At Month 13) | 97 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M14459 Strain ≥ 3-fold (At Month 7) | 6 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M14459 Strain ≥ 2-fold (At Month 7) | 7 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | Y human Serogroup ≥ 3-fold (At Month 7) | 28 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | C human Serogroup ≥ 3-fold (At Month 13) | 96 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M14459 Strain ≥ 4-fold (At Month 3) | 7 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | C human Serogroup ≥ 4-fold (At Month 13) | 93 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M14459 Strain ≥ 3-fold (At Month 3) | 11 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M14459 Strain ≥ 2-fold (At Month 3) | 14 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | NZ98/254 Strain ≥ 2-fold (At Month 3) | 13 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | W human Serogroup ≥ 2-fold (At Month 2) | 50 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | 96217 Strain ≥ 2-fold (At Month 3) | 23 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | W human Serogroup ≥ 3-fold (At Month 2) | 40 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | 96217 Strain ≥ 4-fold (At Month 2) | 14 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M07-0241084 Strain ≥ 2-fold (At Month 7) | 4 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | NZ98/254 Strain ≥ 4-fold (At Month 2) | 17 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | W human Serogroup ≥ 4-fold (At Month 2) | 34 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M07-0241084 Strain ≥ 4-fold (At Month 3) | 4 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | W human Serogroup ≥ 2-fold (At Month 3) | 46 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M07-0241084 Strain ≥ 3-fold (At Month 3) | 5 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M07-0241084 Strain ≥ 2-fold (At Month 3) | 8 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | Y human Serogroup ≥ 4-fold (At Month 7) | 23 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | W human Serogroup ≥ 3-fold (At Month 3) | 34 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M07-0241084 Strain ≥ 4-fold (At Month 2) | 9 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | W human Serogroup ≥ 4-fold (At Month 3) | 28 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M07-0241084 Strain ≥ 3-fold (At Month 2) | 12 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M07-0241084 Strain ≥ 2-fold (At Month 2) | 19 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | W human Serogroup ≥ 2-fold (At Month 7) | 41 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M14459 Strain ≥ 4-fold (At Month 13) | 51 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | NZ98/254 Strain ≥ 3-fold (At Month 2) | 17 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | W human Serogroup ≥ 3-fold (At Month 7) | 28 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M14459 Strain ≥ 3-fold (At Month 13) | 59 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | A human Serogroup ≥ 3-fold (At Month 13) | 80 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | W human Serogroup ≥ 4-fold (At Month 7) | 20 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M14459 Strain ≥ 2-fold (At Month 13) | 74 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M07-0241084 Strain ≥ 4-fold (At Month 13) | 21 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | W human Serogroup ≥ 2-fold (At Month 13) | 94 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M07-0241084 Strain ≥ 3-fold (At Month 13) | 34 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M07-0241084 Strain ≥ 2-fold (At Month 13) | 41 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | Y human Serogroup ≥ 2-fold (At Month 13) | 94 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | W human Serogroup ≥ 3-fold (At Month 13) | 92 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M07-0241084 Strain ≥ 4-fold (At Month 7) | 1 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | W human Serogroup ≥ 4-fold (At Month 13) | 89 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M07-0241084 Strain ≥ 3-fold (At Month 7) | 1 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M14459 Strain ≥ 4-fold (At Month 2) | 12 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | NZ98/254 Strain ≥ 2-fold (At Month 2) | 21 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | Y human Serogroup ≥ 2-fold (At Month 2) | 53 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M14459 Strain ≥ 3-fold (At Month 2) | 15 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | Y human Serogroup ≥ 3-fold (At Month 2) | 41 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M14459 Strain ≥ 2-fold (At Month 2) | 23 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | NZ98/254 Strain ≥ 4-fold (At Month 13) | 26 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | C human Serogroup ≥ 2-fold (At Month 2) | 73 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | Y human Serogroup ≥ 4-fold (At Month 2) | 36 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | NZ98/254 Strain ≥ 3-fold (At Month 13) | 37 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | Y human Serogroup ≥ 4-fold (At Month 13) | 89 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | Y human Serogroup ≥ 2-fold (At Month 3) | 46 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | NZ98/254 Strain ≥ 2-fold (At Month 13) | 49 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | NZ98/254 Strain ≥ 4-fold (At Month 7) | 4 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | Y human Serogroup ≥ 3-fold (At Month 13) | 91 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | Y human Serogroup ≥ 3-fold (At Month 3) | 35 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | NZ98/254 Strain ≥ 3-fold (At Month 7) | 6 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | A human Serogroup ≥ 2-fold (At Month 7) | 8 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | 96217 Strain ≥ 4-fold (At Month 13) | 93 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | A human Serogroup ≥ 3-fold (At Month 7) | 6 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | A human Serogroup ≥ 4-fold (At Month 3) | 14 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | Y human Serogroup ≥ 4-fold (At Month 3) | 31 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | A human Serogroup ≥ 4-fold (At Month 7) | 5 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | A human Serogroup ≥ 3-fold (At Month 3) | 18 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | A human Serogroup ≥ 2-fold (At Month 3) | 24 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | A human Serogroup ≥ 2-fold (At Month 13) | 85 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | 96217 Strain ≥ 2-fold (At Month 13) | 96 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | NZ98/254 Strain ≥ 2-fold (At Month 7) | 7 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | 96217 Strain ≥ 4-fold (At Month 7) | 7 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | C human Serogroup ≥ 3-fold (At Month 2) | 59 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | A human Serogroup ≥ 4-fold (At Month 2) | 20 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | NZ98/254 Strain ≥ 4-fold (At Month 3) | 9 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | C human Serogroup ≥ 4-fold (At Month 2) | 50 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | A human Serogroup ≥ 3-fold (At Month 2) | 30 Percentages of subjects |
| ABCWY_0_11 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | C human Serogroup ≥ 2-fold (At Month 3) | 65 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | Y human Serogroup ≥ 4-fold (At Month 3) | 66 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | 96217 Strain ≥ 2-fold (At Month 7) | 97 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | NZ98/254 Strain ≥ 4-fold (At Month 7) | 33 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M14459 Strain ≥ 2-fold (At Month 13) | 12 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | NZ98/254 Strain ≥ 2-fold (At Month 2) | 12 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | C human Serogroup ≥ 3-fold (At Month 3) | 96 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | 96217 Strain ≥ 4-fold (At Month 3) | 83 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | 96217 Strain ≥ 3-fold (At Month 13) | 62 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | W human Serogroup ≥ 4-fold (At Month 7) | 73 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | Y human Serogroup ≥ 2-fold (At Month 7) | 92 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | A human Serogroup ≥ 2-fold (At Month 13) | 28 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | C human Serogroup ≥ 4-fold (At Month 3) | 92 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | 96217 Strain ≥ 3-fold (At Month 3) | 88 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | 96217 Strain ≥ 2-fold (At Month 13) | 77 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | A human Serogroup ≥ 2-fold (At Month 2) | 17 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | NZ98/254 Strain ≥ 3-fold (At Month 3) | 28 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M07-0241084 Strain ≥ 3-fold (At Month 13) | 10 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | C human Serogroup ≥ 2-fold (At Month 7) | 98 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | Y human Serogroup ≥ 4-fold (At Month 13) | 47 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | 96217 Strain ≥ 3-fold (At Month 2) | 19 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | Y human Serogroup ≥ 3-fold (At Month 3) | 75 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | W human Serogroup ≥ 2-fold (At Month 13) | 61 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | NZ98/254 Strain ≥ 3-fold (At Month 7) | 43 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | C human Serogroup ≥ 3-fold (At Month 7) | 98 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | 96217 Strain ≥ 2-fold (At Month 2) | 26 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M07-0241084 Strain ≥ 2-fold (At Month 13) | 15 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M07-0241084 Strain ≥ 4-fold (At Month 13) | 6 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | NZ98/254 Strain ≥ 2-fold (At Month 3) | 43 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | 96217 Strain ≥ 3-fold (At Month 7) | 96 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | C human Serogroup ≥ 4-fold (At Month 7) | 98 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M14459 Strain ≥ 4-fold (At Month 7) | 49 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | NZ98/254 Strain ≥ 2-fold (At Month 7) | 54 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M14459 Strain ≥ 3-fold (At Month 7) | 54 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | A human Serogroup ≥ 2-fold (At Month 7) | 88 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | W human Serogroup ≥ 3-fold (At Month 13) | 46 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | C human Serogroup ≥ 2-fold (At Month 13) | 92 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M07-0241084 Strain ≥ 4-fold (At Month 7) | 22 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M14459 Strain ≥ 2-fold (At Month 7) | 72 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | 96217 Strain ≥ 4-fold (At Month 7) | 94 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M07-0241084 Strain ≥ 3-fold (At Month 7) | 32 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | Y human Serogroup ≥ 2-fold (At Month 13) | 72 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | C human Serogroup ≥ 3-fold (At Month 13) | 89 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M14459 Strain ≥ 4-fold (At Month 3) | 28 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | 96217 Strain ≥ 4-fold (At Month 13) | 51 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M14459 Strain ≥ 3-fold (At Month 3) | 39 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | Y human Serogroup ≥ 3-fold (At Month 7) | 87 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | W human Serogroup ≥ 4-fold (At Month 13) | 29 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | C human Serogroup ≥ 4-fold (At Month 13) | 85 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | A human Serogroup ≥ 4-fold (At Month 13) | 7 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M14459 Strain ≥ 2-fold (At Month 3) | 50 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M14459 Strain ≥ 4-fold (At Month 2) | 4 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | Y human Serogroup ≥ 3-fold (At Month 13) | 54 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | C human Serogroup ≥ 4-fold (At Month 2) | 42 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | W human Serogroup ≥ 2-fold (At Month 2) | 33 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | 96217 Strain ≥ 2-fold (At Month 3) | 91 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | A human Serogroup ≥ 3-fold (At Month 7) | 77 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | 96217 Strain ≥ 4-fold (At Month 2) | 16 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | NZ98/254 Strain ≥ 4-fold (At Month 2) | 7 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | Y human Serogroup ≥ 2-fold (At Month 2) | 51 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | W human Serogroup ≥ 3-fold (At Month 2) | 22 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M14459 Strain ≥ 3-fold (At Month 2) | 6 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M07-0241084 Strain ≥ 2-fold (At Month 7) | 42 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | A human Serogroup ≥ 4-fold (At Month 3) | 40 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M14459 Strain ≥ 2-fold (At Month 2) | 11 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | C human Serogroup ≥ 2-fold (At Month 2) | 62 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | W human Serogroup ≥ 4-fold (At Month 2) | 18 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M07-0241084 Strain ≥ 4-fold (At Month 3) | 13 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | NZ98/254 Strain ≥ 4-fold (At Month 3) | 19 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M07-0241084 Strain ≥ 3-fold (At Month 3) | 17 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | A human Serogroup ≥ 3-fold (At Month 13) | 15 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | Y human Serogroup ≥ 3-fold (At Month 2) | 43 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | W human Serogroup ≥ 2-fold (At Month 3) | 76 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | A human Serogroup ≥ 3-fold (At Month 3) | 56 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M07-0241084 Strain ≥ 2-fold (At Month 3) | 21 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | NZ98/254 Strain ≥ 4-fold (At Month 13) | 4 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | A human Serogroup ≥ 3-fold (At Month 2) | 13 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | C human Serogroup ≥ 3-fold (At Month 2) | 54 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | W human Serogroup ≥ 3-fold (At Month 3) | 67 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M07-0241084 Strain ≥ 4-fold (At Month 2) | 1 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | A human Serogroup ≥ 4-fold (At Month 7) | 70 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M07-0241084 Strain ≥ 3-fold (At Month 2) | 4 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | Y human Serogroup ≥ 4-fold (At Month 7) | 76 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | Y human Serogroup ≥ 4-fold (At Month 2) | 37 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | W human Serogroup ≥ 4-fold (At Month 3) | 56 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | NZ98/254 Strain ≥ 3-fold (At Month 13) | 7 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M07-0241084 Strain ≥ 2-fold (At Month 2) | 8 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | A human Serogroup ≥ 4-fold (At Month 2) | 7 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | NZ98/254 Strain ≥ 3-fold (At Month 2) | 7 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | NZ98/254 Strain ≥ 2-fold (At Month 13) | 14 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | W human Serogroup ≥ 2-fold (At Month 7) | 89 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M14459 Strain ≥ 4-fold (At Month 13) | 4 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | A human Serogroup ≥ 2-fold (At Month 3) | 74 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | M14459 Strain ≥ 3-fold (At Month 13) | 6 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | C human Serogroup ≥ 2-fold (At Month 3) | 98 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | Y human Serogroup ≥ 2-fold (At Month 3) | 83 Percentages of subjects |
| ABCWY_0_2_6 Group | Percentages of Subjects With Two-, Three- and Four-fold Titer Rise Against Serogroups A, C, W and Y and Serogroup B Test Strains for All Schedules. | W human Serogroup ≥ 3-fold (At Month 7) | 80 Percentages of subjects |
Secondary
The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains.
The area under the curve for percentage of subjects with hSBA titers ≥ LLQ for all serogroups (A, C, W and Y) and for all serogroup B test strains (M14459, 96217, NZ98/254 and M07-0241084) was summarized overall (from Month 0 to Month 13) and by period (from Month 0 to Month 2, Month 2 to Month 3, Month 3 to Month 7 and Month 7 to Month 13) by vaccine groups. It was computed as the sum of the trapezoidal areas and the time unit used was the month. AUC 0\_13 = (r0+r2)(2-0)/2 + (r2+r3)(3-2)/2 + (r3+r7)(7-3)/2 + (r7+r13)(13-7)/2 with ri = percentages of subjects with both hSBA titers \>= LLQ against N. meningitis for all serogroups A, C, W and Y and for all serogroup B test strains at Month 1.
Time frame: From Month 0 to Month 13
Population: Analysis was done on the FAS Month 13 Over Time. All subjects in All Enrolled Set who received a study meningococcal vaccination \& provided evaluable serum samples at one month after the last meningococcal vaccination whose result is available for at least one A,C,W,or Y serogroup or serogroup B test strain.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| ABCWY_ 0_2 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup A- Month 2-3 (LLQ-22.7) | 57.69 Percentage of subjects |
| ABCWY_ 0_2 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup A- Month 3-7 (LLQ-22.7) | 292.53 Percentage of subjects |
| ABCWY_ 0_2 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B M14459- Month 3-7 (LLQ-8.0) | 228.61 Percentage of subjects |
| ABCWY_ 0_2 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup A- Month 7-13 (LLQ-22.7) | 256.04 Percentage of subjects |
| ABCWY_ 0_2 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B M14459- Month 0-2 (LLQ-8.0) | 35.10 Percentage of subjects |
| ABCWY_ 0_2 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B M14459- Month 2-3 (LLQ-8.0) | 55.45 Percentage of subjects |
| ABCWY_ 0_2 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B M07-0241084- Month 0-2 (LLQ-8.9) | 57.74 Percentage of subjects |
| ABCWY_ 0_2 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B M07-0241084- Month 2-3 (LLQ-8.9) | 52.46 Percentage of subjects |
| ABCWY_ 0_2 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B M07-0241084- Month 3-7 (LLQ-8.9) | 213.53 Percentage of subjects |
| ABCWY_ 0_2 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B 96217- Month 3-7 (LLQ-8.6) | 388.93 Percentage of subjects |
| ABCWY_ 0_2 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B M07-0241084- Month 7-13 (LLQ-8.9) | 217.26 Percentage of subjects |
| ABCWY_ 0_2 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B NZ98/254- Month 2-3 (LLQ-8.2) | 55.56 Percentage of subjects |
| ABCWY_ 0_2 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup C- Month 0-2(LLQ-5.2) | 102.82 Percentage of subjects |
| ABCWY_ 0_2 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup C- Month 2-3(LLQ-5.2) | 78.78 Percentage of subjects |
| ABCWY_ 0_2 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup C- Month 3-7(LLQ-5.2) | 331.60 Percentage of subjects |
| ABCWY_ 0_2 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B 96217- Month 2-3 (LLQ-8.6) | 85.03 Percentage of subjects |
| ABCWY_ 0_2 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup C- Month 7-13(LLQ-5.2) | 382.55 Percentage of subjects |
| ABCWY_ 0_2 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B NZ98/254- Month 0-2 (LLQ-8.2) | 30.27 Percentage of subjects |
| ABCWY_ 0_2 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup W-Month 0-2(LLQ-39.6) | 75.66 Percentage of subjects |
| ABCWY_ 0_2 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup W-Month 2-3(LLQ-39.6) | 68.51 Percentage of subjects |
| ABCWY_ 0_2 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B NZ98/254- Month 3-7 (LLQ-8.2) | 227.81 Percentage of subjects |
| ABCWY_ 0_2 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup W-Month 3-7(LLQ-39.6) | 293.42 Percentage of subjects |
| ABCWY_ 0_2 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B 96217- Month 0-2 (LLQ-8.6) | 93.52 Percentage of subjects |
| ABCWY_ 0_2 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup W-Month 7-13(LLQ-39.6) | 305.31 Percentage of subjects |
| ABCWY_ 0_2 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup Y-Month 0-2(LLQ-14.7) | 36.25 Percentage of subjects |
| ABCWY_ 0_2 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup Y-Month 2-3(LLQ-14.7) | 24.51 Percentage of subjects |
| ABCWY_ 0_2 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup Y-Month 3-7(LLQ-14.7) | 100.05 Percentage of subjects |
| ABCWY_ 0_2 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B 96217- Month 7-13 (LLQ-8.6) | 545.92 Percentage of subjects |
| ABCWY_ 0_2 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B M14459- Month 7-13 (LLQ-8.0) | 162.94 Percentage of subjects |
| ABCWY_ 0_2 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup Y-Month 7-13(LLQ-14.7) | 125.13 Percentage of subjects |
| ABCWY_ 0_2 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B NZ98/254- Month 7-13 (LLQ-8.2) | 142.59 Percentage of subjects |
| ABCWY_ 0_2 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup A- Month 0-2 (LLQ-22.7) | 26.52 Percentage of subjects |
| rMenB_0_2 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup Y-Month 2-3(LLQ-14.7) | 79.32 Percentage of subjects |
| rMenB_0_2 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup W-Month 7-13(LLQ-39.6) | 444.54 Percentage of subjects |
| rMenB_0_2 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B NZ98/254- Month 3-7 (LLQ-8.2) | 162.89 Percentage of subjects |
| rMenB_0_2 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup Y-Month 3-7(LLQ-14.7) | 339.26 Percentage of subjects |
| rMenB_0_2 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B M14459- Month 2-3 (LLQ-8.0) | 46.06 Percentage of subjects |
| rMenB_0_2 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup C- Month 7-13(LLQ-5.2) | 567.41 Percentage of subjects |
| rMenB_0_2 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B M07-0241084- Month 7-13 (LLQ-8.9) | 159.73 Percentage of subjects |
| rMenB_0_2 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup W-Month 3-7(LLQ-39.6) | 359.84 Percentage of subjects |
| rMenB_0_2 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup Y-Month 7-13(LLQ-14.7) | 425.13 Percentage of subjects |
| rMenB_0_2 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B 96217- Month 0-2 (LLQ-8.6) | 91.00 Percentage of subjects |
| rMenB_0_2 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup A- Month 0-2 (LLQ-22.7) | 38.01 Percentage of subjects |
| rMenB_0_2 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup W-Month 0-2(LLQ-39.6) | 93.12 Percentage of subjects |
| rMenB_0_2 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B 96217- Month 3-7 (LLQ-8.6) | 373.02 Percentage of subjects |
| rMenB_0_2 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup W-Month 2-3(LLQ-39.6) | 81.75 Percentage of subjects |
| rMenB_0_2 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B 96217- Month 7-13 (LLQ-8.6) | 515.49 Percentage of subjects |
| rMenB_0_2 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup Y-Month 0-2(LLQ-14.7) | 76.31 Percentage of subjects |
| rMenB_0_2 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B NZ98/254- Month 7-13 (LLQ-8.2) | 105.40 Percentage of subjects |
| rMenB_0_2 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup A- Month 3-7 (LLQ-22.7) | 264.81 Percentage of subjects |
| rMenB_0_2 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B NZ98/254- Month 0-2 (LLQ-8.2) | 25.84 Percentage of subjects |
| rMenB_0_2 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup C- Month 0-2(LLQ-5.2) | 129.30 Percentage of subjects |
| rMenB_0_2 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B M14459- Month 0-2 (LLQ-8.0) | 27.81 Percentage of subjects |
| rMenB_0_2 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B M14459- Month 3-7 (LLQ-8.0) | 196.15 Percentage of subjects |
| rMenB_0_2 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B NZ98/254- Month 2-3 (LLQ-8.2) | 40.77 Percentage of subjects |
| rMenB_0_2 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B M07-0241084- Month 3-7 (LLQ-8.9) | 151.20 Percentage of subjects |
| rMenB_0_2 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B M14459- Month 7-13 (LLQ-8.0) | 141.79 Percentage of subjects |
| rMenB_0_2 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup C- Month 2-3(LLQ-5.2) | 91.97 Percentage of subjects |
| rMenB_0_2 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B M07-0241084- Month 2-3 (LLQ-8.9) | 37.16 Percentage of subjects |
| rMenB_0_2 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup A- Month 2-3 (LLQ-22.7) | 60.98 Percentage of subjects |
| rMenB_0_2 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup A- Month 7-13 (LLQ-22.7) | 214.62 Percentage of subjects |
| rMenB_0_2 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B 96217- Month 2-3 (LLQ-8.6) | 80.02 Percentage of subjects |
| rMenB_0_2 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B M07-0241084- Month 0-2 (LLQ-8.9) | 43.20 Percentage of subjects |
| rMenB_0_2 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup C- Month 3-7(LLQ-5.2) | 390.80 Percentage of subjects |
| ABCWY_0_6 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup Y-Month 3-7(LLQ-14.7) | 339.26 Percentage of subjects |
| ABCWY_0_6 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B M07-0241084- Month 2-3 (LLQ-8.9) | 34.01 Percentage of subjects |
| ABCWY_0_6 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B M07-0241084- Month 3-7 (LLQ-8.9) | 111.63 Percentage of subjects |
| ABCWY_0_6 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B 96217- Month 7-13 (LLQ-8.6) | 495.00 Percentage of subjects |
| ABCWY_0_6 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup Y-Month 2-3(LLQ-14.7) | 83.26 Percentage of subjects |
| ABCWY_0_6 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B M07-0241084- Month 7-13 (LLQ-8.9) | 145.97 Percentage of subjects |
| ABCWY_0_6 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup C- Month 0-2(LLQ-5.2) | 148.03 Percentage of subjects |
| ABCWY_0_6 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B 96217- Month 2-3 (LLQ-8.6) | 95.77 Percentage of subjects |
| ABCWY_0_6 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup C- Month 2-3(LLQ-5.2) | 99.22 Percentage of subjects |
| ABCWY_0_6 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B NZ98/254- Month 2-3 (LLQ-8.2) | 37.21 Percentage of subjects |
| ABCWY_0_6 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B M14459- Month 3-7 (LLQ-8.0) | 117.62 Percentage of subjects |
| ABCWY_0_6 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup C- Month 3-7(LLQ-5.2) | 390.79 Percentage of subjects |
| ABCWY_0_6 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B M14459- Month 7-13 (LLQ-8.0) | 82.51 Percentage of subjects |
| ABCWY_0_6 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup C- Month 7-13(LLQ-5.2) | 574.69 Percentage of subjects |
| ABCWY_0_6 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup W-Month 0-2(LLQ-39.6) | 124.89 Percentage of subjects |
| ABCWY_0_6 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B 96217- Month 0-2 (LLQ-8.6) | 124.70 Percentage of subjects |
| ABCWY_0_6 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup A- Month 0-2 (LLQ-22.7) | 98.62 Percentage of subjects |
| ABCWY_0_6 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup W-Month 2-3(LLQ-39.6) | 90.33 Percentage of subjects |
| ABCWY_0_6 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup W-Month 3-7(LLQ-39.6) | 327.79 Percentage of subjects |
| ABCWY_0_6 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup Y-Month 7-13(LLQ-14.7) | 389.69 Percentage of subjects |
| ABCWY_0_6 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup W-Month 7-13(LLQ-39.6) | 434.34 Percentage of subjects |
| ABCWY_0_6 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B NZ98/254- Month 3-7 (LLQ-8.2) | 92.78 Percentage of subjects |
| ABCWY_0_6 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup A- Month 2-3 (LLQ-22.7) | 86.91 Percentage of subjects |
| ABCWY_0_6 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B NZ98/254- Month 7-13 (LLQ-8.2) | 90.34 Percentage of subjects |
| ABCWY_0_6 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup A- Month 3-7 (LLQ-22.7) | 243.86 Percentage of subjects |
| ABCWY_0_6 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup A- Month 7-13 (LLQ-22.7) | 217.88 Percentage of subjects |
| ABCWY_0_6 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B NZ98/254- Month 0-2 (LLQ-8.2) | 48.92 Percentage of subjects |
| ABCWY_0_6 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup Y-Month 0-2(LLQ-14.7) | 99.44 Percentage of subjects |
| ABCWY_0_6 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B M14459- Month 0-2 (LLQ-8.0) | 67.02 Percentage of subjects |
| ABCWY_0_6 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B M14459- Month 2-3 (LLQ-8.0) | 52.36 Percentage of subjects |
| ABCWY_0_6 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B M07-0241084- Month 0-2 (LLQ-8.9) | 53.67 Percentage of subjects |
| ABCWY_0_6 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B 96217- Month 3-7 (LLQ-8.6) | 361.75 Percentage of subjects |
| ABCWY_0_11 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B M14459- Month 0-2 (LLQ-8.0) | 21.09 Percentage of subjects |
| ABCWY_0_11 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup C- Month 2-3(LLQ-5.2) | 82.97 Percentage of subjects |
| ABCWY_0_11 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B 96217- Month 3-7 (LLQ-8.6) | 307.65 Percentage of subjects |
| ABCWY_0_11 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup A- Month 2-3 (LLQ-22.7) | 33.40 Percentage of subjects |
| ABCWY_0_11 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B M07-0241084- Month 0-2 (LLQ-8.9) | 42.74 Percentage of subjects |
| ABCWY_0_11 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup C- Month 0-2(LLQ-5.2) | 126.63 Percentage of subjects |
| ABCWY_0_11 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B M14459- Month 7-13 (LLQ-8.0) | 329.36 Percentage of subjects |
| ABCWY_0_11 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B 96217- Month 2-3 (LLQ-8.6) | 58.55 Percentage of subjects |
| ABCWY_0_11 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup Y-Month 0-2(LLQ-14.7) | 67.83 Percentage of subjects |
| ABCWY_0_11 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup A- Month 3-7 (LLQ-22.7) | 252.54 Percentage of subjects |
| ABCWY_0_11 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B NZ98/254- Month 7-13 (LLQ-8.2) | 242.66 Percentage of subjects |
| ABCWY_0_11 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup Y-Month 2-3(LLQ-14.7) | 58.88 Percentage of subjects |
| ABCWY_0_11 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B M07-0241084- Month 7-13 (LLQ-8.9) | 301.71 Percentage of subjects |
| ABCWY_0_11 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B M07-0241084- Month 3-7 (LLQ-8.9) | 190.79 Percentage of subjects |
| ABCWY_0_11 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B 96217- Month 7-13 (LLQ-8.6) | 561.47 Percentage of subjects |
| ABCWY_0_11 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup A- Month 7-13 (LLQ-22.7) | 446.58 Percentage of subjects |
| ABCWY_0_11 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B NZ98/254- Month 3-7 (LLQ-8.2) | 156.65 Percentage of subjects |
| ABCWY_0_11 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup W-Month 0-2(LLQ-39.6) | 85.71 Percentage of subjects |
| ABCWY_0_11 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B M14459- Month 2-3 (LLQ-8.0) | 16.53 Percentage of subjects |
| ABCWY_0_11 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup W-Month 2-3(LLQ-39.6) | 65.66 Percentage of subjects |
| ABCWY_0_11 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup A- Month 0-2 (LLQ-22.7) | 38.05 Percentage of subjects |
| ABCWY_0_11 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B 96217- Month 0-2 (LLQ-8.6) | 88.27 Percentage of subjects |
| ABCWY_0_11 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup Y-Month 3-7(LLQ-14.7) | 303.62 Percentage of subjects |
| ABCWY_0_11 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup C- Month 7-13(LLQ-5.2) | 589.70 Percentage of subjects |
| ABCWY_0_11 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B M07-0241084- Month 2-3 (LLQ-8.9) | 28.33 Percentage of subjects |
| ABCWY_0_11 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup W-Month 3-7(LLQ-39.6) | 331.64 Percentage of subjects |
| ABCWY_0_11 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B NZ98/254- Month 2-3 (LLQ-8.2) | 15.89 Percentage of subjects |
| ABCWY_0_11 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B M14459- Month 3-7 (LLQ-8.0) | 206.84 Percentage of subjects |
| ABCWY_0_11 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup Y-Month 7-13(LLQ-14.7) | 520.64 Percentage of subjects |
| ABCWY_0_11 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup C- Month 3-7(LLQ-5.2) | 360.70 Percentage of subjects |
| ABCWY_0_11 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B NZ98/254- Month 0-2 (LLQ-8.2) | 22.37 Percentage of subjects |
| ABCWY_0_11 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup W-Month 7-13(LLQ-39.6) | 543.61 Percentage of subjects |
| ABCWY_0_11 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup Y-Month 7-13(LLQ-14.7) | 454.48 Percentage of subjects |
| ABCWY_0_11 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B NZ98/254- Month 0-2 (LLQ-8.2) | 31.33 Percentage of subjects |
| ABCWY_0_11 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B NZ98/254- Month 2-3 (LLQ-8.2) | 24.05 Percentage of subjects |
| ABCWY_0_11 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B NZ98/254- Month 3-7 (LLQ-8.2) | 65.46 Percentage of subjects |
| ABCWY_0_11 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B NZ98/254- Month 7-13 (LLQ-8.2) | 257.90 Percentage of subjects |
| ABCWY_0_11 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B M07-0241084- Month 0-2 (LLQ-8.9) | 58.93 Percentage of subjects |
| ABCWY_0_11 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B M07-0241084- Month 2-3 (LLQ-8.9) | 34.47 Percentage of subjects |
| ABCWY_0_11 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B M07-0241084- Month 3-7 (LLQ-8.9) | 110.94 Percentage of subjects |
| ABCWY_0_11 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B M07-0241084- Month 7-13 (LLQ-8.9) | 282.69 Percentage of subjects |
| ABCWY_0_11 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup C- Month 0-2(LLQ-5.2) | 135.79 Percentage of subjects |
| ABCWY_0_11 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup C- Month 2-3(LLQ-5.2) | 88.21 Percentage of subjects |
| ABCWY_0_11 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup C- Month 3-7(LLQ-5.2) | 339.12 Percentage of subjects |
| ABCWY_0_11 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup C- Month 7-13(LLQ-5.2) | 545.04 Percentage of subjects |
| ABCWY_0_11 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup W-Month 0-2(LLQ-39.6) | 103.94 Percentage of subjects |
| ABCWY_0_11 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup W-Month 2-3(LLQ-39.6) | 75.19 Percentage of subjects |
| ABCWY_0_11 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup W-Month 3-7(LLQ-39.6) | 297.71 Percentage of subjects |
| ABCWY_0_11 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup W-Month 7-13(LLQ-39.6) | 512.92 Percentage of subjects |
| ABCWY_0_11 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup Y-Month 0-2(LLQ-14.7) | 84.92 Percentage of subjects |
| ABCWY_0_11 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup Y-Month 2-3(LLQ-14.7) | 67.70 Percentage of subjects |
| ABCWY_0_11 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup Y-Month 3-7(LLQ-14.7) | 234.85 Percentage of subjects |
| ABCWY_0_11 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B 96217- Month 7-13 (LLQ-8.6) | 411.36 Percentage of subjects |
| ABCWY_0_11 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup A- Month 0-2 (LLQ-22.7) | 57.12 Percentage of subjects |
| ABCWY_0_11 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup A- Month 2-3 (LLQ-22.7) | 47.00 Percentage of subjects |
| ABCWY_0_11 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup A- Month 3-7 (LLQ-22.7) | 119.41 Percentage of subjects |
| ABCWY_0_11 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup A- Month 7-13 (LLQ-22.7) | 343.24 Percentage of subjects |
| ABCWY_0_11 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B M14459- Month 0-2 (LLQ-8.0) | 40.10 Percentage of subjects |
| ABCWY_0_11 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B M14459- Month 2-3 (LLQ-8.0) | 30.88 Percentage of subjects |
| ABCWY_0_11 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B M14459- Month 3-7 (LLQ-8.0) | 84.60 Percentage of subjects |
| ABCWY_0_11 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B M14459- Month 7-13 (LLQ-8.0) | 309.09 Percentage of subjects |
| ABCWY_0_11 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B 96217- Month 0-2 (LLQ-8.6) | 83.08 Percentage of subjects |
| ABCWY_0_11 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B 96217- Month 2-3 (LLQ-8.6) | 52.33 Percentage of subjects |
| ABCWY_0_11 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B 96217- Month 3-7 (LLQ-8.6) | 172.73 Percentage of subjects |
| ABCWY_0_2_6 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup A- Month 0-2 (LLQ-22.7) | 27.86 Percentage of subjects |
| ABCWY_0_2_6 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup Y-Month 7-13(LLQ-14.7) | 537.41 Percentage of subjects |
| ABCWY_0_2_6 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B 96217- Month 3-7 (LLQ-8.6) | 392.59 Percentage of subjects |
| ABCWY_0_2_6 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B M14459- Month 3-7 (LLQ-8.0) | 325.33 Percentage of subjects |
| ABCWY_0_2_6 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup Y-Month 3-7(LLQ-14.7) | 373.95 Percentage of subjects |
| ABCWY_0_2_6 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup Y-Month 2-3(LLQ-14.7) | 75.50 Percentage of subjects |
| ABCWY_0_2_6 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup Y-Month 0-2(LLQ-14.7) | 67.58 Percentage of subjects |
| ABCWY_0_2_6 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup W-Month 7-13(LLQ-39.6) | 550.19 Percentage of subjects |
| ABCWY_0_2_6 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B NZ98/254- Month 3-7 (LLQ-8.2) | 282.91 Percentage of subjects |
| ABCWY_0_2_6 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B M14459- Month 7-13 (LLQ-8.0) | 347.86 Percentage of subjects |
| ABCWY_0_2_6 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup W-Month 3-7(LLQ-39.6) | 392.61 Percentage of subjects |
| ABCWY_0_2_6 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup W-Month 2-3(LLQ-39.6) | 78.97 Percentage of subjects |
| ABCWY_0_2_6 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup W-Month 0-2(LLQ-39.6) | 84.23 Percentage of subjects |
| ABCWY_0_2_6 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup C- Month 7-13(LLQ-5.2) | 595.68 Percentage of subjects |
| ABCWY_0_2_6 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B NZ98/254- Month 2-3 (LLQ-8.2) | 42.93 Percentage of subjects |
| ABCWY_0_2_6 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B 96217- Month 0-2 (LLQ-8.6) | 79.10 Percentage of subjects |
| ABCWY_0_2_6 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup C- Month 3-7(LLQ-5.2) | 398.53 Percentage of subjects |
| ABCWY_0_2_6 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup C- Month 2-3(LLQ-5.2) | 92.85 Percentage of subjects |
| ABCWY_0_2_6 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup C- Month 0-2(LLQ-5.2) | 128.34 Percentage of subjects |
| ABCWY_0_2_6 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B M07-0241084- Month 7-13 (LLQ-8.9) | 320.48 Percentage of subjects |
| ABCWY_0_2_6 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B NZ98/254- Month 0-2 (LLQ-8.2) | 20.13 Percentage of subjects |
| ABCWY_0_2_6 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B 96217- Month 2-3 (LLQ-8.6) | 74.25 Percentage of subjects |
| ABCWY_0_2_6 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B M07-0241084- Month 3-7 (LLQ-8.9) | 251.09 Percentage of subjects |
| ABCWY_0_2_6 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B M07-0241084- Month 2-3 (LLQ-8.9) | 41.65 Percentage of subjects |
| ABCWY_0_2_6 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B M07-0241084- Month 0-2 (LLQ-8.9) | 47.53 Percentage of subjects |
| ABCWY_0_2_6 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B NZ98/254- Month 7-13 (LLQ-8.2) | 277.24 Percentage of subjects |
| ABCWY_0_2_6 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B M14459- Month 0-2 (LLQ-8.0) | 18.57 Percentage of subjects |
| ABCWY_0_2_6 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup A- Month 7-13 (LLQ-22.7) | 436.76 Percentage of subjects |
| ABCWY_0_2_6 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B 96217- Month 7-13 (LLQ-8.6) | 578.42 Percentage of subjects |
| ABCWY_0_2_6 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | B M14459- Month 2-3 (LLQ-8.0) | 44.90 Percentage of subjects |
| ABCWY_0_2_6 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup A- Month 3-7 (LLQ-22.7) | 370.46 Percentage of subjects |
| ABCWY_0_2_6 Group | The Area Under the Curve (AUC) for Percentage of Subjects With hSBA Titers ≥LLQ for All Serogroups and Strains. | Serogroup A- Month 2-3 (LLQ-22.7) | 59.13 Percentage of subjects |